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Introduction 
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Chapter 1. Introduction 
 
 
1. 1  Background 
 
Information on the costs of health interventions is valuable to health decision-
makers for at least two reasons. The first is for budgeting purposes, to identify 
the resources necessary to undertake, sustain or scale up an interventioni. The 
second is for efficiency assessment, to identify if the benefits outweigh the 
costs of undertaking an intervention or which of the many interventions that 
could be undertaken is the best use of scarce health resources. 
 
To ensure that policy makers are provided with consistent evidence, it is 
important that costing studies use comparable and appropriate methods, 
regardless of the form of analysis being used. Otherwise it is not possible to 
compare the efficiency of the various competing alternatives or be sure that 
the interventions claimed to be cost-effective have been analyzed in an 
appropriate manner. 
 
A further complication relates to the fact that thorough economic evaluation of 
health interventions require skilled economists and can be relatively expensive 
to undertake.  In many countries, the necessary financial and human resources 
are not available and policy makers must draw on the results of studies 
undertaken in other settings and try to apply them to their own. For this 
reason, it is not only important to use comparable methods but also to report 
results in a way that allows policy-makers to assess the replicability and 
transferability of results between settings. 
 
The need for consistency and standardization of methods has been recognized 
for some time and has led to the development of several sets of guidelines for 
economic evaluation and for costs. Despite this, considerable diversity is still 
apparent in applied studies. Some of this diversity might be defensible, and 
some might not be. 
 
The overall objective of the thesis is to identify the variability in costing 
methods used in costing and cost-effectiveness studies and to understand the 
possible reasons for this; to test the practicality of applying standard methods 
when conducting costing studies in different settings and in using the results 
                                                 
i This is used to describe any programme or activity designed to improve or 
maintain health, be they promotive, preventive, curative or rehabilitative 
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to provide policy-relevant information; to understand the determinants of 
variation in unit costs; and finally to explore valid methods of transferring cost 
information from one setting to another, when local data do not exist.    
 
The goal is to develop methods and cost data in a way that allows the costs 
and cost-effectiveness of many different types of interventions to be compared, 
and improves the methods of transferability and generalizability of the results 
within and across settings.  Only then will the results of costing exercises be of 
widespread practical value to policy-makers and researchers.   
 
  
1. 2   Methodological issues 
 
Possible reasons for methodological differences in applied studies 
 
There could be a number of reasons for the observed differences in the methods used in 
applied studies. They may be related to disagreements on what is appropriate, reflected 
by varying recommendations in guidelines on specific costing issues.  Other 
possibilities include: areas where guidelines agree on the principles, applied studies 
follow the recommendations but vary in the detail of how they follow them; areas 
where there is agreement among guidelines but applied studies do not follow the 
recommendations; and areas where applied studies use different methods but the 
subject is not discussed in guidelines.  
 
The importance of assessing the nature of these variations stems from the fact that, to 
the extent possible, differences in reported costs across interventions and settings 
should reflect only variations in the quantities of inputs used and/or their prices rather 
than the methods used to collect or evaluate them. Therefore, highlighting differences 
in methods that are known not to be best practices or for which recommendations exist 
but are not being followed is essential. Selected examples of common methodological 
differences that can be found in applied studies are discussed below. 
 
 
1.2. 1   Capacity utilization 
 
Differences in the costs and cost-effectiveness of health interventions across and within 
settings may be due to differences in capacity utilization in the facilities in which the 
studies were undertaken rather than any intrinsic differences in the actual resources 
required or the effectiveness of the interventions. The impact on costs of differences in 
capacity utilization was illustrated in a study of health centre costs and efficiency in 
Egypt.  The cost per visit in 1994 varied from 3 to 60 Egyptian pounds depending on 
the level of capacity utilization, measured by the number of visits per physician per 
day (ranging from 3 to 16).1    
 
This has been recognized by major costing and cost-effectiveness guidelines.2;3 Despite 
this, very few applied studies report the capacity utilization that drives their numbers, 
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or attempt to adjust their costs to a standard level of capacity utilization before 
comparing different alternatives or comparing their results to other studies. Complying 
with the recommendations of guidelines is the obvious solution to increase the 
usefulness of the results presented in applied studies. In addition, exploring ways to 
account for the level of capacity utilization when estimating and extrapolating unit 
costs would be an important contribution to this area of work. This would be 
particularly useful with the increasing demand for country-specific cost estimates such 
as the cost of scaling up interventions to meet the Millennium Development Goals, or 
the WHO 3 by 5 goal of covering three million AIDS patients with antiretroviral (ARV) 
treatment by 2005.4 
 
 
1.2. 2    Practicality of applying standard methods across different settings, e.g., 
measurement of staff time 
 
There is very little discussion in guidelines about valid ways of allocating shared costs, 
particularly staff time, to specific interventions. Accordingly, different methods have 
been used in the literature. Examples of methods to allocate staff time include 
personnel interviews, time and motion studies, self-administered time logs, structured 
questionnaires and interviews with beneficiaries or with staff.5;6 According to Bratt et 
al,7 none of the first three produces estimates that are comparable to the benchmark, the 
time and motion study. The personnel interview method is particularly weak because it 
substantially overestimated contact time between staff and clients while 
underestimating non-productive time.  In fact, the time and motion method recorded 
between six and twelve times as much “non-productive” time as the other three 
instruments.  
 
Despite this, these methods are still being used in applied studies, which limits their 
validity and generalizability. Clearly the gold standard method, the time and motion 
study, is the most expensive option ─ it would be prohibitive to recommend it for all 
studies. Alternatively, understanding the determinants of variation in staff time from 
available time and motion studies may offer an attractive alternative to predict staff 
time for similar settings (always with a check on the degree of similarity) and 
interventions, rather than falling back to the less valid alternatives.  
 
 
1.2. 3   Determinants of variation in unit costs 
 
Studies often do not have the capacity to estimate health facility costs in their settings 
based on a large, randomly selected, number of facilities.   Cost estimates are 
sometimes based on a small number, sometimes only one observation. It is also 
common practice to use average unit costs reported in previous studies as the basis for 
the analysis. A main limitation of these approaches is that average costs based on an 
unrepresentative sample can be biased and hide important differences between and 
within health facilities. For example, using more expensive equipment, higher 
proportions of specialized staff or performing a larger number of diagnostic tests all 
contribute to differences in average costs between and within hospital departments. 
Understanding the determinants of variations in unit costs across and within health 
facilities can provide a means to adjust unit costs so that the results of different studies 
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are comparable and to add more rigour and external validity to the extrapolation of 
costs across studies or settings.   
 
 
1.2. 4   Methods of transferability of cost data and results 
 
Guidelines for cost-effectiveness analysis have warned about making uninformed 
generalizations of study results to other settings,8 and analysts have pointed out 
various reasons why generalizations can be potentially misleading,9 but there has been 
no explicit recommendations on how to actually transfer unit cost estimates. The 
following are the most common recommendations of guidelines for extrapolating cost 
results to settings where data do not exist: use official exchange rates,10 for components 
or subcomponents of costs, to extrapolate the results to other settings; use the same or 
different factor inputs across settings with prices modified to take into account prices in 
the new setting; or separate costs into traded and non-traded components and use the 
official exchange rate to translate the former and purchasing power exchange rates for 
the latter.11-13 
 
Most of these methods, except those involving modification of factor inputs, ignore 
other determinants of variation in unit costs, apart from the price level. Understanding 
the determinants of these variations and controlling for them in the extrapolation 
process is worth exploring.  
 
Another observation related to the transferability of assumptions or cost information 
from one study to another relates to estimating hospital unit costs. Admittedly, some of 
the more accurate methods of estimating costs are expensive or difficult to undertake, 
and budget constraints influence the way a study can be undertaken.  Accordingly, 
some studies have used simple rules-of-thumb, e.g., the cost of an inpatient bed day 
was assumed to equal that of three outpatient visits, to allocate costs between inpatient 
and outpatient departments in a hospital instead of using the gold standard step-down 
allocation method.14;15 The validity of applying the same ratio to all types of hospitals 
within a country has been questioned by Lombard et al (1991), who showed that in 
Cape Town Province of South Africa, the relationship between the cost per inpatient 
day and outpatient visit varied by type of hospital.  It also differed from the commonly 
used 1:3 ratio − the cost per bed day was found to vary between 1.4 to 2 times the cost 
per outpatient visit.16  
 
This raises the question of whether the countries seeking these data to make decisions 
about how to allocate resources between interventions should simply wait until full 
costing studies had been undertaken, or whether there are other alternatives for the 
short term that provided relatively reliable estimates while awaiting the full costing 
studies.  To date, little of this type of work has been undertaken.   
 
 
 
 
 
   CHAPTER 1 
 
5 
1. 3  Research questions 
 
From the above discussion several questions may be formulated. The 
following are addressed in this thesis: 
 
1. What are the reasons for variations in the costing methods used in cost 
and economic evaluation studies? 
2. What is the impact of methodological differences on the results and 
their validity? 
3. Short-cuts or rule of thumb approaches to costing; are they valid 
alternatives to more detailed costing studies?  
4. What are the determinants of variation in unit costs across settings 
and how can they can be used in the transferability of cost estimates 
across settings? 
 
These questions are all related to the central theme of the thesis: 
 
Sources of variability in methods used in costing studies, implications for the 
validity and transferability of results. 
 
 
1. 4  Thesis outline 
 
The subsequent chapters of this thesis are organized as follows.  Chapter 2 
explores the sources of variations in costing methods used in applied studies, 
discusses the nature of these variations relative to the recommendations of 
costing guidelines and the possibility of reducing some of them.  Chapters 3 
and 4 explore the practicality of applying standard methods when conducting 
costing studies in multiple settings and in using the results to provide policy-
relevant information. A set of empirical studies are then presented.  Methods 
of extrapolating unit costs when local data do not exist are examined in 
 Chapter 5. The validity and generalizability of some short-cut costing 
approaches such as using “rules-of-thumb” to estimate hospital unit costs for 
outpatient and inpatient departments are explored in  Chapter 6. This is taken 
a step further in  Chapter 7 by exploring the determinants of variations in unit 
costs across hospital inpatient departments. Moving from hospital to primary 
facility unit costs,  Chapter 8 explores the effect of adopting new interventions 
on the way staff spend their time and on estimating unit costs of new services 
provided at primary facilities. Finally, Chapters 9-12 illustrate how a 
standardized set of costing methods can be used in practical studies to develop 
important policy conclusions.   
  
 
         2 
 
 
 
Cost-effectiveness Analysis: Can 
We Reduce Variability in Costing 
Methods?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from International Journal of Technology Assessment 
in Health Care, 19 (2): Adam T, Evans DB and Koopmanschap 
MA. Cost-effectiveness Analysis: Can We Reduce Variability in 
Costing Methods?  © 2003, with permission from Cambridge 
University Press.
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Chapter 2.     Cost-effectiveness analysis: Can 
we reduce variability in costing methods?  
 
 
 
Summary 
 
 
The need for consistency and standardization of methods for economic 
appraisals has been recognized for some time and has led to the development 
of several sets of guidelines for economic evaluations and for costs. Despite 
this, considerable diversity is still apparent in applied studies. Some of these 
diversities might be defensible, and some might not. The objectives of this 
paper are to explore sources of variations in the methods used in applied 
studies, and to discuss the nature of these variations and the possibility of 
reducing some of them.  
 
We first use a systematic approach to identify the major sources of variation in 
costing methods used in applied economic evaluations.  We then compare the 
methods used to the recommendations made in available guidelines.  
 
Four possible sources of variation are identified.  The first is where guidelines 
do not agree in their recommendations so it is not surprising that applied 
studies use different methods.  The second is where guidelines agree in 
principle but provide little detail on how to comply with their 
recommendations; and the third is where a particular methodological issue is 
not discussed in guidelines. The fourth reason is simply lack of compliance 
with accepted guidelines.  
 
Variability in costing methods used in applied studies raises questions about 
the validity of their results and makes it difficult to compare the results of 
different studies. We discuss the implications for the transferability and 
generalizability of results and suggest ways to minimize the variability in the 
methods so that the results of costing studies and economic evaluations can be 
of more value to policy-makers.  
                                                             CHAPTER 2 
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2. 1   Introduction 
 
Information on the costs of health interventions is valuable to health decision-
makers for two reasons. The first is for budgeting purposes, to identify the 
resources necessary to undertake or sustain an intervention. The second is for 
efficiency assessment, to identify if the benefits outweigh the costs of 
undertaking an intervention or which of the many interventions that could be 
undertaken is the best use of scarce health resources. This paper is concerned 
with measuring costs for efficiency analysis. 
 
To ensure that policy makers are provided with consistent evidence, it is 
important that costing studies use comparable methods, regardless of the form 
of efficiency analysis being used, e.g., cost-effectiveness, cost-utility or cost-
benefit analysis. Otherwise it is not possible to compare the efficiency of 
competing alternatives or be sure that the interventions claimed to be cost-
effective (or good value for the money)  have been analyzed in an appropriate 
manner. 
 
A further complication relates to the fact that thorough economic evaluations 
of health interventions require skilled economists and can be relatively 
expensive to undertake.  In many countries, the necessary financial and 
human resources are not available and policy makers must draw on the results 
of studies undertaken in other settings and try to apply them to their own. For 
this reason, it is not only important to use comparable  methods but also to 
report results in a way that allows policy-makers to assess the replicability and 
transferability of results between settings. 
 
The need for consistency and standardization of methods has been recognized 
for some time and has led to the development of several sets of  guidelines 
covering methods of economic evaluations and costs2;3;10;13;15;17-30 and GISF 
Italian Group for Pharmacoeconomic studies (unpublished document, 2001). 
Despite this, considerable diversity is still apparent in applied work. Studies 
use different frameworks as the basis of data collection, different methods to 
collect data, different forms of analysis and a variety of ways to present their 
results. This is a significant limitation to the comparability and transferability 
of the results, which in turn restricts the value of such studies to decision-
makers. 
 
The purposes of this paper are, therefore, to: 
1. summarize the main sources of variation in the way costs are estimated 
and presented in economic evaluations of health interventions; 
2. identify possible causes of these variations; 
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3. suggest ways of reducing the variability so that the results of costing 
studies and economic evaluations can be of more value to policy-makers. 
 
 
2. 2  Methods 
 
Over the last decade, a number of systematic reviews of costing studies 
undertaken for the purposes of economic evaluation have been published.  We 
do not seek to duplicate these exercises, but draw on their conclusions.  To do 
this we identified recent review articles in which methodological issues 
surrounding economic evaluations of health interventions were discussed. 
Articles were identified by searching Medline and Econlit databases from 1990 
to the present. Initially we used the following search terms: “Costs and Cost 
Analysis” AND method* AND (review or compar*). This search retrieved 2655 
studies that involved costs in different ways but did not capture reviews of 
costing and cost-effectiveness studies. We then searched using “Costs and 
Cost Analysis” as a mesh word which we identified as a major topic.  
“Methods” was used as a qualifier and “review” was selected as the type of 
publication. English, French or Arabic language papers were considered, but 
none were found in French and Arabic. This search identified 87 articles of 
which only 16 compared costing methods across studies. 
 
To exclude the possibility that some articles could have compared costing 
studies but were not classified as reviews, we then searched using the same 
criteria but substituting “compar*” for “review” as publication type. Only one 
additional review was found resulting in a total of 17 articles,31-45 covering 
more than 600 economic evaluations or costing studies. Most focused on 
interventions against particular disease complexes such as parasitic diseases, 
tuberculosis, HIV-AIDS, hypertension, cancers or antenatal care, so they 
covered a wide range of interventions - preventive, curative, palliative and 
rehabilitative. Because our focus is on costs, issues relating to effectiveness are 
not reported here. 
 
These reviews identified several types of variations in costing methods used in 
applied studies. There could be a number of reasons for this. It might be 
related to disagreement between guidelines.  If so, variation in methods used 
in applied studies could be expected. In order to identify additional reasons 
for variability, we defined three other possibilities -  variations associated 
with: areas where guidelines agree on the principles, applied studies follow 
the recommendations but vary in the detail of how they follow them; areas 
where there is agreement among guidelines but applied studies do not follow 
the recommendations; and areas where applied studies use different methods 
but the subject is not discussed in guidelines. 
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To allocate the observed variations in the applied studies to these four 
possibilities, we needed to identify the major guidelines.  This was done by 
searching Medline and Econlit for guidelines and reviews of guidelines. Two 
search strategies were used. In both “Cost and Cost Analysis” was used as the 
mesh term, identified as a major topic. In the first, “guideline* or method* or 
standard*” were used as key words. In the second, the key words were  
“generalis* or generaliz* or  transfer*” to incorporate articles discussing 
generalizability and transferrability of results.  We also identified a number of 
guidelines through contact with regulatory authorities in various countries 
and included in our review a number of recent studies that compared the 
recommendations of these guidelines.46-51 
 
Review process 
 
The recommendations of the guidelines were summarized based on the main 
methodological questions related to costs described in Drummond et al.3 and 
Gold et al.2 and taking into account the fact that the main interest of this paper 
is the question of comparability and transferability of results. Six major 
methodological areas were identified: the framework of analysis; type of costs 
included; data collection methods; valuation of identified costs; methods of 
data analysis; and ways of reporting the results. 
 
The next step was to identify the nature of the recommendations made in the 
guidelines in each of these methodological areas in order to allow the 
variations observed in the applied studies to be linked back to the guidelines. 
Finally, the variation observed in the applied studies in each methodological 
area was identified. The aim was not to record the frequencies with which 
different methods were used but to present the main issues where it has been 
established that there remain significant variations in methods and/or 
presentation of results. 
 
 
2. 3  Results 
 
The results are summarized in Table 2. 1.  The first column describes the six 
major methodological areas divided into sub-components. The second 
summarizes the nature of the recommendations made in the guidelines, while 
the third reports briefly the nature of the major variations observed in applied 
work. The  reasons for the observed variation in applied studies are related to 
the following three categories which are discussed in detail below: 1. 
Disagreement between guidelines;  2. Guidelines agree on principles but do 
not discuss how to comply in practice;  3. Guidelines agree, but studies do not 
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follow the recommendations. The fourth category identified earlier - 
methodological issues that are not discussed in guidelines - was a theoretical 
possibility but we did not find any examples in our review. Therefore, we do 
not consider it further. 
 
 
2.3. 1  Disagreement between guidelines 
 
On a number of issues, the guidelines do not agree or do not provide clear, 
unambiguous guidance and this is reflected in applied studies. Three inter-
related areas of disagreement or ambiguity are the treatment of productivity 
loses/gains, the incorporation of informal care-givers time, and costs incurred 
in added years of life gained by an intervention. 
 
Treatment of productivity losses/gains. On the first, guidelines do not agree 
on whether changes in market production – e.g. reduction in work time 
necessitated by seeking care or increases in work time resulting from 
improved health after an intervention - should be included in the numerator of 
the cost-effectiveness ratio. Gold et al.2 argue that only losses due to time spent 
seeking and obtaining care should be included.  Other types of productivity 
changes, such as increased ability to return to work, should not be included 
because they are already captured in the QALY weights of the denominator.  
Netting them out of the costs in the numerator would result in double 
counting. 
 
On the other hand, Drummond et al.3 argue that productivity changes due to 
care-seeking are not relevant since patients are already off work because of 
their condition – the time spent seeking care does not result in any additional 
productivity loss.  The exception is for preventive interventions such as 
population screening where healthy people using the services and these costs 
should be included.  Further, Drummond et al.3 argue that productivity 
changes occurring as a result of the intervention should be included if they are 
important, but they provide no instruction to the analyst on when and how to 
do so. 
 
The Australian guidelines take another perspective recommending not to 
include either type of productivity effect in the base analysis, but that analysts 
can report them separately if they can show rigorously that they are 
important.19;21;22 The Canadian guidelines, similar to Drummond et al.,3 discuss 
the different theoretical arguments about incorporating these costs without 
providing guidance on how and when to include or exclude them.18;24;52  Other 
guidelines limit their discussion to patient and family time spent seeking and 
obtaining care recommending that they should be included in the 
numerator.10;30 
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The guidelines that recommend including productivity effects do not provide 
guidance about how to value lost or gained time. Some recommend using the 
frictional method proposed by Koopmanschap et al.53;54 which assumes that 
productivity costs only occur during the time it takes to replace a worker - the 
friction period - but they do not discuss how to apply with this 
recommendation.2;3;18;20;24;25;52  Others recommend using the human capital 
approach, by applying average wage rates for people who are in paid 
employment and one of two competing methods for valuing the time of 
people who are not in paid employment.30 
 
Informal care giver time. The second related area of ambiguity is whether to 
incorporate and how to value informal care, i.e., health care provided by 
nonprofessionals such as family and friends of a patient, for which they are 
not financially compensated.  Some guidelines  recommend imputing a 
monetary value for this time10;18;30 others only describe the different theoretical 
arguments without making any recommendations,2;3 and some do not mention 
the topic.17;20;21 Where guidelines recommend including these costs, guidance 
is rarely provided on the appropriate shadow wage to use,2;18 restricting 
discussion to describing the different ways that have sometimes been used in 
applied work.3;10;30 
 
Costs incurred in added years of life. The third area is whether future health 
care costs in years of life extended because of an intervention should be 
included, and if so, which ones.  Most guidelines agree that health care costs 
for diseases or conditions related to the intervention should be included, but 
there is no agreement about costs incurred for unrelated diseases and non-
health care expenditures (e.g., food, clothes, and housing) in added years of 
life.  A number of guidelines simply report the theoretical disagreements 
without making specific recommendations on whether to incorporate these 
costs. They leave it to the analyst’s discretion, with the recommendation that 
the sensitivity of the results to the inclusion or exclusion of these costs should 
be explored.2;3;18;19;22;24;52  
 
Practice in applied studies. Not surprisingly, this disagreement and lack of 
guidance reflects itself in the mixture of methods used in applied studies, 
where some include productivity costs associated with time lost in seeking 
care and treatment, while others include the time spent caring for family 
members.31;34;40;41;43;55  Others net out from the costs of the intervention the 
productivity gains expected to emerge from prevention, though this is not 
common.35  It is relatively common to net out savings in health costs in added 
years of life due to prevention and most studies limit attention to costs due to 
related illnesses.  However, examples can be found where costs due to 
unrelated illness in added years of life, or even additional consumption 
unrelated to health care, are added to the costs of an intervention.32;35;40 Where 
   CHAPTER 2 
13 
productivity or time costs were included, different methods of valuation can 
be found, ranging from valuing time at the average wage of unskilled labour 
to using sex-specific average earnings for the population as a whole.41;55 
 
 
2.3. 2  Guidelines agree in principle but provide no detail of how to comply 
 
Other sources of variation seem to be related to the fact that while guidelines 
agree in principle, they provide little detail of how to comply with the 
principle. Three important examples relate to the allocation of some types of 
shared costs (e.g., staff time or overhead costs), the question of capacity 
utilization, and the use of shadow prices. 
 
Allocation of shared costs. Some guidelines simply state that shared overhead 
costs should be allocated to each specific intervention.  Others describe in 
addition the various ways of doing this without making recommendations 
about which is preferable.2  Some provide examples using the different 
methods of allocating overhead costs using such techniques as direct, step 
down or simultaneous allocation.10;26;47 But there is no discussion of the 
validity of the estimates obtained from these methods, how they might differ 
and which one is preferable. In particular, there is very  little discussion in 
guidelines about how to allocate shared labour costs to specific interventions 
in a valid way. Accordingly, applied studies have used different methods to 
allocate overhead costs.31  In many other cases, published studies do not 
clearly show if shared costs have been included or how they were allocated to 
the intervention, so it is not possible to be confident of their validity.34;43  
Similarly, there are wide variations in the methods used to allocate staff time 
in the published literature. Examples include personnel interviews, time and 
motion studies, self-administered time logs, structured questionnaires and 
interviews with beneficiaries or with staff.34;39 
 
Another example is the allocation of programme costs1, sometimes considered 
as a component of administrative costs. Most guidelines give examples related 
only to the allocation of shared/overhead costs incurred at the site of delivery 
of the intervention - e.g., allocating hospital administration to the level of the 
ward – rather than higher level shared costs.  Some guidelines assume the 
problem away by arguing that costs that are similar between the interventions 
compared in a study can be ignored.  Apart from a few notable exceptions,10;13 
details of how to take programme costs into account cannot be found in 
guidelines. 
 
Capacity utilization. Variations in estimated costs and cost-effectiveness 
might be due to differences in capacity utilization in the setting in which the 
studies were undertaken rather than to any intrinsic differences in the 
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efficiency of the interventions. A hospital-based intervention might seem very 
inefficient in one setting simply because it is located in a hospital that has a 
50% occupancy rate rather than because the intervention is inefficient of itself.  
This is recognized by two of the major guidelines.2;3 For example, Gold et al.2 
recommend that capacity utilization should be identified and reported when 
estimating the costs of an intervention or service.  If information on capacity 
use is not available, they recommend using a benchmark rate of 80% under an 
apparent assumption that in the long run, that is the approximate rate that 
applies in the US.   Despite this, very few applied studies report the capacity 
utilization that drives their numbers, or attempt to adjust their costs to a 
standard level of capacity utilization.56 
 
Shadow prices. A final example of where guidelines agree but do not provide 
detail on how to follow the recommendations relates to the use of shadow 
prices.  All guidelines argue that for the social perspective, opportunity costs 
should be used to value inputs rather than financial expenditures.  Most 
recognize that there are market imperfections and that the use of shadow 
pricing might be needed.  However, apart from discussing the opportunity 
cost of labour,2;3;10;13;30 little detail is provided on how to shadow price other 
inputs or how to value traded and non-traded goods.26 
 
Not surprisingly, very few applied studies41;43 have tried to separate traded 
goods from non-traded goods, for example. Many studies have used the 
official exchange rate to present their cost estimates in foreign currency units 
(e.g. US dollars) with no discussion of whether this is appropriate or whether 
shadow exchange rates (or conversion factors) should be used instead.43  It is 
rare to find examples of the type of rigorous shadow pricing common in 
economic appraisals undertaken in other sectors.57;58 
 
 
2.3. 3  Guidelines agree but applied studies do not follow the 
recommendations 
 
We now turn our attention to variations in costing methods which need not 
occur, particularly related to areas where there is agreement in the guidelines 
but variation in the applied studies. Examples relate to the perspective of the 
analysis, the types of costs included and using the ingredient approach to 
collect and report cost information. 
 
Perspective of the analysis. Despite the fact that all guidelines argue that the 
social perspective is appropriate (even if they also recommend other 
perspectives in addition), many applied studies include only health care costs 
borne by the provider.31;33;41;43  In fact, in some studies it is not possible to 
determine what perspective is being taken.33;36 In selected circumstances it 
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might be justifiable to exclude some of these other costs, but these 
circumstances are limited to cases where the other costs are a very small 
proportion of total costs, or if including them will simply strengthen the 
results (e.g., increase an already high cost-effectiveness ratio).3;59 
 
Costs included. A second example is where components of direct costs are 
overlooked.  Some studies exclude donated items (such as drugs, vaccines, 
supplies or equipment or the costs of recruitment and invitation of target 
groups, e.g., in screening programmes.41;43 Some use charges instead of costs 
with no comment on how they might differ from actual costs37 despite the fact 
that most guidelines provide examples of how to adjust charges to obtain 
more accurate estimates of costs.47;60 
 
Ingredients approach. Virtually all guidelines recommended that costs be 
estimated and reported using the ingredients approach, in which physical 
quantities of inputs are reported separately to their unit prices. But it is 
uncommon to find  published economic evaluations providing this 
information apart from few notable exceptions.34;37;41;43 
 
 
                                                             
  
Table 2. 1 i: Comparison between recommendations made in guidelines and nature of variations in applied studies. 
 
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
I.) The framework of analysis 
a. Perspective: societal 
versus provider 
− Guidelines agree that the perspective needs 
to be clearly stated in a study. They 
generally recommend that the societal 
perspective is the appropriate one to use but 
allow that other view points to be included 
depending on the question to be answered. 
− Most studies adopted the provider’s 
perspective (health system), a smaller 
number used some form of societal 
perspective. 
− Other perspectives used were the 
employer’s (private), patient or 
community. In many studies the 
perspective is not specified or is 
difficult to determine. 
b. Choice of 
comparator: 
− Most guidelines recommend using an 
incremental analysis, comparing the new 
intervention to the best current alternative. 
− The recently published WHO guidelines 
argue that in addition to incremental 
analysis, comparison to doing nothing is 
always relevant. 
− Some compare a new alternative to 
current practice using incremental 
analysis. Others compare a new 
alternative to doing nothing. 
 
 
II.) Types of costs included 
a. Overhead costs − Most guidelines agree that overhead costs 
should be included. But  alternative 
− Often difficult to understand whether 
overhead costs were included or not 
      
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
methods of allocation and their validation 
are not fully discussed 
− The main discussion involved methods of 
allocating overhead costs in health facilities, 
e.g., hospitals. Methods of allocating shared 
costs at higher levels, e.g.,  the district or 
national-levels, were rarely  discussed. 
due to aggregate presentation of 
results. 
− Where it is clear, many studies 
apparently overlook part or all of these 
costs, e.g., administration costs at 
higher levels of the health system, e.g., 
planning, lobbying,  training of medical 
staff, supervision etc.. 
c. Other shared costs 
including allocation of 
labour time 
− Methods to collect and allocate labour costs 
were briefly described in guidelines. 
However, validation of these methods was 
not discussed, nor recommendations made 
about which to use. 
− In general, methods of allocation of 
shared costs were not specified. Among 
the methods used were: staff rosters, 
time and motion studies, personnel 
interviews or self-administered time 
logs kept by clinician. 
d. Indirect costs and 
inclusion of 
productivity gains 
into net costs (for 
valuations of time cost 
see section IV b.) 
− Guidelines do not agree on whether indirect 
costs due to illness or informal care should 
be included. 
− Volunteer time should always be identified 
and included unless deemed to  be minimal 
− Most do not include indirect costs or 
consequences 
− Some include lost time in seeking care 
(mainly by patients and to a lesser 
degree by caregivers). 
− Costs of lost non-market time, 
including leisure time, is rarely 
included. 
− Very few included volunteer time. 
e. Health care costs for 
unrelated illness in the 
− Most agree that future costs associated with 
current illness should be included but there 
− Very few included costs in future life 
gained when evaluating interventions 
                                                             
  
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
added years of life is no agreement whether future costs due to 
unrelated illness should be incorporated in 
the analysis. 
with long term effects. Of those who 
included these costs, some included 
medical costs due to related illness, or 
medical and/or non-medical of 
unrelated illness. Some did not specify 
which future costs were included 
 
III.) Data collection methods 
a. Sources of cost data − Some guidelines describe the different 
sources of data collection but issues 
regarding the validity and the reliability of 
data collection instruments are not 
discussed, e.g.,  recall bias, question formats, 
answer formats etc. 
− Sources of cost data included: 
expenditure records, case registers, 
interviews with clinicians or patients, 
surveys and questionnaire. Others used 
assumptions made by investigators, 
projections and modeling or clinician 
consensus or resources use from trials. 
 
IV.)The valuation step 
a. Bottom-up versus 
top-down ii 
 
− Methods and issues to consider when using 
either approach were not discussed, 
particularly related to the determination of 
capacity utilization when collecting and 
reporting unit costs iii. 
- The importance of reporting capacity 
− Some used a top-down approach, some 
used a bottom-up, others used a 
combination of bottom up and unit 
costs from the literature, while still 
others used a combination of bottom 
up to collect patient costs and a step 
      
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
utilization and the methods used to measure 
it were not discussed in guidelines. 
down costing to allocate overhead 
costs. 
b. Price adjustments: 
 
1. price 
distortions  
(e.g., shadow 
prices, 
transfer 
payments) 
 
2. Exchange 
rates 
 
- Generally agree that prices should 
theoretically be adjusted for market 
distortions. Some say that the gains from 
doing this are not worth the effort. Little 
detail is provided on how to do it, for 
example, methods for comparing traded 
goods with non-traded goods are not 
discussed. 
- Most guidelines recommend presenting 
results in local currency.  No discussion of 
how and when to report in foreign exchange 
currency (e.g., US $) or international dollars. 
− Generally no discussion on whether 
market prices are a realistic reflection of 
opportunity costs. 
− Details are rarely provided about how 
traded and non-traded goods have 
been treated. 
− Where studies report results in foreign 
currency units, official exchange rates 
have mostly been used.  Rare use of 
purchasing power parity exchange 
rates 
b. Valuation of time 
costs (e.g., volunteer 
time, home 
production, 
productivity loss due 
to illness) 
− Guidelines discussed the different valuation 
methods, e.g., human capital approach or 
willingness to pay, but the majority did not 
recommend which one to use. 
− No discussion on how to collect wage rates 
in developing countries particularly in 
agricultural areas or where labour markets 
do not exist. 
− When included, the valuation methods 
were not systematically mentioned. 
Among the methods used were market 
values of professional labour that could 
substitute this input, or the wage rate 
which this person could earn in 
alternative paid work. 
c. Capital costs − Guidelines discuss alternatives, e.g., rental 
versus annualized costs, but there is no 
recommendation on how to collect this data 
− Sometimes it was difficult to determine 
whether capital costs were included or 
not. When they were included, many 
                                                             
  
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
in a valid way e.g., appropriateness of using  
rented equivalents in developing countries, 
especially rural areas where markets do not 
exist. Or using replacement versus historical 
costs when calculating annualized costs. 
− The recommendations vary from restricting 
analysts to using a specified discount rate 
and life spans of capital items to leaving it 
open to analysts to choose which ones to use 
within a certain range. 
studies did not systematically report 
how they were treated, i.e., using rental 
values or annualized costs and in the 
latter case which discount rate was 
used as well as the useful life of capital 
items. 
d. Prices or charges − Guidelines agree that resources that are 
important for the specific study should be 
valued based on costs not charges, and if 
charges are to be used they should be 
adjusted. 
− Methods of adjustment of charges to 
approximate costs were discussed for the 
US. 
− In a large number of studies ( mostly 
done in the US), costs were based on 
charges with no comment on how they 
differ from actual costs. 
 
V.) The methods of data analysis 
a. Discounting costs − All guidelines agree that costs should be 
discounted and a range of rates is usually 
given iv 
− Many studies discounted costs. Some 
did not when they should, e.g., when 
they aggregate annual costs of a 
programme for several years to present 
      
Methodological areas Nature or recommendations made in guidelines Nature of variations in applied studies 
 
value. Studies used different rates 
ranging from 2.5 to 14%. 
b. Capacity utilization − Guidelines recommend that capacity 
utilization should be identified when 
developing cost estimates of an intervention 
or service. However, none of the guidelines 
provide guidance on how to measure 
capacity utilization or how to use the results 
for policy analysis. 
− This issue was not discussed in 
reviews, and rarely reported in applied 
studies. 
− Applied studies rarely report capacity 
utilization associated with their 
estimates. 
c. Sensitivity analysis 
and other statistical 
analysis of variations 
in units costs 
− All guidelines agree that sensitivity analysis 
should be performed. Only one country 
specific guideline provided 
recommendations, favouring multi-way 
analysis. 
− Not systematically done and when 
done, it was often done inadequately. 
Often authors did not provide 
justification of the ranges of values 
employed in the analysis and many key 
study parameters were not accounted 
for. 
− One-way sensitivity analysis was the 
most commonly used. Other methods 
were multi-way analysis and threshold 
analysis. 
VI.) Reporting results 
a. Ingredient approach 
and transparency in 
describing methods 
and results 
− General agreement on the usefulness of 
using the ingredient approach in estimating 
and reporting results. 
− It is rarely possible to identify the 
physical inputs separately from unit 
costs in published studies. 
                                                             
  
Table footnotes: 
 
i The classification of this table is based on  the main methodological issues surrounding the steps required to estimate costs 
described in Drummond et al.3 and Gold et al.2 
ii Bottom-up approach means that the unit cost of each service in each product line is computed as the sum of the resource 
inputs used in that service’s production. The top-down approach uses total costs figures obtained from the financial 
accounts of the health care provider as the primary sources for determining the unit costs per unit of output. 
iii The bottom-up approach runs greater risks of forgetting slack time than the top down approach. For example, one of the 
methods of allocating staff time is based on observing the average time spent in patient encounters. If analysts do not add a 
proportion of down time to the overall estimate of staff time/patient, this will underestimate labour costs and biases the 
cost-effectiveness ratio.  On the other hand, top down may give biased estimates in case of heterogeneous production (e.g. 
radiology) 
iv It is still debated whether or not outcomes of interventions should be discounted. This is not addressed here.
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2. 4  Discussion and policy implications 
 
Despite the presence of guidelines on economic evaluation and costing 
methods, there is still considerable variation in the methods used and the 
approaches taken in applied costing studies.32;33;36;37;40;41;44  This paper has 
identified a number of possible reasons for this by relating the observed 
variations to the recommendations of the guidelines.  The categories identified 
were:  where there is disagreement between guidelines;  where guidelines 
agree on principles but do not discuss how to comply in practice;  and where 
guidelines agree but studies do not follow the recommendations. 
 
The variability associated with the first is likely to remain for the foreseeable 
future because it is related to fundamental disagreement among economists on 
questions like the boundaries to be drawn around the analysis. As mentioned 
above, economists simply do not agree on whether and how to incorporate 
productivity losses in seeking or obtaining care, or whether productivity gains 
in added years of life resulting from an intervention should be subtracted out 
of the costs of the intervention (called net costs).59;61 
 
Economists also disagree on the theoretically correct approach to treating time 
lost in providing informal care,62;63 or if future unrelated costs in added years 
of lives due to an intervention should be included in the economic evaluation 
of health interventions.64-66   It is not possible for us to resolve these debates 
here.  We simply note that there will continue to be some variations in costing 
practices observed in applied studies until these theoretical debates are settled. 
 
The second source of some of the variability is linked to the fact that 
guidelines do not provide details of how to follow their general 
recommendations. This gives analysts the flexibility to comply in a number of 
ways. Does this create significant variation in the cost estimates? Bratt et al.7 
recently compared the estimates produced by different methods of allocating 
shared staff costs to specific interventions  - provider interviews (PI), self-
administered timesheets (ST), patient flow analysis (PFA) and an 
observational time and motion technique (TM) taken to be the benchmark.  
None of the first three produced estimates comparable to the benchmark. The  
PI method was particularly weak because it substantially overestimated 
contact time between staff and clients while underestimating non-productive 
time.  In fact, TM recorded between six and twelve times as much “non-
productive” time as the other three instruments. 
 
This suggests that it may be important to reach agreement not only on the 
principles underlying costing studies, but also on the most appropriate ways 
to collect critical data. While it is necessary to allow some flexibility in 
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collecting costs, it is important to ensure that the methods used are valid. This 
is not generally discussed in guidelines, possibly because they have focused 
more on the big picture rather than on the specifics of how to comply with 
recommendations. 
 
Admittedly, some of the more accurate methods of estimating costs are 
expensive or difficult to undertake, and budget constraints influence the way a 
study can be undertaken.  Accordingly, it would be valuable to compare the 
gold standard methods to simpler, less costly alternatives e.g., using a simple 
rule-of-thumb to allocate costs between inpatient and outpatient departments 
in a hospital versus the gold standard step-down allocation method.15;67 This 
will identify the tradeoffs that exist between the level of accuracy obtained and 
the costs of undertaking each method. To our knowledge, little of this type of 
work has been undertaken. 
 
Similar conclusions apply to the area of capacity utilization which is rarely 
reported in the results of applied studies.3;18;19;21;22;24;47;52  Yet the impact of 
variations in capacity use on costs can be substantial.  For example, a study of  
costs per outpatient visit in 19 health centers in Egypt in 1994 showed that a 
major determinant of the differences in costs (ranging from three Egyptian 
pounds per visit to 60) was the variation in the number of visits per physician 
per day (ranging from 3 to 16).1  The costs of facility based interventions, 
perhaps antenatal care, would differ greatly depending on what level of 
capacity use was assumed.  Accordingly, it is important for guidelines to 
develop more specific recommendations on how to measure, report and adjust 
estimates taking into account capacity use. 
 
Finally, a considerable reduction in the variability of methods used in studies 
could be achieved if future studies complied more closely to the guideline 
recommendations. For example, studies should ensure that all costs are 
included and that resources are valued in an appropriate manner.  This task is 
facilitated by using an ingredients approach to measuring and reporting costs, 
as recommended by the guidelines.  This will also help the generalizability 
and credibility of cost estimates.  In this way, analysts in a different setting 
could determine if they would use the same types of inputs – e.g. perhaps they 
would use nurses rather than doctors to perform a particular task – and adjust 
the inputs accordingly.  They could also adjust the prices used to their local 
situation, making the results more applicable to their settings. By presenting 
information on capacity utilization and the methods used to obtain those 
estimates, it will be possible for decision-makers to estimate the costs of the 
same programme in their setting after applying the average capacity use 
observed in their setting using the same measurement methods. 
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The past few years have shown a considerable increase in the number of 
applied studies reporting the costs or economic efficiency of health 
interventions.39  This reflects increasing interest in providing policy-makers 
with information to assist them in the efficient allocation of scarce resources. 
To ensure that they are provided with consistent evidence, it is important that 
costing studies use consistent and comparable costing methodology. 
Otherwise it is not possible to compare the efficiency of competing 
interventions or be sure that the interventions claimed to be cost-effective have 
been analyzed in an appropriate manner. 
 
This paper suggests that it is possible to reduce some, though not all, of the 
observed variability in the methods used in applied work. This can be 
achieved, firstly, if guidelines – or companion volumes to guidelines - provide 
more detail about how to follow their recommendations. More empirical 
research is needed to guide this process, for example, on issues related to 
validation of different data collection and measurement methods.  Particularly 
valuable would be efforts to validate relatively rapid, low cost data collection 
techniques compared to more expensive gold standard methods.  Secondly, it 
is important that studies which do not comply with established standards are 
not funded or published.  A more careful review process is required from 
funding agencies and journals.  A minimum requirement should be that 
studies use an ingredients approach to measure and report costs, and that 
these data are provided to reviewers, to other analysts and to policy-makers as 
desired.  This would reduce the number of studies published despite having 
apparently omitted important components of costs, or without enough detail 
to convince readers that their results are valid. 
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Chapter 3.    Does the Integrated Management of 
Childhood Illness cost more than routine care? Results 
from Tanzania        
 
 
 
Summary 
 
 
Integrated Management of Childhood Illness (IMCI) is a strategy designed to 
address the five leading causes of childhood mortality, which together account 
for 70% of the ten million child deaths in the world each year.  Although IMCI 
is associated with improved quality of care, it is not yet widely adopted, partly 
because it is assumed to be more expensive than routine care. Here we report 
the cost of IMCI compared with routine care in four districts in Tanzania. 
 
A plausibility design compared two districts with IMCI with two contiguous 
comparison districts where routine care continued. Total costs of child care 
were estimated from the societal perspective and were collected from the 
household, primary health facility, hospital, district and national levels.  
 
The annual cost per child of caring for under-fives in districts with IMCI was 
US $ 11.19, 44% lower than in the comparison districts ($16.09) using routine 
care. The average cost per under-five visit to a health facility was $1.39 in 
facilities with IMCI, compared to $1.61 in comparison facilities. IMCI facilities 
spent 30% less per visit on drugs and vaccines than comparison facilities.   
 
We found no evidence that IMCI was associated with higher costs than routine 
child care in the four study districts in Tanzania. Given the evidence of 
improved quality of care in the IMCI districts, it is important to take rapid 
steps to scale up the adoption and coverage of IMCI.                               
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3. 1 Introduction 
 
More than 10 million children die each year before they reach their fifth 
birthday and 70% of these deaths are due to five conditions: diarrhea, 
pneumonia, malaria, measles and malnutrition.68;69 The Integrated 
Management of Childhood Illness (IMCI) strategy seeks to reduce these deaths 
through improvement of skills of health staff, health systems and family and 
community practices. Tanzania is one of over 80 developing countries in 
which the Integrated Management of Childhood Illness (IMCI) strategy has 
started to be implemented.  The Multi-Country Evaluation (MCE) of the IMCI 
is a set of studies in five countries using complementary designs that assess 
the effectiveness, cost and impact of the strategy, see www.who.int/imci-mce.   
It has already been shown that IMCI is associated with improved quality of 
care, something that should result in improved outcomes.70-73 However, 
concern about the costs of implementing IMCI, especially in terms of human 
resources, is likely to have prevented some countries from adopting it.74;75 
 
In Tanzania the study uses a ‘plausibility’ design to document process and 
outcome indicators in two districts with IMCI (Morogoro Rural and Rufiji) and 
in two contiguous comparison districts (Kilombero and Ulanga) where routine 
case management continued. Plausibility statements are derived from 
evaluations that – despite not being randomized – are aimed at making causal 
statements using observational designs with a comparison group.76  
 
Here we present results from the cost component of the MCE study in 
Tanzania, the first such study for which detailed cost data are available. The 
specific objectives of the costing study were to estimate the total economic 
costs of starting-up and implementing IMCI in a district —i.e., the full cost to 
society of IMCI-based services to children under five; and the additional 
economic costs (additional to those previously expended on under-fives) of 
introducing and running IMCI.  
 
 
3. 2  Methodology 
 
3.2. 1  Study setting 
 
We compared two rural districts where IMCI has been implemented since late 
1997 (“intervention” districts) with two neighbouring rural districts where 
implementation began in 2002 (“comparison” districts). The four districts had 
reasonably well-functioning health services, comparable levels of per-capita 
health expenditure, high utilization rates of government health facilities and 
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high coverage of selected key interventions (e.g., EPI). Large numbers of non-
governmental health actors were also active in the districts, many of which 
were involved in health worker training and community activities, although 
their coverage was patchy. The two districts where IMCI was implemented 
had engaged in activities designed to strengthen district management skills, 
and had authority for priority setting and control over the health budget 
decentralized to them.  A high level of coverage of IMCI training for health 
workers was achieved, but there had been no increase in the provision of 
under-five interventions at the community level, as opposed to the facility 
level. More detail about the study setting and IMCI as implemented in 
Tanzania can be found elsewhere.73;77 
 
 
3.2. 2  Data collection and cost analysis 
 
Cost data were collected for the start-up period of implementing IMCI (from 
1996 to 1997) and subsequently for maintaining child health services including 
IMCI during  the year of 1999. The start-up period is defined as the time from 
the national decision to implement IMCI to the time when IMCI was provided 
to the first under-five child through trained health workers in primary 
facilities. Annual costs for maintaining IMCI were collected for 1999. Costs are 
presented in 1999 US$. The start up costs were annualised and inflated to 1999 
values using GDP deflators.78 
 
Costs were estimated from the societal perspective and were collected for the 
national, district, hospital, health facility and household levels (Panel 3. 1). 
Cost at all these levels was summed to obtain the total cost to the district of 
providing care for under-fives.  To allow comparison across districts, cost 
estimates were standardized to a hypothetical district with a population of 
50,000 under-fives.  This corresponds to a total population of around 300,000, 
which is roughly the average district population for Tanzania. Estimates of the 
additional cost to the district of implementing IMCI were based on the 
difference in cost of under-five care between IMCI and comparison districts.  
The total cost of care for under-fives in a standard comparison district was 
subtracted from the total cost in a standard IMCI district.  The difference is the 
estimated change in under-five costs attributable to IMCI.79  
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Panel 3. 1  Cost data collected at each level  
 
 
1. National: National costs of start-up and annual post-
implementation costs of IMCI, and of other activities related to 
under-fives such as the Expanded Programme on Immunization 
(EPI), nutrition and malaria programmes, were collected using 
interviews and record reviews based on a national-level cost 
questionnaire. 
2. District: District-level start-up and post-implementation costs of 
under-five care were estimated through interviews and record 
review using a district-level cost questionnaire. 
3. Hospital: The proportion of under-five children admitted to 
hospital during the previous year was estimated through 
interviews with a representative sample of households using a 
household survey questionnaire.80 This information was combined 
with local estimates of costs per bed-day and average length of 
stay in hospital 81;82 to estimate total costs of providing inpatient 
care for under-fives in each district. 
4. Primary facility: Primary health facility costs at government health 
facilities were estimated through interviews and record reviews 
using the facility cost questionnaire during a cross-sectional survey 
of a representative sample of health facilities (75 facilities in 
total).77;83;84  During the same survey the proportion of time health 
workers spent with under-fives and with over fives was collected 
through observation of health workers using time-and-motion 
study observation record forms.  Primary health care costs at non-
government facilities are partly represented as out-of pocket 
payments made at these facilities, collected at the household-level.  
It is not in the scope of this analysis however to determine the 
extent to which these out-of-pocket payments relate to actual cost 
per visit made at non-government facilities.  
5. Household: Out-of-pocket payments for services provided at 
facilities that were not included in the above categories, and time 
spent in seeking all types of care, were estimated through 
interviews with a representative sample of households using a 
household survey questionnaire (around 2000 households in 
total).80 
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In addition, ordinary least squares multivariate regression analysis was 
performed to explore whether  IMCI had an effect on the costs of providing 
services at health facilities, independent from the effect of other factors not 
related to IMCI such as facility size and availability of vehicles. Finally, 
sensitivity analysis was used to test the sensitivity of the results by using a 
range of values for the uncertain variables. The variables selected for 
uncertainty analysis were the useful life ofcapital inputs, district-level cost per 
child (i.e., the district component of total district cost per child), hospitalization 
rate and average number of facility visits per child per year.77 WHO CostIt85 
and STATA software86 were used for the analysis of cost data. Further detail of 
the data collection methods and analysis are given elsewhere.77 
 
 
3.2. 3  Quality control and data processing 
 
For national, district and primary health facility data, all forms were checked 
for completeness and consistency, and follow-up visits were made to re-collect 
inconsistent or incomplete data.  During the household survey, a field 
supervisor checked all forms, sat in on one or two interviews, and made 
random re-visits to a sample of households each day.  
 
Two data-entry clerks made double entries of the household survey into a 
FoxPro database system.  The two files were compared, any inconsistency was 
verified with reference to the original forms, and range and consistency checks 
were carried out regularly. Excel was used to process data on national, district 
and primary health facility costs.  Quality was checked visually and through 
range and consistency checks.  
 
 
3. 3  Results  
 
For 1999, the cost per child of caring for under-fives in the districts with IMCI 
was US$11.19, which was 44% lower than in the comparison districts 
($16.09).77 The lower cost per child in IMCI districts was due to lower 
hospitalization and administrative costs at the district level.  There was no 
difference in costs incurred at primary care facilities and at the household level 
(see Figure 3. 1).   
 
District-level costs were 50% lower  in IMCI districts, linked to less frequent 
trips for supervision and drug distribution than in comparison districts. It is 
not possible to know if the lower costs resulted from the introduction of IMCI 
or were due to external factors. Similar costs of training were observed in 
comparison and IMCI districts during the study period. This was unexpected 
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given the emphasis of IMCI on training, but a wide variety of training courses 
were performed in comparison district for preventive, curative and 
administrative issues during the study period. These included training for 
immunization, case management of malaria and use of insecticide-treated 
bednets and the use of district Health Management Information System forms. 
 
Figure 3. 1  Components of cost of under-five care per child in a standard1 
district in Tanzania (1999 US$) 
 
1 standard district with 50,000 under-fives. 
 
 
Hospital-level costs were 250% higher in comparison districts than in districts 
with IMCI, not because of differences in the cost per under-five admission, but 
because more under-fives were hospitalized in the year prior to July-August 
1999 in these districts relative to IMCI districts (6% in IMCI districts against 
15% in comparison districts, p<0.001).  Because this difference in hospital 
admissions may or may not have been related to IMCI, we also calculated total 
costs without the component of hospital costs, which resulted in a 6% lower 
cost per under-five child in districts with IMCI ($ 8.30) than in districts 
without IMCI ($ 8.76)  (Table 3. 1).   
 
At the primary health facility level, including both government health centres 
and dispensaries, IMCI facilities had a 16% lower average cost per under-five 
visit (including vaccination visits) than comparison facilities ($1.39 and  $1.61 
in IMCI and comparison districts respectively,  p=0.5). The average number of 
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visits per child per year was 30% higher in IMCI districts (3.28) compared with 
comparison districts (2.49). The lower cost per visit together with the higher 
number of visits per child per year in IMCI districts explains the similar cost 
per child at government health facilities in the two types of district.  
 
 
Table 3. 1  Differences between IMCI and comparison districts in Tanzania 
in the annual cost per child for health care, in 1999 US $. 
 
Level 
 
Average 
cost IMCI 
districts 
Average cost 
Comparison 
districts 
Difference 
in cost per 
child in IMCI 
districts 
Ratio 
Compa-
rison : 
IMCI 
National   $0.17 $0.07 $0.10 0.43 
District  $2.30 $3.35 $-1.06 1.46 
Hospital  $2.89 $7.33 $-4.44 2.54 
Primary facility  $3.16 $2.94 $0.22 0.93 
Household  $2.68 $2.40 $0.28 0.90 
Total per child 
cost $11.19 $16.09 $-4.90 1.44 
Total excluding 
hospital costs $8.30 $8.76 $-0.46 1.06 
Estimates are adjusted for a standard district with 50,000 under-fives. 
 
 
Results of the two major components of cost per visit at government facilities, 
i.e., personnel and drug costs, are presented in turn. With respect to personnel 
cost per visit, the time-and-motion study, where health workers are observed 
to record the time they spent on different activities, showed that IMCI health 
workers spent, on average, almost two more minutes per consultation with 
each under-five than did those in comparison facilities (8.2 vs 6.3 minutes, 
p=0.0003, see Figure 3. 2).  This difference was largest in health centres, which 
received only 18% of the total visits by under-fives. It is worth noting, 
however, that health centre workers did not compensate by spending less time 
with over-fives (p=0.4).  It appears, therefore, that the increase in time spent 
with children in health centres was due to a shift in the time spent in 
administrative activities or non-productive time, part of which was used to 
provide clinical services for under-fives. Because the longer time spent with 
under-fives was mainly observed in health centres, which receive a smaller 
proportion of under-five visits than dispensaries, overall, the average 
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personnel cost per under-five visit was similar between IMCI and comparison 
districts ($0.49 compared with $0.57 in comparison districts, p=0.41).  
 
 
Figure 3. 2  Comparison of average time spent per consultation visit, by 
facility type and age group, in districts with and without IMCI in Tanzania. 
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With respect to drug costs, IMCI facilities spent an average of $0.29 on drugs 
and vaccines per visit, 30% less than facilities in comparison districts, although 
because of the considerable variation in drug costs per visit, the difference was 
not statistically significant (Table 3. 2). Further analysis of drug expenditure 
showed no difference in the availability or shortage of particular drugs 
between facilities with and without IMCI. Two separate analyses of 
prescription patterns, using different sources of information from both the 
quality of care70 and costing components of the MCE study, confirmed a more 
rational use of antibiotics and injectables in IMCI facilities, suggesting higher 
efficiency and better health outcomes than in comparison facilities.   
 
The results of the regression analysis to explore the relationship between total 
costs of under-five care at health facilities and factors such as whether the 
facility had implemented IMCI, facility type (health centre or dispensary) and 
availability of vehicles are shown in Table 3. 3.  By taking into account 
differences in the other determinants of costs across facilities, the multivariate 
regression analysis increased the precision of  comparison between the two 
types of management strategies, showing that total costs of under-five care 
and the cost per under-five visit were around 30% lower in IMCI facilities 
(p<0.001).  
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Table 3. 2  Comparison of average drug costs (1999 US$) per under-five visit 
to a primary government facility in districts with and without IMCI in 
Tanzania. 
 
IMCI district Comparison district Category 
Mean  SD n Mean  SD n 
Dispensaries $0.30 $0.20 33 $0.46 $0.48 29 
Health centres $0.22 $0.19 6 $0.19 $0.11 6 
Weighted average  $0.29 $0.20 39 $0.41 $0.45 35 
Differences not statistically significant at the 0.05 level. 
 
 
Table 3. 3  Regression analysis of determinants of primary health facility 
costs; dependent variable: natural log of total costs of under-five care, in 
1999 US$ 
 
Adjusted R2 = 0.79       F-statistic = 74.41          p<0.0001             N=73  
Variable Description β coef S.E. t p 
IMCI Dummy variable, 
IMCI=1  
- 0.34 0.06 -5.22 <0.0001 
Dispensary Dummy variable, 
Dispensary=1 and 
health centres =0 
- 0.65 0.12 -5.48 <0.0001 
Vehicle 
dummy 
Dummy variable, 
facility has vehicles=1  
0.69 0.14 4.94 <0.0001 
Log visits Natural log of total 
under-five visits 
(vaccine and curative) 
0.19 0.05 3.47 0.001 
Constant  14.07 0.48 29.4 <0.0001 
Only significant variables are presented. 
 
 
Sensitivity analysis showed the importance of hospitalization costs in the 
interpretation of total district costs - the difference between IMCI and 
comparison districts was not sensitive to variation in parameters other than 
the assumption about rates of hospitalization.77  If it is believed that the 
observed difference in hospital admissions per child was not related to IMCI, 
it can be concluded that there is no difference in the cost of under-five care in 
the two types of districts.  Otherwise, the costs in IMCI districts are lower than 
in the comparison districts. 
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3. 4  Discussion and policy implications 
 
We believe this study to be the first attempt to estimate the actual cost of IMCI 
implementation in comparison with routine care.  Our estimate of the total 
economic cost of implementing IMCI and the additional cost compared to 
routine care showed that, for 1999, there is no evidence that IMCI was 
associated with higher costs.  These findings were unexpected, as IMCI has 
often been assumed to be more expensive than routine care for under-fives.74;75 
 
We found that hospital costs were a main determinant of the district cost per 
child of caring for under-fives. There are two possible explanations: (1) 
improved quality of care and drug availability for under-fives at IMCI 
primary facilities reduced the need for referral and subsequent admission to 
hospital; or (2) factors other than IMCI, such as differences in the quality of the 
hospitals in the different settings or access to them meant that children in 
comparison districts were more likely to seek care at hospitals. Even if we 
assume that this difference was entirely due to other factors, and exclude the 
hospital component from the analysis, total costs per under-five child in IMCI 
districts were still lower than in comparison districts (6%).  
 
The US$ 11.19 cost per child of treating children under five using IMCI in 
Tanzania translates into a per capita cost of $ 1.79 compared to $2.56 for 
routine care.  This is similar to previous estimates of the per capita cost of 
IMCI in resource poor countries.87 In addition, the Tanzania evaluation had 
similar findings with respect to the lower drug costs associated with IMCI as 
previous studies.88 However,  our study reaches different conclusions 
regarding staff requirements than earlier work.89  In Tanzania, health centre 
staff were able to accommodate IMCI within their usual working hours by 
reallocating part of their non-clinical or slack time to provide better care for 
under-fives.  No additional staff were required during the period of the 
study.90 
 
The effects of IMCI can be assessed in terms of changes in intermediate 
outcomes, such as improved quality of care at health facilities, or final 
outcomes such as changes in under-five mortality or DALYs averted. No 
information is yet available on the impact of IMCI on mortality.  However, 
some information on the effect in terms of intermediate outcomes is available. 
In the Tanzania evaluation, a health facility survey was carried out in 2000 to 
compare the quality of case-management and health systems support in IMCI 
and comparison districts. The results indicate that children in IMCI districts 
received better care than children in comparison districts: their health 
problems were more thoroughly assessed, they were more likely to be 
diagnosed and treated correctly as determined through a gold-standard re-
examination, and the caretakers of the children were more likely to receive 
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appropriate counselling and reported higher levels of knowledge about how 
to care for their sick children.73 In Brazil and Uganda, as well as in Tanzania, 
there is evidence of better anti-microbial prescribing patterns with IMCI than 
with routine child care.70 This suggests that IMCI is a cost-effective 
intervention in the Tanzanian setting.  It is no more costly than standard care, 
yet achieves a better outcome in terms of quality of care.  Given the evidence 
that improved health worker performance and prescription patterns lead to 
reductions in child mortality,68 it is reasonable to claim that IMCI is no more 
costly than standard care and is more effective at saving lives.68 
 
A number of qualifications should be taken into account when interpreting the 
results.  Firstly, utilisation rates for public health facilities in these districts 
were high relative to those reported from other developing countries − 41% of 
children reporting an illness in the two weeks prior to the MCE household 
survey had been taken to a public health facility as the first point of contact for 
care.80 Secondly, districts differed in ways that could affect the cost of child 
care (e.g., the number and proportion of facilities managed by non-
government organizations and under-five hospital admissions). Thirdly,  in 
the intervention districts IMCI was implemented concurrently — and because 
of — measures designed to strengthen district management such as evidence-
based planning and expenditure mapping at district level. Our findings, 
therefore, can be interpreted as the costs of IMCI in the presence of a 
strengthened health system with adequate managerial capacity. In addition, 
an ideal study design would have assessed the costs of care over a number of 
years before IMCI implementation in all four districts.  This would have 
allowed before-and-after analysis to control for any cost changes resulting 
from district-specific factors or from trends in costs or utilization over time.  
Because IMCI was already in place, in 1999 when this study commenced, this 
type of analysis was not possible. 
 
In conclusion, we found no evidence that treating children using IMCI was 
associated with higher costs than routine care. The costs are either similar or 
lower in IMCI districts depending on the interpretation of the rates of 
hospitalization in those areas. Given the evidence of improved quality of care 
in the IMCI districts, more active steps should be taken to rapidly scale up the 
adoption and coverage of IMCI. 
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Chapter 4. Effectiveness and costs of facility-
based IMCI in Tanzania   
 
 
 
Summary 
 
 
Integrated Management of Childhood Illness (IMCI) has been adopted by over 
80 countries as a strategy for reducing child mortality and improving child 
health and development. It includes complementary interventions designed to 
address the major causes of child mortality at community, health facility, and 
health system levels. The Multi-Country Evaluation of IMCI Effectiveness, 
Cost and Impact (IMCI-MCE) is a global evaluation to determine the impact of 
IMCI on health outcomes and its cost-effectiveness. The MCE is coordinated 
by the Department of Child and Adolescent Health and Development of the 
World Health Organization. MCE studies are under way in Bangladesh, 
Brazil, Peru, Tanzania and Uganda.  
 
In Tanzania, the IMCI-MCE study uses an observational design comparing 
four neighbouring districts, two of which have been implementing IMCI in 
conjunction with evidence-based planning and expenditure mapping at 
district level since 1997, and two of which are beginning IMCI implementation 
in 2002. In these four districts, child health and child survival are documented 
at household level through cross-sectional, before-and-after surveys and 
through longitudinal demographic surveillance respectively.  
 
Here we present results of a survey conducted in August 2000 in stratified 
random samples of government health facilities to compare the quality of 
case-management and health systems support in IMCI and comparison 
districts. The results indicate that children in IMCI districts received better 
care than children in comparison districts: their health problems were more 
thoroughly assessed, they were more likely to be diagnosed and treated 
correctly as determined through a gold-standard re-examination, and the 
caretakers of the children were more likely to receive appropriate counselling 
and reported higher levels of knowledge about how to care for their sick 
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children. There were few differences between IMCI and comparison districts 
in the level of health system supports for child health services at facility level.  
 
This study suggests that IMCI, in the presence of a decentralised health 
system with practical health system planning tools, is feasible for 
implementation in resource-poor countries and can lead to rapid gains in the 
quality of case-management. IMCI is therefore likely to lead to rapid gains in 
child survival, health and development if adequate coverage levels can be 
achieved and maintained.  
 
 
4. 1  Introduction 
 
More than 10 million children continue to die in the world every year.91 Just 42 
developing countries account for 95% of these deaths. Inequities in child 
survival between the rich and poor countries are unacceptably wide, as are the 
differences in survival between richer and poorer children within most 
countries.76  Although child survival globally has increased over the past 30 
years, the rate of increase peaked around 1980 and has virtually stagnated in 
sub-Saharan Africa. In some countries, child survival has even declined, and 
HIV/AIDS is only partly to blame.92  The main causes of child death in the 
world are neonatal disorders, diarrhoea, pneumonia and malaria, although 
HIV/AIDS accounts for at least 10% of child deaths in some African 
countries.91  Undernutrition is a major underlying cause, and has been 
estimated to contribute to over half of all child deaths.91  
 
Effective interventions are available that could prevent or treat over 60% of all 
child deaths.93  Yet mothers and children are not receiving these interventions: 
coverage levels remain unacceptably low.94 The Integrated Management of 
Childhood Illness (IMCI) is a strategy for improving child health and 
development through the combined delivery of essential child health 
interventions. Originally, IMCI consisted of case-management guidelines for 
sick children in peripheral first-level health facilities, to be adapted for each 
country.68  Later, the strategy expanded to include guidelines for delivering 
child survival interventions at household, community and referral levels, with 
three components: (1) improvements in case-management, (2) improvements 
in health systems, and (3) improvements in family and community practices. 
By the end of 2003, the first two components of IMCI were in the early 
implementation or expansion phase in 108 developing countries, including 
virtually all African countries south of the Sahara.95  The Multi-Country 
Evaluation of IMCI (IMCI-MCE) seeks to generate information on the 
effectiveness, cost and impact of IMCI that can be used to strengthen the 
delivery of child health interventions and the implementation of the IMCI 
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strategy, and includes in-depth studies in Bangladesh, Brazil, Peru, Tanzania 
and Uganda.96  
 
Tanzania has an under-five mortality rate of 147 per 1000 births resulting in 
almost a quarter of a million child deaths each year.97  The country has a Gross 
Domestic Product of US$501 per capita98 and is undergoing health sector and 
local government reforms. As districts gain more control over their health 
budgets, IMCI is one of the strategies recommended by the Ministry of Health 
to address major child health problems, such as malaria, pneumonia, 
malnutrition and diarrhoea, which together account for over 83% of post-
perinatal under-five deaths.99  Here we report the effectiveness of facility-
based IMCI, by which we mean the first two components of the strategy, on 
child health and survival in rural Tanzania. We compared child health, 
household-level child health behaviours, and child survival in two districts 
with facility-based IMCI and two neighbouring comparison districts without 
IMCI over the time period from 1997 to 2002. 
 
4. 2  Methods 
 
4.2. 1  Design  
 
We used a non-randomised controlled trial, or “plausibility” design,100  to 
compare child health and survival in four neighbouring rural districts of 
Morogoro and Coast Regions, southern Tanzania, in 1999 and 2002. The two 
‘IMCI districts’, Morogoro Rural and Rufiji, started to implement IMCI in 
1997-8, while the two ‘comparison districts’, Kilombero and Ulanga, started 
implementation in 2002. IMCI and comparison districts are separated by a 
large uninhabited game reserve, making population movement between 
intervention and comparison areas minimal.  Figure 4. 1 shows the timing of 
implementation of IMCI and each of the five main study components.  Firstly, 
we assessed the quality of case-management for child illness, drug and vaccine 
availability, and supervision involving case-management, through a cross-
sectional survey in a sample of health facilities from all four districts in August 
2000: detailed methods and findings are reported elsewhere, with a summary 
given here for completeness.73  Secondly, household surveys were used to 
assess child health indicators in July-August 1999 in a probability sample of 
children from all four districts,101  early in the implementation phase, and 
again three years later in July-August 2002. Thirdly, child survival in a part of 
each district was tracked through demographic surveillance102 throughout the 
study, with particular emphasis on a pre-defined two-year period from mid-
2000, by which time IMCI implementation was thought to have reached high 
enough coverage for a long enough period for an effect on child survival to be 
                                                                CHAPTER 4 
 42 
measurable. Fourth, information on contextual factors – programs and issues 
other than IMCI that might have affected child health in the four districts over 
the study period – was gathered through interviews with all health actors in 
the study districts and desk review of plans, budgets and reports, together 
with data from the child health surveys. Fifthly, we estimated the economic 
cost of child health care in IMCI and comparison districts through interviews 
and record review at national, district, facility and household levels: detailed 
methods and findings are reported elsewhere, and summarized here for 
completeness.77;84   
 
 
Figure 4. 1   Timing of implementation of IMCI and the different 
components of this study  
 
 
 
 
 
4.2. 2  Study setting 
 
Kilombero, Morogoro Rural, Rufiji and Ulanga Districts are in southern 
Tanzania and have a total population of about 1.2 million people, of whom 
200,000 are children under five years. (http://www.tanzania.go.tz/census. 
Accessed November 16, 2003). Kilombero and Rufiji are low-lying and much 
of the land is in the fertile flood plain of the Kilombero and Rufiji rivers: 
Morogoro Rural and Ulanga have mountainous areas as well as low-lying 
plains. There are two main rainy seasons, October-December and February-
May. There is a broad mix of ethnic groups although Swahili, the national 
language, is widely spoken. The majority of people are subsistence farmers. 
Most dwellings have wood-framed mud walls with thatched or corrugated 
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roofs. Most rural roads are unpaved and transport can be difficult in the rainy 
season. The public health system has a network of hospitals, health centres 
and dispensaries, with 3,300 to 7,000 people served by each facility. Over 70% 
of the population live within 5km of a health facility. Utilisation of health 
facilities is relatively high, with routine Health Management Information 
System reports suggest 3.0 under-five visits per child per year for curative care 
in 1999. Malaria, pneumonia and waterborne diseases such as cholera and 
diarrhoea are the major health problems of the area as reported through the 
health services and as perceived by local people. For Tanzania as a whole, per 
capita expenditure on health was USD 11.37 in 1999-2000, including private, 
out-of-pocket expenses.103 Monthly total per capita household consumption 
and expenditure in 2001 was around $10, of which around 70% was for 
food.104 
 
 
4.2. 3  IMCI implementation  
 
Implementation of IMCI in Tanzania is described elsewhere.73 Briefly, the 
Tanzania Ministry of Health began IMCI implementation in 1996, and adapted 
generic IMCI case-management guidelines to reflect national child health 
policies (e.g., first- and second-line treatments for malaria and pneumonia) 
and local terms for illness symptoms and providers. All materials were 
translated into Swahili and used as the basis for preparing national and district 
level trainers. The target audience for the 11-day training was all health 
workers in first-level health facilities who provide case-management to 
children. The majority of these health workers have a 2-3 year training in 
clinical medicine following primary education: around a quarter have public 
health training following primary education. Through local government and 
health sector reforms, local councils have increased autonomy and control 
over their own health budgets and plans, and they have access to a limited 
amount of donor-supported “basket” funding from the health Sector-Wide 
Approach (SWAp)105 (The term “council” refers to the local government of 
both rural districts and urban municipalities). The Council Health 
Management Team (CHMT) of Morogoro Rural and Rufiji Disticts decided to 
adopt IMCI, and to give highest priority to its introduction and 
implementation, based on evidence available to them from a sentinel burden-
of-disease information tool and a district health budget mapping tool 
developed by the Tanzania Essential Health Interventions Project (TEHIP).106 
In addition TEHIP provided financial resources to districts of approx $0.92 per 
capita per year to simulate sector-wide “basket” funding105 three years in 
advance of the actual start of “basket” funding. CHMTs of Morogoro Rural 
and Rufiji reported that over 80% of health workers managing children in first-
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level facilities had been trained in IMCI by mid-2000 based on an 11-day 
course with approximately 30% of the training time spent in clinical practice.  
 
 
4.2. 4  Health Facility Survey 
 
 Detailed methods are given elsewhere.73  A representative sample of 75 health 
facilities was selected from government dispensaries and health-centres. 
Within chosen health facilities, the first 6 sick children aged 2 to 59 months 
attending on the day of the survey for an initial visit for any illness, and whose 
mother consented, were eligible for inclusion. Through observation of case-
management, exit interviews with caretakers, re-examination and interviews 
with health care providers we collected information on 29 indicators relating 
to assessment, classification and treatment of the child, counselling and 
communication with the mother, and health systems support.  
 
 
4.2. 5  Household surveys  
 
Detailed information on the 1999 survey is given elsewhere.101  Briefly, a 
representative cluster sample of approximately 2,300 rural households was 
taken from the four districts in July-August 1999. Thirty rural clusters, each of 
20 households, were chosen from three of the four districts and 25 rural 
clusters of 20 households were chosen from the fourth district, Kilombero, 
using a modified EPI-type scheme107 that ensured an equal probability of 
selection for every household. A modular questionnaire about the health of all 
children under five years was administered to consenting household heads, 
generating information on household-level child health indicators as agreed 
by an inter-agency working group on IMCI including representatives from 
WHO, UNICEF, the United States Agency for International Development 
(USAID), the US Centers for Disease Control, and the USAID-funded BASICS 
Project.  Information on proxy markers of household socio-economic status 
was collected, such as household ownership of a radio, a tin roof, a bicycle, 
and the education and occupation of the household head. Mothers or carers 
(here we use the term ‘mother’ to denote the main carer) of all children under 
five years were then interviewed about their educational level, whether or not 
the child was currently breastfed and if so what other food or drink the child 
had received over the previous 24 hours. Information on routine vaccinations 
was documented either directly from health cards or, where no health card or 
other written record was available, according to the mothers’ recall. Mothers 
were asked whether the child had received vitamin A supplementation, and if 
so, how many months ago. Mothers were then asked about any illness each 
child had during the 2 weeks prior to the survey, and what action had been 
taken. For children who had been sick, further modules elicited detailed 
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information about utilisation of appropriate (non-traditional) health care 
providers including village health workers, dispensaries, health centres, 
hospitals, or private doctors. Information on the care the child received at each 
such provider, and any other treatments the child had taken, was collected. 
Special attention was given to the care of children with danger signs: those 
with fast or difficult breathing, fits or convulsions, very sleepy, vomiting 
everything, or unable to drink/breastfeed.73 Children were invited to attend a 
measuring station set up in the middle of the village where they were weighed 
on digital scales (Seca Vogel & Halke GmbH & Co, Hamburg, Germany) and 
their height (≥2 years) or length (<2 years old) was measured using purpose-
made instruments. A generic version of the questionnaire is available from the 
authors on request. 
 
In July-August 2002, a similar follow-up survey was done. Households were 
selected from the same villages (clusters) as in 1999. Within selected villages, 
the chance of visiting the same household was small: a single sub-village 
(kitongoji) was chosen at random and 20 households selected. Care was taken 
to ensure that no survey staff visited a village that they had worked in during 
the earlier survey. The questionnaire was translated to Swahili, back 
translated, pre-tested, and pilot-tested. Quality control measures in each 
cluster included supervisors accompanying 1-3 interviews; households 
reported to be empty were visited by a supervisor; up to 2 mothers bringing 
their children to be weighed and measured were re-interviewed by a 
supervisor, with information from the two interviews compared and 
discrepancies discussed and resolved with the original interviewer; and 
weight and height measurements were repeated for up to 2 children.  
 
 
4.2. 6  Analysis of household survey data   
 
Weight for age, height for age and weight for height Z-scores were calculated 
with reference to the US National Centers for Health Statistics (NCHS) 
standards using the EPINUT module of EPI-Info v6.0 (CDC Atlanta, Georgia, 
US). Underweight, stunting and wasting were defined respectively as weight-
for-age, height-for-age and weight-for-height z-scores of less than –2, 
excluding outliers (z-score of <-5 or>3).  Because stunting is most prevalent at 
ages 24-59 months, and wasting at 12-23 months,108 analyses were carried out 
for these subgroups. Data was processed in FoxPro (v2.6, Microsoft 
Corporation, Seattle, WA, USA) and analysed in Stata,86 following an 
analytical plan which had previously been agreed by the investigators. All 
analyses were adjusted for clustering was made using standard STATA 
commands such as svymean and svylogit. P-values should be interpreted with 
caution given the non-randomised study design and the large number of tests. 
We did significance testing to look for evidence of four types of differences: (1) 
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between IMCI and comparison districts in each of the two surveys; (2) 
between 1999 and 2002 for all 4 districts combined;  (3) between IMCI and 
comparison areas, combining 1999 and 2002 data; and (4)  whether the 
difference between IMCI and comparison districts changed on average 
between 1999 and 2002, ie. for an interaction between IMCI and time. The 
latter effects are potentially IMCI-attributable, provided there were no 
contextual factors that explained them.  
 
 
4.2. 7  Demographic surveillance 
 
As routine registration of births and deaths in Tanzania is uncommon, we 
used demographic surveillance systems (DSS) to measure child survival in a 
part of each of the four districts. These systems are described in detail 
elsewhere102  a brief overview is given here.  
 
Kilombero and Ulanga districts. The DSS started in 1996 with a baseline census in 
a population of 52,000, covering 6 contiguous villages of Kilombero district 
(10% of the district population) and 12 contiguous villages of Ulanga (16%). 
These areas are not a representative sample of either district. Since January 
1997, an interviewer – one of about 40 full-time staff – has visited each 
household every four months and collected information on pregnancies, 
births, deaths and migrations, using the household registration system 
(HRS).109 Births and deaths are also reported  on a continuous basis by key 
informants based in each kitongoji. Extensive quality control measures include 
repeat interviews in a randomly selected 10% of all households. Data from 
each week’s work is used to update the HRS database before a weekly field 
meeting.  Checking programs are run and queries referred back to the field 
team for correction within 2 weeks of the original interview. 
 
Rufiji district. Field procedures, quality control and data management are 
similar to those in Kilombero and Ulanga DSS (above). Rufiji DSS started in 
1998 with a baseline census in a population of about 70,000 people covering 32 
villages (44% of the district population).  
 
Morogoro Rural district. Demographic and mortality surveillance began in 1992 
with an initial census, which has since been repeated annually in about 85,000 
people in 50 villages (16% of the district population). Continuous mortality 
surveillance provides information on numbers and probable causes of death 
using ‘verbal autopsies’. About 70 villagers act as enumerators for the annual 
census update, and as key informants for reporting deaths, each of which is 
followed up by one of 4 clinical officers from the CHMT. Data entry uses a 
tailor-made FoxPro database system. Data quality is assured by checks in the 
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field, during and after data entry.  Supervisors visit a random sample of 
households to verify entries on the census forms, to check that all households 
visited have been included in the census, and that no non-existent households 
have been included.  Following each census re-interviews of a sample of 
households for each enumerator are conducted.  
 
 
4.2. 8   Analysis of mortality data 
 
 Our primary focus was to compare mortality over the two-year period 
starting in mid-2000, by which point IMCI implementation was thought to 
have reached sufficient sustained coverage for any effect on child survival to 
be measurable, as judged by an independent review panel. Following an 
agreed analytical plan, we compared under-five mortality rates per 1000 
children per year between IMCI and comparison areas from mid-2000 to mid-
2002, checking for any differences in 1999, which served as a baseline for the 
mortality analysis. Adjustments for age (0-1 and 1-4 years) and rainfall 
(estimated from remote sensing data) were made using Poisson regression 
models, and the between-district differences compared using t-test-based 
methods of adjusted residuals, as appropriate for clustered data with a small 
number of clusters.110  With only four districts, p-values from this approach 
are likely to be conservative and we also calculated p-values from Poisson 
regression ignoring between-district variation. Secondary analysis made use of 
all available DSS data to summarise longer-term trends in child survival in 
relation to IMCI. We used Poisson regression for the data from each DSS area 
separately, testing for the size and statistical significance of the trend in 
mortality rates over time. Due to data completeness problems, analysis was 
repeated with and without Morogoro data for the year 2000.  
 
 
4.2. 9  Contextual factors  
 
We summarised factors other than IMCI that may have affected child health in 
the four districts, with emphasis on those that might have changed over the 
study period, including geographic, environmental and demographic features, 
health care infrastucture and activities, and other health-related programs, 
activities or events (including disasters, famines, etc). These factors were 
related to quantifiable indicators from the household surveys. In addition to 
using data from the household surveys, we contacted around 40 health actors 
in the four study districts, including CHMT’s, TEHIP, non-governmental 
organisations, religious Missions, bilateral and multilateral aid organisations. 
Information on routine health care delivery and other relevant activities was 
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systematically collated from written reports and interviews with key 
informants.  
 
 
4.2. 10  Economic costs 
 
Detailed methods are given elsewhere.77;84  Briefly, cost data were collected for 
the start-up period of implementing IMCI (1996 to 1997) and for maintaining 
under-five health services including IMCI subsequently. Costs were estimated 
from the societal perspective and were collected from the national, district, 
hospital, health facility and household levels. Among those included were 
drugs and vaccines; training costs attributable to under-five care, including 
but not restricted to IMCI; the annualized cost of capital items; and the 
opportunity cost of staff time spent in consultation with under-fives (assessed 
through a time-and-motion study) and time spent attending meetings and 
performing supervision visits. Household costs included travel and out-of-
pocket expenditures to obtain care for under-fives but did not include a 
monetary value of time lost in seeking care. Costs at all these levels were 
summed to obtain the total cost to the district of providing care for under-
fives.  To allow comparison across districts, cost estimates were standardized 
to a hypothetical district with a population of 50,000 under-fives. Estimates of 
the additional cost to the district of implementing IMCI were based on the 
difference in cost of under-five care between the standardized IMCI and 
comparison districts. 
 
 
4. 3  Results  
 
4.3. 1  Quality of care measured through the health facility survey 
 
The introduction of facility-based IMCI was associated with improved quality 
of care as measured through the health facility survey in August 2000, after the 
end of the IMCI phase-in (Figure 4. 1). Nearly all children observed in the 
IMCI facilities were checked for cough, diarrhoea and fever (95% of 231), 
compared with 36% of 188 children in the comparison districts (p<0.001; Table 
4. 1).73 In IMCI districts, 63% of sick children were correctly classified 
compared with 38% in the comparison districts (p<0.0001). Drug availability 
was reasonably good and comparable in IMCI and comparison areas at the 
time of the survey (Table 4. 1, p=0.47). However, more than twice as many sick 
children needing oral antibiotics and/or oral antimalarials were prescribed 
them correctly in the IMCI districts, compared with the comparison districts 
(73% vs 35%; p<0.001). Over 70% of caretakers in the IMCI districts who had 
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received a prescription for Oral Rehydration Salts (ORS), oral antibiotic or an 
oral antimalarial, reported correctly at the facility exit how to give the 
treatment, compared to 56% of those in comparison districts (p=0.02). 
Supervisory visits that included observation of case-management were more 
common in IMCI districts than in comparison districts, with over half of IMCI 
facilities having had such a visit in the 6 months before the survey, compared 
with 21% of comparison facilities (p=0.007). Follow-up visits after IMCI 
training were not included in these calculations. IMCI facilities were 
significantly better than, or comparable to, comparison facilities for all but one 
indicator out of a total of 29.  
 
 
Table 4. 1  Selected indicators showing quality of care and health systems 
support in IMCI and comparison districts in August 200073 
 
IMCI Comparison 
 Morogoro 
& Rufiji % 
Ulanga & 
Kilombero% 
P-
value* 
 Child checked for the presence of 
cough, diarrhoea, and fever 
95%  
n=231 
36% 
n=188 
<0.001 
Child correctly classified 63%  
n=219 
38% 
n=176 
<0.001 
Child needing an oral antibiotic 
and/or an oral antimalarial is 
prescribed correctly 
73%  
n=219 
35%  
n=178 
<0.001 
Caretaker of child who received a 
prescription for an oral medication** 
reports correctly at facility exit how 
to give the treatment 
72% 
n=225 
56% 
n=179 
0.02 
Index of availability of essential oral 
treatments (mean) 
0.93 
n=39 
0.95 
n=35 
0.47 
Health facility received at least one 
supervisory visit that included 
observation of -case management 
during the previous six months (%) 
51%  
n=37 
21% 
n=34 
0.007 
* F-tests comparing areas with and without IMCI, unless otherwise stated 
**ORS and/or oral antibiotic and/or antimalarial 
 
 
4.3. 2  Household surveys 1999 and 2002 
 
In 1999, data was available from 2,006 children under 5 years of age living in 
1,321 households with children under-five in the 120 rural clusters, 
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representing 93% of eligible households.101 In the 2002 survey, 1,932 children 
were identified living in 1,341 households with children under-five within the 
same villages, representing 94% of eligible households (residents of 142 (6%) 
households were away and 9 (0.4%) households refused to take part). The age 
profile of children involved in the two surveys was similar, with 24% and 21% 
of children being under one year of age in 1999 and 2002 respectively.  
 
Appropriate care-seeking, home management, caretaker knowledge, nutrition, 
and feeding: Just over one-third of all children were reported by their carers as 
having been ill in the two weeks preceding the survey in 1999 and 2002 
respectively (36%,  717/2,006 in 1999 and 35%, 678/1,932 in 2002). Of these, 
42% sought care from an appropriate health care provider in 1999, compared 
with 36% in 2002 (Table 4. 2, p=0.02). There was no evidence of any difference 
in care-seeking between IMCI and comparison districts (p=0.45), and neither 
was there any evidence of a differential change in care-seeking between IMCI 
and comparison districts over time (p=0.36). Care-seeking was generally more 
common for children reported as having had danger signs: in 1999, 53% 
(86/162) of such children had reportedly been taken to an appropriate 
provider in IMCI districts, and 68% (100/147) in comparison districts. In the 
2002 survey, care-seeking for children with danger signs had risen slightly in 
the IMCI districts to an average of 55% (78/142) and had dropped in 
comparison districts to 43% (49/113) (p=0.006 for the differential change over 
time). Over 10% (200/1971) of children had been admitted to a health facility 
in the year before the 1999 survey, with this being more common in the 
comparison districts than in the IMCI districts (14% 139/976 and 6% 61/995, 
p=<0.001). Although this difference persisted in the 2002 survey,  it was much 
less marked as hospital admissions had risen by 1% on average in the IMCI 
districts, and dropped by 3% in the comparison districts (p=0.002 for the 
differential change between IMCI and comparison areas). 
 
Among children sick with diarrhoea in the 2 weeks before the survey, the use 
of oral rehydration solution (ORS) showed large variations between the 
districts, from 6% to 41%. Despite this, ORS was consistently more common in 
IMCI than comparison areas in both surveys (p=0.03 in 1999 and p=0.01 in 
2002).  
 
Appropriate home management of disease, measured in part by the 
proportion of children sick on the day of the survey who had received 
increased fluids and continued feeding, was under 10% in all districts and 
both surveys. Nevertheless there was evidence of differential improvement in 
the IMCI districts compared to comparison areas (p=0.05), with IMCI districts 
increasing by 4% on average between 1999 and 2002, and the comparison areas 
decreasing by 1%. 
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In 1999, more than one-fifth of carers knew at least two signs for seeking care 
immediately, and this knowledge increased in all districts by 2002 to around 
one-third of carers (p<0.001 for the average change over time). There was no 
evidence of a differential change in such knowledge between IMCI and 
comparison districts (p=0.93). 
 
Anthropometric indicators of nutritional status show that underweight is 
common in the study area, with 28% of all children affected in 1999 
(526/1852). The prevalence of underweight had dropped in all districts by 
2002, to 22% (394/1826;  p<0.0001). Underweight affected 4 - 5% more children 
in the IMCI districts than in the comparison districts in both years (p=0.03).  
Wasting was found in 11% of children aged 12-23 months in 1999 (42/367) and 
dropped to 6% (23/368) children in 2002 (p=0.02), with no evidence of 
differences between IMCI and comparison areas (p=0.43), nor a differential 
change over time (p=0.79). Stunting affected 60% (297/497) of children aged 
24-59 months in IMCI districts in 1999, about 10 percentage points more than 
in comparison areas (51%; 247/483; p=0.04). By 2002, however, children in 
IMCI areas had “caught up”, and stunting was comparable in IMCI and 
comparison areas (43% (191/477) vs 40% (249/585); p=0.07 for the differential 
change over time). When expressed as a mean height-for-age z-score in 
children aged 24-59 months, the differential change between IMCI and 
comparison districts reached conventional statistical significance (p=0.05, 
Table 4. 2). 
 
Exclusive breastfeeding in children under 4 months of age was practiced by 
23% (41/180) of mothers in 1999, rising to 27% (22/119) by 2002 (p<0.0001). 
For children aged 6-9 months, 93% (141/152) received breast milk and 
complementary feeding in 1999, rising to 99% (154/156) by 2002 (p=0.008). 
Neither of these breastfeeding indicators showed evidence of a difference 
between IMCI and comparison districts (p=0.69, p=0.23), nor of a differential 
change over time (p=0.89, p=0.26). Breastfed one-year-old children in IMCI 
districts received an average of 2.7 meals each day in 1999, compared to 3.0 in 
comparison areas (p=0.05). By 2002, these differences were no longer evident, 
and children in IMCI districts were receiving an average of 3.1 meals per day, 
similar to the average number of 3.2 meals given to children in comparison 
areas (p=0.03 for the differential change over time). 
 
                                                
 
Table 4. 2  Indicators of feeding, nutrition, caretaker knowledge, home management of disease, utilisation and care in 
1999 and 2002 
 
DISTRICT P-values  INDICATOR YEAR 
Morogoro 
Rural 
(IMCI) 
Rufiji 
(IMCI) 
Ulanga 
(No 
IMCI) 
Kilombe-
ro 
(No IMCI) 
IMCI vs 
compa-
rison 
areas 
Change 
over 
time 
1999 to 
2002 
Difference 
between 
IMCI and 
comparison 
Difference 
between IMCI 
and comparison 
changed over 
time 
4.2.1. UTILISATION & CARE  
1999 36% (n=239) 
46% 
(n=273) 
38% 
(n=273) 
47% 
(n=229) 0.81 CS28. Appropriate care-
seeking 
2002 32% (n=229) 
45% 
(n=302) 
35% 
(n=276) 
31% 
(n=151) 0.17 
0.02 0.45 0.36 
1999 51% (n=78) 
55% 
(n=84) 
62% 
(n=74) 
74%  
(n=73) 0.02 AI21. Care-seeking rate for 
children with danger signs 
2002 48% (n=64) 
60% 
(n=78) 
46% 
(n=71) 
38%  
(n=42) 0.15 
0.05 0.54 0.006 
1999 7% (n=450) 
5% 
(n=545) 
12% 
(n=570) 
17% 
(n=406) <0.001 AI19. Proportion of children admitted in last 
year* 2002 9% (n=503) 
6% 
(n=547) 
11% 
(n=504) 
13% 
(n=360) 0.06 
0.45 0.002 0.002 
1999 13% (n=45) 
38% 
(n=40) 
15% 
(n=48) 
6%  
(n=47) 0.03 AI33. ORS use among 
children with diarrhoea 
2002 14% (n=42) 
41% 
(n=54) 
27% 
(n=55) 
8% 
 (n=26) 0.01 
0.31 0.08 0.07 
  
DISTRICT P-values  INDICATOR YEAR 
Morogoro 
Rural 
(IMCI) 
Rufiji 
(IMCI) 
Ulanga 
(No 
IMCI) 
Kilombe-
ro 
(No IMCI) 
IMCI vs 
compa-
rison 
areas 
Change 
over 
time 
1999 to 
2002 
Difference 
between 
IMCI and 
comparison 
Difference 
between IMCI 
and comparison 
changed over 
time 
4.2.2.      HOME MANAGEMENT OF DISEASE 
1999 1% (n=136) 
5% 
(n=125) 
9% 
(n=140) 
6%  
(n=107) 0.02 CP15. Sick child (today) 
receives increased fluids 
and continued feeding 2002 8% (n=133) 
5% 
(n=117) 
8% 
(n=149) 
4% 
 (n=76) 0.89 
0.31 0.23 0.05 
4.2.3.      CARETAKER KNOWLEDGE 
1999 24% (n=316) 
19% 
(n=357) 
21% 
(n=385) 
26% 
(n=286) 0.54 CP17. Caretaker knows at least two signs for seeking 
care  immediately 2002 33% (n=384) 
27% 
(n=400) 
32% 
(n=379) 
38% 
(n=284) 0.16 
<0.001 0.11 0.93 
4.2.4. FEEDING & NUTRITION 
1999 29% (n=429) 
32% 
(n=518) 
28% 
(n=559) 
23% 
(n=344) 0.10 CP4. Low weight for age 
2002 23% (n=483) 
24% 
(n=518) 
22% 
(n=494) 
16% 
(n=331) 0.07 
<0.0001 0.03 0.45 
1999 -1.29 (n=429) 
-1.32 
(n=518) 
-1.29 
n=559) 
-1.13 
n=344) 0.38 CP5. Mean weight for age 
z-score 
2002 -1.21 (n=483) 
-1.22 
(n=518) 
-1.13 
n=494) 
-0.91 
n=331) 0.007 
<0.0001 0.04 0.92 
CS2-JP. Stunting  
prevalence in children aged 1999 
61% 
(n=233) 
59% 
(n=264) 
54% 
(n=303) 
46% 
(n=180) 0.04 <0.0001 0.07 0.07 
                                                
 
DISTRICT P-values  INDICATOR YEAR 
Morogoro 
Rural 
(IMCI) 
Rufiji 
(IMCI) 
Ulanga 
(No 
IMCI) 
Kilombe-
ro 
(No IMCI) 
IMCI vs 
compa-
rison 
areas 
Change 
over 
time 
1999 to 
2002 
Difference 
between 
IMCI and 
comparison 
Difference 
between IMCI 
and comparison 
changed over 
time 
24-59 months 2002 42% (n=289) 
44% 
(n=296) 
45% 
(n=282) 
32% 
(n=195 0.45 
1999 -2.25 (n=233) 
-2.27 
(n=264) 
-2.07 
n=303) 
-1.87 
n=180)  CS4-JP. Mean height for age z- score for children 
aged 24-59 months 2002 -1.83 (n=289) 
-1.84 
(n=296) 
-1.92 
n=282) 
-1.47 
n=195)  
<0.0001 0.02 0.05 
1999 17% (n=72) 
9%  
(n=95 
9% 
(n=115) 
13% 
 (n=85) 0.52 CS3-JP. Wasting prevalence in children aged 
12-23 months 2002 5% (n=91) 
8% 
(n=100 
6% 
(n=110) 
4%  
(n=67) 0.66 
0.02 0.43 0.79 
1999 25% (n=52) 
17% 
(n=59) 
26% 
(n=42) 
26% 
 (n=27) 0.46 CP1. Child under 4 months of age is exclusively 
breastfed 2002 23% (n=30)  
22% 
(n=36) 
30% 
(n=30) 
35%  
(n=23) 0.34 
<0.0001 0.69 0.89 
1999 83% (n=30) 
94% 
(n=49 
98% 
(n=41 
94% 
 (n=32 0.17 CP2. Child aged 6-9m receives breast milk & 
complementary feeding 2002 97% (n=38) 
100% 
(n=43 
97% 
(n=39) 
100% 
(n=36) 0.96 
0.008 0.23 0.26 
1999 2.6 (n=67) 
2.8 
 (n=87 
2.8 
(n=98) 
3.2  
(n=82) 0.05 AI3. Mean meal frequency 
for breastfed 1-year-olds  
2002 2.9 (n=81) 
3.3 
 (n=98 
3.1 
(n=99) 
3.2 
( n=57) 0.61 
0.01 0.06 0.03 
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4.3. 3  Survival  
 
Mortality levels in children under five years, from the area of each district 
under demographic surveillance, are shown in Table 4. 3. In the period from 
July 1999 to June 2000, during the phase-in of IMCI, under-five mortality was 
27.2 per 1000 per year and 27.0 per 1000 per year in IMCI and comparison 
districts respectively, giving a rate ratio of 1.01 and a rate difference of 0.2 
deaths per 1000 children per year.  Over the two following years, from July 
2000 to June 2002,  mortality levels were 13% lower in the IMCI districts than 
in the comparison districts (rate ratio = 0.87), corresponding to a rate 
difference of 3.8 fewer deaths per 1000 children per year associated with IMCI. 
Adjusting for the difference between the areas in 1999, this corresponds to an 
adjusted rate ratio of 0.86, almost identical to the unadjusted value. 
Adjustments for age (0-1 and 1-4 years) and estimated rainfall were made 
using Poisson regression models, but had no effect on the estimated rate ratio 
(data not shown). Ignoring between-district variation, the confidence interval 
for the 13% reduction in mortality associated with IMCI was (5%, 
21%)(p=0.004 from likelihood-ratio χ2 -test). Allowing for variation between 
districts and using a Normal approximation based on the log rate ratio, the 
confidence interval was (-7, 30) (p=0.28 using a t-test).  
 
Table 4. 3  Mortality levels from July 2000-June 2002.  
 
Time 
period 
District Deaths  Child-
years 
Death 
Rate 
(/1000 
child-yrs) 
Rate 
Ratio 
 
Rate 
Difference 
(/1000/yr) 
   Morogoro 252 11,303 22.3   
   Rufiji 387 12,212 31.7   
IMCI districts 639 23,516 27.2 1.01 0.2 
   Kilombero 146 4,687 31.1   
   Ulanga 96 4,289 22.4   
July 
1999-
June 
2000 
Comparison 
districts 
242 8,977 27.0   
   Morogoro 522 23,985 21.8   
   Rufiji 698  25,979 26.9   
IMCI districts 1,220 49,964 24.4 0.87 3.8 
   Kilombero 362 12,685 28.5   
   Ulanga 257 9,280 27.7   
July 
2000-
June 
2002 
Comparison 
districts 
619  21,965 28.2   
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Additional mortality data were available from some of the DSS sites from 
January 1997 until December 2002 (Figure 4. 2). We used all available data 
from complete years to assess trends over time in each district. This analysis 
found no evidence of a change over time in under-five mortality in one of the 
two comparison districts, Kilombero, over the six years from January 1997 to 
December 2002, where there was an estimated 2% annual increase in under-
five mortality rate, 95% CI (-2%, 6%), p=0.23). In the second comparison 
district, Ulanga, there was an annual decrease in under-five mortality of 6% 
(95% CI 2,10) , p=0.002) (Figure 4. 2). In districts with IMCI, data was less 
complete, but analysis of all available data for whole calendar years showed 
an annual drop of 11% in mortality in Rufiji district between 1999 (February) 
until December 2002 (95% CI 7, 16;  p<0.0001), and an annual drop of 14% 
from January 1997 until December 2001 in Morogoro Rural district (95% CI 11, 
17, p<0.0001). Due to data completeness problems, the Morogoro Rural 
analysis was repeated without data from the year 2000, and found an 11% 
annual drop in under-five mortality (95% CI 8, 15, p<0.0001). 
 
Figure 4. 2  All-cause mortality in children under five years of age, from 
1997-2002.  
 
0
10
20
30
40
1997 1998 1999 2000 2001 2002
D
ea
th
s 
pe
r 1
00
0 
pe
r y
ea
r
Morogoro (IMCI)
Rufiji (IMCI)
Ulanga
Kilombero
IMCI Phase-in
 
 
 
 
 
 
 
 
CHAPTER 4 
 57 
4.3. 4  Contextual factors 
 
The desk reviews of plans, budgets, reports, and expenditure, and interviews 
with health actors suggested a number of factors other than IMCI relevant to 
child health which differed between IMCI and comparison districts. We were 
particularly concerned to identify those factors which might account for the 
observed differential changes in survival between IMCI and comparison 
districts, ie. factors which changed rapidly, and differentially, over the study 
period. The factors identified were limited to malaria control efforts, 
vaccination programmes, and vitamin A supplementation coverage.  
 
For children who had fever in the two weeks before the 1999 household 
survey, 42% (300/717) had been given an antimalarial drug (Table 4. 5). In 
2002, only 28% of such children had received an antimalarial drug (p<0.0001), 
with no evidence of differential change in IMCI and comparison districts 
(p=0.35). In 1999, the majority of these children (85%) received chloroquine, 
whereas in 2002 the most commonly used drugs were SP (53%), quinine (24%) 
and amodiaquine (17%).  A second malaria control effort that differed between 
the districts was that of social marketing of treated mosquito nets, and we 
were also concerned that coverage of untreated nets purchased through the 
private sector might also have changed differentially. Use of untreated nets the 
night before the 1999 household survey varied markedly between districts, 
from 14% (64/449) in Morogoro rural district (IMCI) to 59% (236/399) in 
Kilombero district (without IMCI). Coverage increased dramatically in all four 
districts by 2002, reaching 85% (299/352) in Kilombero and 35% (175/500) in 
Morogoro rural. Although the coverage increase was larger in IMCI than 
comparison districts when measured as a ratio of 2002 / 1999 coverage (1.95 
compared with 1.57; p=0.03), coverage remained significantly higher in 
comparison districts than in IMCI districts in 2002 (66% (567/856) on average 
in comparison districts compared with 41% (429/1047) in IMCI districts; 
p<0.0001).  Use of nets that had been treated in the 6 months before the survey 
was uncommon in all districts in 1999, at less than 7%, and increased in all 
districts by 2002, by 4 to 14 percentage points, with no evidence of a 
differential change between IMCI and comparison areas over time (p=0.14). 
Although vaccine coverage was generally high (over 80%) in all districts and 
during both surveys, there was evidence of a small drop in coverage of BCG 
vaccine between the two surveys, from 97% to 96% (p=0.02). We also found a 
differential decline in coverage of DPT vaccine from the 1999 level of 86% 
(342/397). In 2002, DPT coverage increased to 95% (176/185) in the 
comparison districts but had dropped to 82% in the IMCI districts (p=0.03 for 
the differential change over time). Vitamin A coverage was only 14% in 1999, 
and comparable in IMCI and comparison areas. In 2002 coverage had 
dramatically increased in all districts, to an average of 76% (p<0.0001), with no 
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apparent difference between the districts (p=0.73) nor any evidence of a 
differential change over time (p=0.98).  
 
For vaccination coverage and malaria control efforts, the higher coverage in 
comparison districts would have tended to negate any apparent effect of IMCI 
on child survival. For Vitamin A, levels were similarly low in all four districts 
in 1999 and rose equally by 2002, and cannot therefore account for the greater 
drop in mortality in the IMCI areas over the study period.  
 
4.3. 5  Economic costs of under-five care 
 
IMCI was not associated with higher economic costs than conventional care. In 
fact, the reverse was found: the cost of under-five care per child was estimated 
at $11.19 in IMCI districts and $16.09 in comparison districts (Table 4. 4).77;84 
The major components of cost were at district, hospital, primary facility and 
household levels, with the estimate of hospital-level costs in the comparison 
districts accounting for almost half of total cost of under-five care per child 
(46%). Since we would not have expected IMCI to have affected hospital-level 
costs to such an extent, and because access to hospitals was better in 
comparison than in IMCI districts, we re-calculated the cost of under-five care 
per child without the hospital component, and found similar total costs per 
child in IMCI and comparison areas ($8.30 in the IMCI districts, $8.76 in the 
comparison areas). 
 
Table 4. 4  Cost of under-five care per child, in standardised districts of 
50,000 under-fives, with and without IMCI. Costs are in Tanzanian shillings 
(US$ in brackets) (refer to  Chapter 3) 
 
Standardised 
district with 
IMCI 
Standardised 
district without 
IMCI 
Level 
 
  Tsh          (US$) 
% 
  Tsh          (US$) 
     % 
National      129          (0.17) 1       55         (0.07) 0 
District  1,784          (2.30) 21  2,605         (3.35) 21 
Hospital 2,243          (2.89) 26  5,692         (7.33) 46 
Primary-facility 2,455          (3.16) 28  2,283         (2.94) 18 
Household  2,083          (2.68) 24  1,867         (2.40) 15 
Total 8,695         (11.19) 100 12,503       (16.09) 100 
Total excluding 
hospital costs 
6,452         (  8.30)    6,810        (8.76)  
  
Table 4. 5  Indicators reflecting programs and issues other than IMCI that may have affected child health and survival 
over the study period. 
 
DISTRICT P-values  
INDICATOR YEAR Morogoro 
Rural 
(IMCI) 
Rufiji 
(IMCI) 
Ulanga 
(No 
IMCI) 
Kilombero 
(No IMCI) 
IMCI vs 
compa-
rison 
areas 
Change 
over 
time 
1999 to 
2002 
Difference 
between 
IMCI and 
comparison 
Difference 
between 
IMCI and 
comparison 
changed 
over time 
1999 39% (n=174) 
40% 
(n=199) 
32% 
(n=180) 
58% 
(n=164) 0.23 CP16. Child with fever receives antimalarial 
drug 2002 31% (n=177) 
25% 
(n=217) 
24% 
(n=178) 
35% 
(n=107) 0.86 
<0.0001 0.33 0.35 
1999 14% (n=448) 
27% 
(n=543) 
31% 
(n=565) 
59% 
(n=397) <0.001 AI36. Child sleeps 
under net  2002 35%  n=500) 
46% 
(n=547) 
53% 
(n=504) 
85% 
(n=352) <0.0001 
<0.0001 <0.0001 0.03 
1999 3%  (n=448) 
3% 
(n=543) 
5% 
(n=565) 
7% 
 (n=397) 0.10 CP10. Child sleeps 
under treated net 
(treated in the last 6m) 2002 8%  (n=500) 
16% 
(n=547) 
9% 
(n=504) 
21% 
(n=352) 0.54 
<0.0001 0.22 0.14 
1999 88% (n=368) 
93% 
(n=440) 
87% 
(n=497) 
88% 
(n=331) 0.23 
CP6. Anemia in 
children >=6m 
(Hb<11.0 g/dL) 
 2002 
81% 
(n=434) 
86% 
(n=476) 
84% 
(n=452) 
69% 
(n=309) 0.06 
<0.0001 0.07 0.67 
AI13. BCG vaccine 
coverage (informed or 1999 
100% 
(n=80) 
94% 
(n=100) 
95% 
(n=118) 
99%  
(n=98) 0.97 0.02 0.94 0.97 
                                                                                         
 
DISTRICT P-values  
INDICATOR YEAR Morogoro 
Rural 
(IMCI) 
Rufiji 
(IMCI) 
Ulanga 
(No 
IMCI) 
Kilombero 
(No IMCI) 
IMCI vs 
compa-
rison 
areas 
Change 
over 
time 
1999 to 
2002 
Difference 
between 
IMCI and 
comparison 
Difference 
between 
IMCI and 
comparison 
changed 
over time 
registered) 2002 95% (n=91) 96% (n=104) 
95% 
(n=108) 
97%  
(n=69) 0.97 
1999 84% (n=80) 90% (n=100) 
81% 
(n=118) 
91%  
(n=98) 0.68 AI11. DPT vaccine coverage (informed or 
registered) 2002 75% (n=72) 88% (n=95) 
95% 
(n=108) 
96%  
(n=68) 0.001 
0.40 0.15 0.03 
1999 81% (n=80) 86% (n=100) 
80% 
(n=118) 
88%  
(n=98) 0.90 AI12. Polio vaccine coverage (informed or 
registered) 2002 61% (n=57) 85% (n=92) 
85% 
(n=97) 
92%  
(n=65) 0.007 
0.21 0.11 0.12 
1999 88% (n=80) 89% (n=100) 
84% 
(n=118) 
96%  
(n=98) 0.83 AI10. Measles vaccine coverage (informed or 
registered)  2002 88% (n=84) 89% (n=96) 
92% 
(n=105) 
94%  
(n=67) 0.14 
0.51 0.33 0.72 
1999 15% (n=79) 13% (n=99) 
14% 
(n=111) 
14%  
(n=96) 0.71 
CP14. Vitamin A 
supplementation 
coverage 
 2002 77% (n=73) 
75% 
(n=81) 
78% 
(n=89) 
75%  
(n=53) 0.84 
<0.0001 0.73 0.98 
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4. 4  Discussion 
  
We conducted an effectiveness evaluation to estimate the impact of a program 
that was selected and implemented by district health staff in rural Tanzania. 
We found evidence of improved case-management, a 13% lower under-five 
mortality rate in districts with IMCI than in comparison areas, and that costs 
of child health were comparable or lower with IMCI than with conventional 
case-management, suggesting that facility-based IMCI is highly cost-effective. 
Our findings on mortality levels and trends in the presence of facility-based 
IMCI, while not supporting the same type of inference as a randomised 
controlled trial covering a large number of districts, strongly support going to 
scale with this intervention in the context of health sector reform, basket 
funding, good facility access and high utilisation of health facilities.  
 
Several design issues must be borne in mind when interpreting the findings of 
the present evaluation. We set out to do an effectiveness evaluation of an 
integrated delivery strategy encompassing a number of interventions – such as 
antibiotics, antimalarials, oral rehydration therapy, etc - whose efficacy is 
already well documented.96 Our objective was to estimate the impact of a 
program that was managed by district health staff under routine 
circumstances, similar to a Phase IV study of a drug or vaccine. A randomised 
design would not have been possible because IMCI had already started to be 
implemented in two of the four districts that had demographic surveillance 
systems. Therefore, much emphasis was placed on documenting and assessing 
the effect of contextual factors that might confound the observed results. It is 
reassuring that the observed distribution of contextual factors would tend, if 
anything, to underestimate the true impact of IMCI, but in a non-randomized 
design with a small number of units of analysis it is not possible to rule them 
out completely. The study was designed to detect a 20% reduction in 
mortality, which seemed feasible given that IMCI includes several life-saving 
interventions, and that baseline mortality levels were high. We found a 
smaller impact than we had expected, and the confidence intervals for this 
estimate included the value of zero, or no impact. Nevertheless, in large scale 
public health evaluations the number of available units of analysis is often 
small, and even if the result had been statistically significant it would be hard 
to interpret on strict probabilistic terms. This is why we took so much effort in 
documenting intermediate changes that could be ascribed to IMCI 
implementation, and also contribute to reducing mortality, thus strengthening 
the plausibility111 of a mortality impact. For example, health worker 
performance – including prescription of life saving drugs – improved 
markedly; key indicators that could be ascribed to IMCI implementation (such 
as home management of disease and some care-seeking and feeding practices) 
showed improvements, although most were still well below what could be 
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desirable; and mean height for age, an excellent indicator of overall child 
health that could be a result of improved disease management and feeding 
practices,108 was significantly improved. Taken together, these results support 
the hypothesis that IMCI implementation led to a mortality reduction. 
 
We identified several areas within facility-based IMCI that deserve careful 
attention, with a view to rethinking parts of this strategy. Results from Uganda 
suggest that supportive supervision is associated with improved quality of 
care.112  We found that although general visits from supervisory teams were 
frequent, many such visits did not involve case-management. Supportive 
supervision involving case-management observation was more common in the 
districts with IMCI than in comparison areas, yet there was still room for 
improvement, with one-fifth of such staff not having had such a visit in the 
previous 6 months. Despite many attempts to develop an ‘IMCI supervision 
checklist’ this has proved impossible to implement due to the many duties that 
supervisors are expected to do. An integrated approach may help, and is 
under consideration in Tanzania. We also found that less than one-fifth of 
children needing referral were actually referred (17%, confidence interval 0,41, 
n=12),73  despite an expectation that IMCI guidelines would lead to a massive 
increase in referrals.113  More than 60% of first-level health facilities are over 
two hours travel time from their closest referral facility (data not shown), and 
a lack of transport and money together with the need to care for other children 
often means that mothers are unable to travel such distances with a sick 
child.114  Health workers are part of the communities they serve, and it seems 
likely that they do not refer children who are unlikely to be taken to a referral 
facility.  The IMCI guideline on “Where referral is not possible”, which is part 
of the IMCI training course in Tanzania, goes some way towards supporting 
health workers to offer these children the best possible treatment. 
 
The potential impact of IMCI is likely to depend largely on the efficacy and 
availability of appropriate treatment for malaria, which is the leading cause of 
morbidity and mortality in the study area. Nationally, the first-line 
antimalarial drug changed in 2000 from chloroquine to SP, due to widespread 
drug resistance. This change was followed by initial quality control and 
delivery problems, and these may have led to the drop in treatment of fever 
with antimalarials, from 42% to 28% in children sick in the two weeks before 
each survey. Despite increased efficacy, it appears that the newly introduced 
SP was neither so widely available nor so popular as chloroquine had been in 
1999, and this is likely to have reduced the potential effectiveness of IMCI in 
the time-frame of this study. 
 
From its origins as a case-management strategy, IMCI later developed into 
three linked components: case-management, health facility support, and 
household and community support. The third component, often known as 
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‘community IMCI’, consists of health education messages and programmes in 
support of 17 ‘key family practices’, focussed around growth promotion and 
development, disease prevention, care-seeking and compliance to health 
workers advice. This package has not been implemented in our study area. 
Despite this, it should be noted that many of the activities with high coverage 
in all four districts are compatible with community IMCI, including the use of 
treated mosquito nets and vitamin A. Tanzania has a long history of 
community-based activities and programs: for example, all villages in 
Morogoro Region had two Village Health Workers trained in the 1980s, and in 
a few villages these people remain active in health promotion, including 
growth monitoring of children, supplemental feeding of those identified to be 
at risk, and village health days to promote vaccination. The potential gains 
from such outreach are clear, but there is currently no mechanism by which 
such community-based health workers can be motivated, supervised, and 
supported on a large scale. Given the difficulties in providing support and 
supervision to peripheral facility-based health workers, it remains unclear 
how a much larger force of unsalaried lower-level workers could be managed 
and sustained. 
 
The finding that economic costs of IMCI were similar or less than costs of 
conventional child health care was unexpected. The explanation is that 
substantial amounts of money were spent on child health in comparison 
districts, and that this roughly equalled the cost of IMCI. There is no evidence 
to suggest that these districts are atypical of rural Tanzania: as is often the 
case, there was an ongoing donor investment in health programs including 
from multilateral agencies such as UNICEF, from bilateral agencies such as the 
Swiss Agency for Development and Co-operation, and from NGOs such as 
Plan International. Estimated funding for health from major donors such as 
SDC and Ireland Aid was around $0.8 per capita in the comparison districts, 
not very different from the TEHIP funding of $0.92 per capita. Furthermore, 
IMCI was implemented at a financial cost within the basket funding available 
to all districts through health sector reform. For example, the cost of training 
48 health workers would use between 1% and 6% of current basket-funding 
allocated to each district. Implementation in the comparison districts started in 
2002. 
 
More than ten years ago, an early estimate of the likely cost-effectiveness of 
IMCI reported that “implementation of the integrated cluster of treatments, 
including hospital services, would cost between $30 and $100 per DALY 
saved”.87  Further, it was thought that if health services were well-used, child 
deaths might be reduced by 50 to 70 percent.  With the benefit of hindsight, 
these expectations appear somewhat optimistic. Implementation of IMCI has 
proved to be far more challenging than was first thought: although virtually 
every country in Africa has started to implement the strategy,95  not one 
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country yet has high enough coverage at national level to achieve a 
measurable impact on mortality. This lack of high-level coverage, and an 
intervention perceived to be very expensive by many donors, may have led to 
a general feeling among international policy-makers that IMCI has no impact 
on child survival. Our data suggest that high coverage of facility-based IMCI 
leads to reduced child mortality and that this is achievable within existing 
health budgets. In our setting, simple, practical planning and management 
tools for strengthening the capacity of district health systems were the 
essential first step to achieving this impact. 
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Chapter 5.    Econometric estimation of country-
specific hospital costs    
 
 
 
Summary 
 
 
Information on the unit cost of inpatient and outpatient care is an essential 
element for costing, budgeting and economic-evaluation exercises. Many 
countries lack reliable estimates, however.  WHO has recently undertaken an 
extensive effort to collect and collate data on the unit cost of hospitals and 
health centres from as many countries as possible; so far, data have been 
assembled from 49 countries, for various years during the period 1973–2000. 
The database covers a total of 2173 country-years of observations. Large gaps 
remain, however, particularly for developing countries. Although the long-
term solution is that all countries perform their own costing studies, the 
question arises whether it is possible to predict unit costs for different 
countries in a standardized way for short-term use. The purpose of the work 
described in this paper, a modelling exercise, was to use the data collected 
across countries to predict unit costs in countries for which data are not yet 
available, with the appropriate uncertainty intervals.  
 
The model presented here forms part of a series of models used to estimate 
unit costs for the WHO-CHOICE project. The methods and the results of the 
model, however, may be used to predict a number of different types of 
country-specific unit costs, depending on the purpose of the exercise. They 
may be used, for instance, to estimate the costs per bed-day at different 
capacity levels; the "hotel" component of cost per bed-day; or unit costs net of 
particular components such as drugs.   
 
In addition to reporting estimates for selected countries, the paper shows that 
unit costs of hospitals vary within countries, sometimes by an order of 
magnitude.  Basing cost-effectiveness studies or budgeting exercises on the 
results of a study of a single facility, or even a small group of facilities, is likely 
to be misleading.    
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5. 1  Introduction 
 
Information on hospital unit costs is valuable to health decision-makers and 
researchers for at least three purposes: budgeting (now receiving more 
attention with the availability of additional funds for health in poor countries 
through the Global Fund to Fight AIDS, Tuberculosis and Malaria); the 
assessment of hospital efficiency; and the assessment, by means of either cost-
benefit or cost-effectiveness analysis, of the efficiency of different health 
interventions.  Recognizing the need to make this information available on a 
country-specific basis, WHO has undertaken an extensive effort to collate all 
sources of data on unit costs from as many countries as possible.i116 Large gaps 
remain, however, particularly for developing countries.  Although the long-
term solution is that all countries perform their own costing studies, the 
question arises whether it is possible to predict unit costs for different 
countries in a standardized way for short-term use. The purpose of the work 
described in this paper is to use the data collected across countries to predict 
unit costs in countries for which data are not yet available.  Both point 
estimates and uncertainty intervals are reported.  
 
The model presented here forms part of a series of models that can be used to 
predict country-specific unit costs for a number of purposes. They may be 
used, for instance, to estimate: (i) unit costs at different capacity levels for the 
purposes of efficiency analysis or economic evaluation of health interventions;  
(ii) the "hotel" component of average cost per bed-day for budgeting exercises; 
or (iii) unit costs excluding components that might be funded from other 
sources, such as drugs.  The paper first reviews the literature on cost-function 
estimations. Next, it describes the data sources and methods used. It concludes 
with a discussion of the results, the application of the models, and continuing 
work and future directions. 
 
5. 2  Background 
 
Health economics has a long tradition of estimating hospital-cost functions 
econometrically.67;117-124 Econometric models explain how total costs change in 
response to differences in service mix, inputs, input prices, and scale of 
operations. They allow cost and production functions to be specified with 
sufficient flexibility that a non-linear relationship can be demonstrated 
                                                 
i This work is part of the WHO-CHOICE (CHOosing Interventions that are Cost-
Effective – see www.who.int/evidence) project, which makes use of a standardized set 
of methods and tools developed to analyze the costs and population health impact of 
current and possible new interventions in a standardized and generalizable way.23;115 
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between costs and quantity of inputs: total costs can rise at a lower rate than 
prices.67  
 
Previous studies have commonly used microeconomic data to analyse and 
estimate hospital-cost functions. This literature indicates two main 
approaches: behavioural cost functions and cost minimization functions. 
67;117;123;125 Behavioural cost functions have been used to explain the variations 
in cost per unit of output among hospitals. They have used as determinants all 
variables for which a causal relationship to hospital costs is hypothesized and 
data are available—e.g., bed size, global indicators of hospital activity such as 
average length of stay and occupancy rate, dummy variables for teaching 
status, etc. On the other hand, the literature on cost minimization has 
described the minimum cost of providing a given volume of output as a 
function of an exogenous vector of input prices and the volume of output.  The 
purpose is to determine whether hospitals are cost-minimizers (profit 
maximizers).  
 
When testing the hypothesis of cost-minimization, the explanatory variables 
typically comprise only of output quantities ( e.g., number of bed days) and 
input prices.  The remaining variables used in the behavioural cost function 
specification are not part of the cost minimization question but can be used to 
explain deviation of observed unit costs from the theoretical minimum 
functions – e.g., possible reasons for inefficiency.117 
 
To our knowledge, all previous studies have used within-country data sets; we 
know of none that has attempted to estimate hospital-cost functions across 
countries. Such studies require a large number of observations from as many 
countries as possible. 
 
The model described here follows the tradition of the behavioural cost 
function literature because its purpose is to estimate country-specific costs per 
bed-day, not to test the hypothesis of cost-minimization.  The analysis controls 
for across-country price-level differences by using unit costs adjusted for 
purchasing-power parity, namely in international dollars; and for differences 
in quantity and complexity of resource use by using macro-level indicators 
such as per capita GDP.126-128  
 
5. 3  Objectives 
 
The specific objectives of this paper are to: 
explain the observed differences in hospital inpatient cost per bed-day across 
and within countries; and 
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use the results to predict cost per bed-day for countries for which these data 
are not yet available.  
 
5. 4  Methods 
 
5.4. 1  Data 
 
The search sources used to obtain the data were: Medline, Econlit, Social 
Science Citation Index, regional Index Medicus, Eldis (for developing-country 
data), Commonwealth Agricultural Bureau (CAB), and the British Library for 
Development Studies Databases. The range of years was set at 1960 to the 
present. Data covering costs and charges were included. 
 
The search terms used were: “costs and cost analysis” and hospital costs or 
health centre or the abbreviations HC (health centre) or PHC (primary health 
centre) or outpatient care. The language sources searched were English, 
French, Spanish and Arabic; no Arabic study was found. In addition, a 
number of studies were found in the grey literature, from such sources as 
electronic databases, government regulatory bodies, research institutions, and 
individual health economists known to the authors.56;67;129-162 Also included 
were data from a number of WHO-commissioned studies on unit costs.  
 
A standard template was used for extracting data from all sources.  Database 
variables include: ownership; level of facility (see Annex 5. 1 for a definition of 
hospital levels); number of beds; number of inpatient and outpatient 
specialties; cost data (cost per bed-day, outpatient visit, and admission); 
utilization data (bed-days, outpatient visits, admissions); types of cost 
included in the cost analysis (capital, drugs, ancillary, food) and whether they 
were based on costs or charges; capacity utilization (occupancy rate, average 
length of stay, bed turnover, and average number of visits per doctor per day); 
reference year for cost data; currency, and methods of allocation of joint costs. 
The database consists of unit-cost data from 49 countries for various years 
between 1973–2000, totalling 2173 country-years of observations.  Some 
studies provided information on 100% of the variables described above; at the 
other extreme, some provided information on less than 15%. The number of 
observations used in this analysis was 1171 (see Annex 5. 2 for percentage of 
missing data in the model variables and Annex 5. 3 for the list of countries). 
 
Data cleaning comprised consistency checks and direct derivation of some of 
the missing variables, when possible, from other variables from the same 
observation (e.g., occupancy rate was calculated from number of beds and 
number of bed-days).  STATA software was used for data analysis.163 
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Cost data were converted to 1998 International dollars by means of GDP 
deflators164 and purchasing-power-parity exchange rates used as the basis for 
WHO’s national health accounts estimatesii.   
 
5.4. 2  Data Imputation  
 
Most statistical procedures rely on complete-data methods of analysis: 
computational programs require that all cases contain values for all variables 
to be analyzed. Thus, as default, most software programs exclude from the 
analysis observations with missing data on any of the variables (list-wise 
deletion). This can give rise to two problems: compromised analytical power, 
and estimation bias.  The latter occurs, for example, if the probability that a 
particular value is missing is correlated with certain determinants. For 
example, if the complete observation sets tend to be from observations with 
unit costs that are systematically higher or lower than average, the conclusions 
for out-of sample estimation drawn from an analysis based on list-wise 
deletion will be biased upwards or downwards.165  
  
There is a growing literature on how to deal with missing data in a way that 
does not require incomplete observation sets to be deleted, and several 
software programs have been developed for this purpose.  If data are not 
missing in a systematic way, missing data can be imputed using the observed 
values for complete sets of observations as covariates for prediction purposes. 
Multiple imputation is an effective method for general-purpose handling of 
missing data in multivariate analysis; it allows subsequent analysis to take 
account of the level of uncertainty surrounding each imputed value, as 
described below.166-169 The statistical model used for multiple imputation is the 
joint multivariate normal distribution.  One of its main advantages is that it 
produces reliable estimates of standard errors: single imputation methods do 
not allow for the additional error introduced by imputation. In addition, the 
introduction of random error into the imputation process makes it possible to 
obtain largely unbiased estimates of all parameters.166  
 
In this study, multiple imputation was performed with Amelia, a statistical 
software program designed specifically for multiple imputation of missing 
data.165;167;170;171  First, five completed-data sets are created by imputing the 
unobserved data five times, using five independent draws from an imputation 
model.  The model is constructed to approximate the true distributional 
relationship between the unobserved data and the available information.  This 
reduces potential bias due to systematic difference between the observed and 
the unobserved data.  Second, five complete-data analyses are performed by 
                                                 
ii Purchasing power parity exchange rates used in this analysis are available from the 
WHO-CHOICE website: www.who.int/evidence/cea 
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treating each completed-data set as an actual complete-data set; this permits 
standard complete-data procedures and software to be utilized directly.  
Third, the results from the five complete-data analyses are combined172 to 
obtain the so-called repeated-imputation inference, which takes into account 
the uncertainty in the imputed values. 
 
5.4. 3  Model specifications 
 
From the tradition of using cost functions to explain observed variations in 
unit costs, we estimate a long-run cost-function by means of Ordinary Least 
Squares regression analysis (OLS); the dependent variable is the natural log of 
cost per bed-day.67;117;120-122;173 The primary reason for using unit cost rather 
than total cost as the dependent variable is to avoid the higher error terms due 
to non-uniform variance (heteroscedasticity) in the estimated regression. This 
could arise if total cost were used as the dependent variable, as the error term 
could be correlated with hospital size.67;117 The reason for using cost per bed-
day rather than cost per admission is that "bed-days" are better than 
"admissions" as a proxy for such hospital services as nursing, accommodation 
and other "hotel services"117, permitting more flexibility in the use of estimated 
unit costs. 
 
As the relationship between unit costs and the explanatory variables are 
expected to be non-linear, the Cobb-Douglas transformation was used to 
approximate the normal distribution of the model variables. Natural logs were 
used. The Cobb-Douglas functional form can be written as follows: 
 
Equation 5. 1 
21
210
ααα XXY =     or , 
 
Equation 5. 2 
)ln()ln()ln( 2211 XXY ααδ ++=  
 
where δ  = )ln( 0α . This function is non-linear in the variables Y, X1 and X2, 
but it is linear in the parameters 21 ,, ααδ , and can be readily estimated using 
Ordinary Least Squares.174 
 
Log transformation has the added advantage that coefficients can be readily 
interpreted as elasticities.117;174 
 
Therefore, the cost function specification of the OLS regression model may be 
written as: 
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Equation 5. 3 
ii
n
i
ii eUC +Χ+= ∑
=1
0 αα      
  
Where UCi is the natural log (ln) of cost per bed-day in 1998 I $ in the ith 
hospital; X1 is ln of GDP per capita in 1998 I $; X2 is ln of occupancy rate; X3,4 
are dummy variables indicating the inclusion of drug or food costs (included 
=1);X5,6  are dummy variables for hospital levels 1–2 ( the comparator is level 3 
hospital  X7,8 are dummy variables indicating facility ownership ( comparator 
is private not-for-profit hospitals); X9 is a dummy variable controlling for USA 
data ( USA=1); and e denotes the error term.  
 
The choice of explanatory variables is partly related to economic theory and 
partly determined by the purpose of the exercise, which is to estimate unit 
costs for countries where the data are not available. In this case, the chosen 
explanatory variables must be available in the out-of-sample countries. 
Country-specificiii per capita GDP in international dollars (I $) is used as a 
proxy for level of technology;126-128 occupancy rate as a proxy for level of 
capacity utilization; and hospital level as a proxy for case mix.   Unit costs are 
expected to be correlated positively with GDP per capita and case mix and 
negatively with capacity utilization. 
 
The inclusion of the seven control variables makes it possible to estimate unit 
cost for different purposes to suit different types of analysis—  for example, 
cost per bed-day in a primary-level hospital, which does not provide drugs or 
food; or the cost in a tertiary level hospital, with drugs and food included. 
 
The dummy for the USA was included because all data were charges rather 
than costs and because there were a large number of observations from that 
country. Dummies for countries other than the USA with a large number of 
observations, such as China and the United Kingdom, were also tested as was 
the use of dummy variables to capture whether the cost estimates included 
capital or ancillary costs. These variables were not included in the model 
which best fit the data. Utilization variables, such as number of bed-days or 
outpatient visits, and hospital indicators, such as average length of stay, were 
not included as explanatory variables because most out-of-sample countries 
do not have data on these variables, and prediction of unit costs would, 
therefore, be impossible. 
 
                                                 
iii Whenever possible,  provincial GDP per capita was used — for China  for example. 
The source of these data was the National Statistics report. 
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5.4. 4  Model-fit 
 
Regression diagnostics were used to judge the goodness-of-fit of the model. 
They included the tolerance test for multicollinearity, its reciprocal variance 
inflation factors and estimates of adjusted R square and F statistics of the 
regression model.  
 
 
5.4. 5  Predicted values and uncertainty analysis 
 
Two types of uncertainty arise from using statistical models: estimation  
uncertainty arising from not knowing β and α perfectly − an unavoidable 
consequence of having a finite number of observations; and fundamental 
uncertainty represented by the stochastic component as a result of 
unobservable factors that may influence the dependent variable but are not 
included in the explanatory variables.170 To account for both types of 
uncertainty, statistical simulation was used to compute the quantities of 
interest, namely average cost per bed-day and the uncertainty around these 
estimates. Statistical simulation uses the logic of survey sampling to learn 
about any feature of the probability distribution of the quantities of interest, 
such as its mean or variance.170 
 
It does so in two steps. First, simulated parameter values are obtained by 
drawing random values from the data set to obtain a new value of the 
parameter estimate. This is repeated 1000 times.  Then the mean, standard 
deviation, and 95% confidence interval around the parameter estimates are 
computed. Second, simulated predicted values of ŷ (the quantity of interest) 
are calculated, as follows: (1)  one value is set for each explanatory variable; (2) 
taking the simulated coefficients from the previous step, the systematic 
component (g) of the statistical model is estimated, where g= f (X,B); (3) the 
predicted value is simulated by taking a random draw from the systematic 
component of the statistical model; (4) these steps are repeated 1000 times to 
produce 1000 predicted values, thus approximating the entire probability 
distribution of ŷ. From these simulations, the mean predicted value, standard 
deviation, and 95% confidence interval around the predicted values are 
computed. In this way, this analysis accounts for both fundamental and 
parameter uncertainty. 
 
The predicted log of cost per bed day, ln UC , can then be calculated from: 
 
Equation 5. 4 
++= 110 lnln XUC αα ∑
=
n
i 1
ii Xα  
CHAPTER 5 
 75 
where 0α and ni..α are the estimated parameters, and Xi..n are the independent 
variables. If 0β =anti log ( 0α ) and 1β = 1α , back-transforming Equation 5. 4 
(reduced to 1 independent log-transformed variable for simplicity) gives the 
power function. 
 
Equation 5. 5 
1
0
ββ XUCbiased =  
 
where biasedUC  denotes a biased estimate of the mean cost per bed-day due to 
back-transformation. This is because one of the implicit assumptions of using 
log-transformed models is that the least-squares regression residuals in the 
transformed space are normally distributed. In this case, back-transforming to 
estimate unit costs gives the median and not the mean. To estimate the mean it 
is necessary to use a bias correction technique. The smearing method 
described by Duan (1983) was used to correct for the back-transformation 
bias.175 The smearing method is non-parametric, since it does not require the 
regression errors to have any specified distribution (e.g., normality). If the n 
residuals in log space are denoted by ri, and b is the base of logarithm used, 
the smearing correction factor, biasC , for the logarithmic transformation is 
given by: 
 
Equation 5. 6 
∑
=
=
n
i
r
bias ib
n
C
1
1
 
 
Multiplying the right side of Equation 5. 5  by Equation 5. 6 almost removes 
the bias, so that: 
 
Equation 5. 7 
1
0
ββ XCUC bias=  
The smearing correction factor ( biasC ) for our model was 1.25. 
 
 
5. 5  Results 
 
Table 5. 1 shows the variable names, description, mean and standard error, 
estimated after combining the results of the five datasets of the multiple 
imputation estimates.  Table 5. 2 presents the results of the best-fit regression 
model. The adjusted R square of the combined regressions is 0.80, with an F 
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statistic of 509 (p<0.0001), indicating that the model explains a large part of the 
variation of the cost per bed-day across countries.176 The signs of the 
coefficients are consistent with the earlier hypotheses. For example, the GDP 
per capita is positively correlated with cost per bed-day, while the lower the 
occupancy rate the higher is the cost per bed-day.  Unit costs are lower in 
level-one hospitals than in those of levels two and three. The coefficients for 
the two main explanatory variables (GDP per capita and occupancy rate) are 
highly significant (p<0.0001), as well as most of the control dummies, e.g., 
hospital level. The coefficient for food costs is not significant at the 5% level 
but was included in the model because it added to its  explanatory power.  
 
The tolerance test and its reciprocal variance inflation factors (VIF) showed no 
evidence for multicollinearity between the model variables (Tolerance ranged 
between 0.2 and 0.89, mean VIF 1.97)iv. 
 
 Table 5. 1  Descriptive statistics of the multiple imputation estimates   
N=1171 
 
Variable Description Mean SE 
Ln cost per 
bed day 
Natural log of cost per bed day in 1998 
I $ 
  4.98 1.63 
Ln GDP per 
capita 
Natural log of GDP per capita in 1998 I 
$ 
  8.90 1.06 
Ln occupancy 
rate 
Natural log of occupancy rate  -0.41 0.61 
Drug costs  Dummy variable for inclusion of drug 
costs. Included =1 
  0.96 0.18 
Food costs Dummy variable for inclusion of food 
costs. Included =1 
  0.93 0.25 
Level 1 
hospital 
Dummy variable for level 1 hospital (1)   0.33 0.47 
Level 2 
hospital 
Dummy variable for level 2 hospital   0.41 0.49 
Public Dummy variable for level public 
hospitals (2) 
  0.84 0.36 
Private for 
profit 
Dummy variable for level private for 
profit hospitals 
  0.08 0.27 
USA Dummy variable for USA. USA  =1    0.17 0.37 
(1) Dummies for levels of hospital are compared with level 3 hospitals 
(2) Dummies for hospital ownership are compared with public not-for-profit hospitals 
 
                                                 
iv Tolerance less than 0.05 and VIF more than 20 indicate presence of 
multicollinearity. 
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Table 5. 2  Multiple Imputation regression coefficients and SE 
 
Dependent variable: Natural log of cost per bed-day in 1998 I $   
Adjusted R2= 0.80        F statistic = 509          p of F statistic <0.00001        N: 1171 
Variable B Coef. SE t test P 
Ln GDP per capita  0.7624 0.0295 25.813 <0.0001 
Ln occupancy rate -0.2318 0.0474  -4.886 <0.0001 
Drug costs   0.6410 0.1769   3.624 <0.0001 
Food costs  0.2116 0.1394   1.518    0.152 
Level 1 hospital -0.5777 0.0742  -7.787 <0.0001 
Level 2 hospital -0.3118 0.0594  -5.253 <0.0001 
Public -0.2722 0.1172  -2.323    0.021 
Private for profit  0.2444 0.1316   1.857    0.064 
USA  1.7471 0.1022 17.104    0.000 
Constant -2.5036 0.3264 -7.672    0.026 
 
 
Figure 5. 1 shows the three regression lines of levels one, two and three 
hospitals, respectively, plotted against the log of GDP per capita (the Y-axis is 
log of cost per bed-day). The regression lines were estimated for public 
hospitals, with occupancy rate of 80% , including food costs and excluding 
drugs. Because the original data had a lower average occupancy rate (mean 
71% , SD 39%), and most observations included drug costs, it is to be expected 
that the regression lines will be slightly lower than the actual data points in the 
database. The regression lines do not pass through the USA data points 
situated at the upper right side of the graph because they have been calculated 
for the case where the US dummy was set at zero.   
 
Overall, Figure 5. 1 shows that the regression lines have a good fit with the 
data used to develop the model. They not only illustrate the relationship 
between cost per bed-day, hospital level and GDP per capita, but also show 
that there remains substantial variation in unit costs for any given level of 
GDP per capita.  It would be inadvisable, therefore, to base cost estimates on a 
single estimate of hospital costs in a particular setting, something that is a 
common feature of cost-effectiveness studies.  
 
 
 
 
 
 
                                                                CHAPTER 5 
 78 
Figure 5. 1  Regression lines for level one, two and three hospitals against 
the natural log of GDP per capita. (The Y-axis is the dependent variable: 
natural log of cost per bed day)  
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To use the equation reported in Table 5. 2 to predict unit costs for a number of 
in and out-of-sample countries, with the appropriate uncertainty interval, 
requires consideration of the probability distributions of the predicted unit 
costs, given a specified level of the model variables. In order to derive these 
distributions, simulation techniques were used following the steps described 
in the Methods section. Table 5. 3 presents for selected countries in different 
regions of the world the average simulated predicted values and 95% 
uncertainty intervals. The estimates are presented in 2000 I $, based on the 
2000 GDP per capita in I $ and assuming that the estimated coefficients will 
remain constant over a short time period. They are specific to public hospitals, 
at an occupancy rate of 80%, excluding drug, but including food costs. 
Regional estimates of cost per bed day, with the same characteristics described 
above, are available from the WHO-CHOICE website: www.who.int/choice.  
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Table 5. 3  Predicted cost per bed-day (i) in 2000 I $  
 
Cost per bed day Country GDP 
per 
capita 
(I$) 
In or 
out-of-
sample 
Hospital 
level Mean 
(I $) 
95% 
uncertainty 
interval 
Low 
 
95% 
uncertainty 
interval 
high 
SD 
I 7.39 5.46 9.80 1.36 
II 9.64 7.07 12.73 1.74 
Mali 
 
581 Out 
III 13.14 9.58 17.40 2.44 
I 8.70 6.45 11.43 1.58 
II 11.35 8.32 15.01 2.03 
Mozambi-
que 
720 Out 
III 15.46 11.31 20.42 2.85 
I 14.82 10.95 19.45 2.65 
II 19.35 14.26 25.45 3.39 
Algeria 1,449 Out 
III 26.34 19.41 34.63 4.72 
I 26.90 19.86 35.19 4.77 
II 35.12 26.05 46.12 6.11 
Indonesia 3,167 Out 
III 47.80 35.38 63.28 8.44 
I 27.50 20.30 35.95 4.88 
II 35.90 26.63 47.17 6.25 
Ecuador 3,260 In 
III 48.87 36.17 64.71 8.63 
I 29.88 22.05 39.11 5.30 
II 39.00 28.86 51.25 6.79 
Romania 3,634 Out 
III 53.09 39.23 70.35 9.37 
I 44.88 33.02 59.23 8.03 
II 58.58 43.25 76.84 10.28 
Greece 6,192 Out 
III 79.73 59.01 104.62 14.10 
I 54.75 40.17 72.43 9.86 
II 71.48 52.73 94.24 12.62 
Russian 
Federation 
8,035 In 
III 97.27 71.79 127.92 17.27 
I 84.41 61.48 112.10 15.52 
II 110.19 80.27 146.22 19.85 
Bahrain 14,159 Out 
III 149.93 110.19 198.97 27.01 
I 111.30 80.27 148.59 20.81 
II 145.28 105.96 191.58 26.62 
United 
Arab 
Emirates 
20,330 Out 
III 197.66 144.13 263.01 36.09 
I 127.76 91.83 170.79 24.11 
II 166.77 121.08 221.00 30.85 
United 
Kingdom 
24,348 In 
III 226.87 164.90 302.91 41.76 
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Cost per bed day Country GDP 
per 
capita 
(I$) 
In or 
out-of-
sample 
Hospital 
level Mean 
(I $) 
95% 
uncertainty 
interval 
Low 
 
95% 
uncertainty 
interval 
high 
SD 
I 142.51 102.03 190.22 27.11 
II 186.02 134.55 247.23 34.69 
Canada 28,087 Out 
III 253.05 183.16 337.26 46.89 
(i) Cost per bed day is estimated for public hospitals with 80% occupancy rate, 
excluding drug costs and including food costs. 
 
 
5. 6  Discussion and Policy Relevance 
 
This paper describes recent work on developing models to predict country-
specific hospital unit costs, by level of hospital and ownership, for countries 
where these data are not available. The main purpose of this work was to feed 
into estimates of the costs and effects  of many types of health interventions in 
different settings. Estimates are typically available for variables such as the 
number of days in hospital, or the number of outpatient visits, for certain 
types of interventions, but unit prices are not available for many countries. 
The model presented in this paper used all data on unit costs that could be 
collected after a thorough search to estimate costs for countries where this 
information does not exist. Data imputation techniques were used to impute 
missing data, which has the advantage of eliminating the bias introduced by 
list-wise deletion of observations in cases where information for some of the 
variables required by the model is missing.  
 
The goodness-of-fit of the model was tested by various regression diagnostic 
techniques including the tolerance test for multicollinearity, adjusted R square 
and F statistic. All suggested a good fit of the model with the data and that 
GDP per capita could be used to capture different levels of technology use 
across countries. Although this is the first time that costs have been compared 
across countries, the signs of the coefficients are consistent with results from 
previous microeconomic studies within countries.  For example, these studies 
have found that occupancy rate was negatively correlated with cost per bed-
day while hospital level had the opposite relationship, something also found 
in the model presented in this paper.178;179 This adds confidence to the 
estimated results. 
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In addition, the estimates produced by this model were sent to health 
economists and researchers in different countries to check their face validity. 
Experts from countries in all WHO regions, covering wide differences in GDP 
per capita and in technologies typically found in hospitals were consulted, 
including Benin, Canada, Ecuador, Egypt, Kenya, Netherlands and Thailand. 
They were provided with a description of the estimated unit cost (e.g., which 
costs were included) and were asked whether they thought they approximated 
the average cost per bed-day in their countries. All indicated that the results 
had face validity.  
 
It is of particular note that the model incorporates a more extensive database 
on unit costs by hospital level and ownership than has previously been 
available.  Increasing the range of observations will increase the validity of 
extrapolations of cost estimates for countries in which these data are not 
available. Additional sources of data are being sought for this purpose and to 
assist countries to develop their own studies. As this body of information 
grows, the predictive power of unit-cost models will continue to increase.   
 
There are other possible uses of this model such as estimating the possible 
costs of scaling-up health interventions for the poor, which is receiving 
increasing attention with the activities of such bodies as the Global Fund to 
Fight AIDS, Tuberculosis and Malaria. This can be done in many ways, 
according to the objectives of the analysis. It may be used, for instance, to 
estimate: 
unit costs at different capacity levels for purposes of efficiency analysis or 
economic evaluation of health interventions;   
the "hotel" component of average cost per bed-day; 
unit costs, excluding specific items such as drugs or food costs. 
 
Finally, it must be emphasized that there is wide variation in the unit costs 
estimated from studies within a particular country (Figure 5. 1).  These 
differences are sometimes of an order of magnitude, and cannot always be 
attributed to different methods.  This implies that analysts cannot simply take 
the cost estimates from a single study in a country to guide their assessment of 
the cost-effectiveness of interventions, or the costs of scaling-up.  In some 
cases, they could be wrong by an order of magnitude.   
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Annex 5. 1  Definition of facility types as coded in the unit cost database 
 
Facility type Description 
Primary-level 
hospital 
Has few specialities, mainly internal medicine, 
obstetrics-gynecology, pediatrics, and general 
surgery, or only general practice; limited laboratory 
services are available for general but not for 
specialized pathological analysis; bed capacity 
ranges from 30 to 200 beds; often referred to as a 
district hospital or first-level referral. 
Secondary-level 
hospital 
Highly differentiated by function with five to ten 
clinical specialities; bed capacity ranging from 200-
800 beds; often referred to as provincial hospital.  
Tertiary-level 
hospital 
Highly specialized staff and technical equipment, 
e.g., cardiology, ICU and  specialized imaging 
units; clinical services are highly differentiated by 
function; may have teaching activities; bed capacity 
ranges from 300 to1,500 beds; often referred to as 
central, regional or tertiary-level hospital. 
 Definition of hospital levels (adapted from Barnum and Kutzin 1993 67) 
 
 
Annex 5. 2  Percentage of missing data in the model variables prior to data 
imputation 
 
Variable name  Description % missing 
Ln GDP per 
capita 
Natural log of GDP per capita in 1998 I $ 0 
Ln occupancy 
rate 
Natural log of occupancy rate 48 
Drug costs  Dummy variable for inclusion of drug 
costs. Included =1 
3 
Food costs Dummy variable for inclusion of food 
costs. Included =1 
19 
Level 1 hospital Dummy variable for level 1 hospital 16 
Level 2 hospital Dummy variable for level 2 hospital 16 
Public Dummy variable for level public 
hospitals 
1 
Private for 
profit 
Dummy variable for level private for 
profit hospitals 
1 
USA Dummy variable for USA to control for 
charges data. USA=1  
0 
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Annex 5. 3  Countries included in the model 
 
Country N Country N 
Australia 64 Nepal 3 
Bangladesh 21 Netherlands 1 
Benin 1 New Zealand 4 
Bolivia 1 Niger 2 
Cambodia 1 Norway 6 
China 367 Papua New Guinea 8 
Colombia 1 Poland 4 
Ecuador 70 Republic of Korea 32 
Egypt 5 Russian Federation 22 
Ethiopia 1 Rwanda 4 
Ghana 2 Saint Lucia 1 
Indonesia 5 Sri Lanka 93 
Italy 2 Thailand 41 
Jamaica 3 Turkey 1 
Kenya 7 United Kingdom 176 
Lebanon 4 United Republic of 
Tanzania 
7 
Malawi 2 United States of America 203 
Mexico 2 Zimbabwe 2 
Namibia 2 Total 1171 
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Chapter 6.     Determinants of variation in the 
cost of inpatient stays versus outpatient visits in 
hospitals. A Multi-country analysis 
 
 
Summary 
 
 
Information on hospital costs is key to many types of economic analyses yet 
many countries lack reliable estimates due partly to the time and resource 
requirements to undertake detailed costing studies.  Accordingly, some 
analysts have used simple rules of thumb to estimate hospital unit costs, e.g., 
total hospital costs are allocated between departments assuming that the cost 
of an inpatient day equals a fixed number of outpatient visits. This paper first 
explores the extent to which these simple rules apply within and across 
countries.  It then identifies determinants of variation in the relationship 
between the cost of outpatient visits and inpatient days, then uses the 
estimated relationship to calculate average costs of inpatient and outpatient 
stays for countries where data are not yet available.  Cost information from 832 
hospitals in 28 countries are used.  Simple rules of thumb do not prove to be 
an accurate basis for cost estimates. The ratio of inpatient to outpatient unit 
costs varies with GDP per capita, hospital size, ownership, and occupancy 
rate.  We show how the estimated relationship can be used to calculate a mean 
cost of inpatient stays and outpatient visits, taking into account differences in 
the levels of key determinants, and argue that this method can be used to 
estimate costs in settings where data are unavailable.  Moreover, we suggest 
that the observed great variation in unit costs for similar hospitals in the same 
country means that this method might well be preferable to basing policy 
advice on the results of costing studies that cover only one, or a few hospitals, 
which might well be outliers.   
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6. 1  Introduction 
 
The increasing recognition of the importance of evidence-based decision 
making in health policy, both at the national and international level, has 
highlighted several gaps in unit cost information. For example, to inform 
resource allocation decisions, good quality information on the costs and 
outcomes associated with different ways of using these resources is necessary.  
In many developing countries, such data are not available at all, or are based 
on only a few observations.  Moreover, variations in methods used to estimate 
costs makes it difficult to be sure that differences reflect true differences in 
resource use and/or their prices rather than differences in the estimation 
methods.180  
 
Information on hospital costs is an example.  It is a key requirement for many 
types of policy decisions and is used, for example, as an input to assessing the 
relative efficiency of various types of treatment, and of treatment compared to 
prevention.  It is also essential for budgeting and planning exercises, to 
identify the resources necessary to undertake or sustain interventions or to 
scale up coverage of current interventions.67;148;181 Many countries lack reliable 
estimates, and when they are available they are often available for a small 
number of hospitals, sometimes only one, or limited to the costs of 
hospitalization for specific diseases or conditions.139;148;149;181-184  
 
Admittedly, some of the more accurate methods of estimating costs, such as 
step-down costing - considered to be the gold standard - are expensive or 
difficult to undertake, and budget constraints often mean they cannot be used.  
Accordingly, some analysts have used simple rules-of-thumb, where the cost 
of an inpatient bed day is assumed to equal the cost of a specific number of 
outpatient visits, generally three or four. These ratios are then used to allocate 
total hospital costs between inpatient and outpatient departments in a 
hospital.16;67;185;186  
 
This approach is relatively straightforward as it requires only information on 
total hospital costs, and the numbers of in- and out-patients. However, the 
validity of applying the same ratio to all types of hospitals within a country 
has been questioned by Lombard et al (1991), who showed that in Cape Town 
Province of South Africa, the relationship between the cost per inpatient day 
and outpatient visit varied somewhat by type of hospital -   the average cost 
per bed day varied between 1.4 to 2 times the cost per outpatient visit,16 
compared to the three or four assumed in earlier studies.16;67;185;186 
 
Recognizing the need to make unit cost information available on a country-
specific and hospital-level basis, WHO collated data on unit costs from as 
many countries and hospitals as possible, as part of its WHO-CHOICE 
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project.116 No information could be obtained for many countries. This raised 
the question of whether the countries seeking this data to make decisions 
about how to allocate resources between interventions should simply wait 
until full costing studies had been undertaken, or whether there was a short 
term method that provided relatively reliable results while awaiting the full 
costing studies.  This study therefore had three objectives.  The first was to 
determine if the simple rules of thumb that have been suggested are relatively 
accurate for the countries and hospitals for which data were available.  The 
second was to understand possible determinants of any observed variations in 
the ratio of outpatient to inpatient unit costs, while the third was to determine 
if these determinants could be used predict costs in countries where data did 
not exist - in the event that the simple rules of thumb proved to be 
inappropriate.   
 
The paper first describes the data sources and methods.  It then presents the 
results and considers their implications for policy decisions in countries with 
scanty data. 
 
 
6. 2  Methods 
 
6.2. 1  Data 
 
The sources of primary hospital cost data were derived from indexed search 
engines such as Medline and Econlit, the grey literature, electronic hospital 
unit cost databases, government regulatory bodies, research institutions, and 
individual health economists known to the authors.  Data from a number of 
WHO-commissioned studies on unit costs were also included.  Inclusion 
criteria included whether sufficient detail was provided on: the methods used 
for costing, e.g., step-down or direct allocation of indirect costs; costs versus 
charges data; and which costs were included, e.g., drugs, diagnostics, capital 
costs etc. The availability of this information permits controlling for key 
sources of variation in unit cost estimates.  
 
A standard template was used for extracting the data on costs and possible 
explanators. Database variables included: ownership; level of hospital (see 
Table 6. 1 for a definition of hospital levels); number of beds; number of 
inpatient and outpatient specialties; cost data (cost per bed-day, outpatient 
visit, and admission); utilization data (bed-days, outpatient visits, admissions); 
types of cost included in the original study (capital, drugs, ancillary, food); 
whether reported data were costs or charges; capacity utilization (occupancy 
rate, average length of stay, bed turnover, and average number of visits per 
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doctor per day); reference year for cost data; currency; and methods of 
allocation of joint costs.    
 
The main database used for this analysis consists of unit-cost data from 72 
countries for various years between 1980 and 2000, totalling 2415 hospital-
years of observations. Some studies provided information on 100% of the 
variables described above; at the other extreme, some provided information on 
less than 15%.  Only 832 data points from 28 countries provided sufficient data 
to enable the ratio of outpatient to inpatient unit costs to be calculated. Annex 
6. 3 reports the list of countries. 
 
Data cleaning comprised consistency checks and direct derivation of some of 
the missing variables, when possible, from other variables from the same 
observation (e.g., occupancy rate was calculated from number of beds and 
number of bed-days).  STATA software was used for data analysis.86 
 
Cost data were converted to 1998 international dollars by means of GDP 
deflators164 and purchasing-power-parity exchange rates taken from WHO’s 
national health accounts estimates which are published annually in the Annex 
tables of the World Health Report.187  The PPP exchange rates are available on 
www.who.int/choice).   
 
 
6.2. 2  Data Imputation  
 
Before model selection, missing data were explored to determine the nature of 
missing variables and if there was any systematic pattern of missing data. The 
number of hospital beds, occupancy rate, average length of stay and the types 
of costs included in the estimates were the main variables with missing data.  
Annex 6. 2 shows the percentage of missing data for the variables used in the 
final model. Because the variables appeared to be missing at random, 
imputation of missing data was performed. The observed values for the 
variables that were available were used to predict a distribution of likely 
values for the unobserved data.  
 
Multiple imputation is an effective method for doing this and it allows 
subsequent analysis to take account of the level of uncertainty surrounding 
each imputed value, as described below.166-169 The statistical model used for 
imputation is the joint multivariate normal distribution. One of its main 
advantages is that it produces reliable estimates of standard errors while 
single imputation methods do not allow for the additional error introduced by 
imputation. In addition, the introduction of random error into the imputation 
process makes it possible to obtain largely unbiased estimates of all 
parameters.166  
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Amelia, a statistical software program designed specifically for multiple 
imputation of missing data and used widely for this purpose, was 
used.165;167;170;171 The first step is to create five completed-data sets by imputing 
the unobserved data five times, using five independent draws from an 
imputation model constructed to approximate the true distributional 
relationship between the unobserved data and the available information. This 
reduces potential bias due to systematic differences between the observed and 
the unobserved data. The second step is to perform five separate complete-
data analyses. This permits standard data analysis procedures and software to 
be used. The third step is to combine the results from the five complete-data 
analyses to obtain the “repeated-imputation inference” which takes into 
account the uncertainty in the imputed values.172 
 
 
6.2. 3  Model specification 
 
Following Lombard et al (1991), we used multiple regression to estimate the 
determinants of the ratio of the costs of an outpatient visit to an inpatient day 
– hereafter called “the ratio”.16 Natural logarithmic transformation of the 
dependent variable (the ratio) was used to overcome problems of 
heteroskedasticity arising from the variability in hospital size and the 
country’s overall level of income and, therefore, the level of resources used in 
inpatient and outpatient departments.16 The continuous explanatory variables 
explored in this model were not normally distributed in natural units, so the 
natural logarithmic transformation was used - it best approximated a normal 
distribution for these variables (the explanatory variables explored in the 
model are described subsequently). Log transformation has the added 
advantage that coefficients can be readily interpreted as elasticities.117;174 
  
The functional specification of the Ordinary Least Squares (OLS) regression 
model may be written as: 
 
Equation 6. 1 
ii
n
i
i
i
e
UCBD
UCOP +Χ+=⎟⎠
⎞⎜⎝
⎛ ∑
=1
0ln αα  , i = 1…n  
  
where 
iUCBD
UCOP ⎟⎠
⎞⎜⎝
⎛ln  is the natural log (ln) of the ratio of the cost per 
outpatient visit to the cost per bed-day in 1998 international dollars(I$) in the 
ith hospital;  0α and n...1α are the estimated parameters; ei denotes the error 
term ; and the independent variables Χ 1-11 are as explained in Table 6. 1. 
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Table 6. 1  Variable names and description 
 
Variable Description 
Ln GDP per capita Natural log of GDP per capita in 1998 I $ 
Ln occupancy rate Natural log of occupancy rate 
Ln hospital beds Natural log of hospital beds 
Public  Dummy variable for level public hospitals 
(public = 1, private =0) 
Food costs Dummy variable for inclusion of food costs. 
Included =1 
Sri Lanka Dummy variable for Sri Lanka. Sri Lanka=1 
Thailand Dummy variable for Thailand. Thailand=1 
China Dummy variable for China. China=1 
Ecuador Dummy variable for Ecuador. Ecuador=1 
 
 
The choice of explanatory variables is partly related to economic theory and 
partly determined by one of the eventual uses of the exercise, which is to 
estimate unit costs for countries where the data are not currently available. In 
this case, the chosen explanatory variables must be available in the out-of-
sample countries. Country-specific per capita GDP in international dollars is 
used as a proxy for the available level of technology;126-128 occupancy rate to 
capture the level of capacity utilization; and hospital beds as a proxy for 
hospital level and the complexity of cases treated. Whenever possible, sub-
national GDP per capita was used — in China, for example, provincial GDP 
per capita was used. 
 
Dummy variables were introduced for all countries with relatively large data 
sets. In addition, unit costs in a minority of countries included food and 
ancillary services.  It was not possible to extract these from the total costs 
because of lack of access to the raw data, so dummies were used for 
observations including food or ancillary services. Various interaction terms 
were also tested, such as the interaction between hospital beds and country 
dummies. Other types of possible determinants, such as number of bed-days 
or outpatient visits, and average length of stay, were not included partly 
because they were not available in many of the studies, and partly because 
most out-of-sample countries do not have data on these variables readily at 
hand, and prediction of unit costs would, therefore, be impossible.   
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6.2. 4  Model-fit 
 
Regression diagnostics were used to judge the goodness-of-fit of the model. 
They included the tolerance test for multicollinearity, its reciprocal variance 
inflation factor, the plot of the residual versus fitted values and residuals 
versus each of the independent variables, and estimates of adjusted R square 
and F statistics of the regression model. 
 
 
6.2. 5  Predicted values and uncertainty analysis 
 
The expected values were computed using statistical simulation to account for 
the uncertainty around the estimated parameters of the model. Statistical 
simulation uses the logic of survey sampling to estimate any feature of the 
probability distribution of the quantity of interest, such as its mean and 
variance.170 This is done as follows. First, simulated parameter values ( βα , ) 
are obtained by drawing random values from the parameter estimates and the 
variance-covariance matrix of the estimated model. This is repeated 1000 
times. Second, the predicted values of ŷ (the quantity of interest) are computed 
for each value of the simulated parameters and a set value for the explanatory 
variables. In this way, 1000 predicted values are estimated, thus 
approximating the entire probability distribution of ŷ. From these estimates of 
ŷ , the mean predicted value, standard deviation, and 95% confidence interval 
around the predicted values are computed.  
 
To estimate the expected ratio of cost per outpatient visit to cost per bed day 
the dependent variable is transformed to the normal scale using the Duan 
smearing factor. This factor  corrects for the back-transformation bias arising 
from the fact that while the error term is normally distributed in the log scale, 
this might not be the case in the normal scale.175 The smearing method is non-
parametric, since it does not require the regression errors to have any specified 
distribution (e.g., normality). If the n residuals in log space are denoted by ri, 
and b is the base of logarithm used, the smearing correction factor, biasC , for 
the logarithmic transformation is given by: 
 
Equation 6. 2 
∑
=
=
n
i
r
bias ib
n
C
1
1
 
 
The expected ratio of cost per outpatient visit to cost per bed day can then be 
calculated by multiplying the anti log of the product of Equation 6. 1 by 
Equation 6. 2. This gives: 
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Equation 6. 3 
1
0
ββ XC
UCBD
UCOP
bias=⎟⎠
⎞⎜⎝
⎛
 
where biasC  is the Duan smearing correction factor, 0β =anti log 0α  and 
iβ =anti log iα  (i=1…n). 
The smearing correction factor ( biasC ) for our model was 1.13. 
 
 
6.2. 6  Practical application of the model  
 
As a practical application of the model, the average cost per bed-day or 
outpatient visit can be derived in at least one of two ways. First, from the 
ratios computed in Equation 6. 3, the unit cost per outpatient visit can be 
calculated as:  
 
Equation 6. 4 
iii VUCBD
UCOPTCUCV /* ⎟⎠
⎞⎜⎝
⎛=  ,     
   
where iUCV  is the unit cost per outpatient visit of hospital i, iTC   
is total hospital cost, ⎟⎠
⎞⎜⎝
⎛
UCBD
UCOP is the ratio of cost of the outpatient 
departments to cost of inpatient departments (assuming an 
average ratio is used but the specific ratio for hospital i could be 
used instead) and ijV  the number of outpatient visits of the ith 
hospital. 
 
Similarly, the cost per bed day can be calculated as: 
 
Equation 6. 5 
iii BDUCBD
UCOPTCCBD /1* ⎟⎠
⎞⎜⎝
⎛ −=  
where iCBD  is the unit cost per bed day of hospital i, iBD  is the number of 
bed days of the ith hospital and all other variables as in Equation 6. 4. 
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The second alternative to estimating hospital unit costs from the equations 
presented in this paper is to multiply the estimated ratio with available 
estimates of unit cost per bed day (e.g., from Adam T et al 2003)188 to derive 
the unit cost per outpatient visit. This alternative is particularly useful when 
information on total hospital costs are not readily available. This is illustrated 
in Table 6. 3 below for a selected number of countries.  
 
 
6.2. 7  Face Validity 
 
To validate the results of the model, the estimated cost per outpatient visits 
described in the second alternative above, and presented in Table 6. 3, were 
compared to the literature and shared with economists in several countries to 
determine their face validity.  
 
6. 3  Results 
 
Table 6. 2 shows the results of the best-fit regression model (the description of 
variable names can be found in Table 6. 1). The adjusted R-square of the 
combined regressions is 0.63, with an F statistic of 85 (p<0.0001). The tolerance 
test and its reciprocal variance inflation factors (VIF) showed no evidence of 
multicollinearity between the model variables. Tolerance fell between 0.05 and 
0.81 and the mean VIF was 4.91 (tolerance less than 0.05 and VIF more than 20 
indicate presence of multicollinearity). Residual plots showed a uniform 
distribution of the model residuals with a mean of zero and no specific pattern 
of distribution. 
 
The positive signs of the coefficients of the inpatient occupancy rate and the 
number of hospital beds are consistent with a priori expectations. Other things 
being equal, unit costs of inpatient care should fall (so the ratio would rise) the 
greater is the occupancy rate and the greater the size of the hospital – 
assuming no diseconomies of scale.  
 
For GDP per capita, a positive correlation was found. Several explanations are 
possible. Higher income countries may be more likely to spend additional 
resources on outpatient infrastructure or to provide a greater range of 
outpatient services than lower income countries. They might also be able to 
spend more time per outpatient than in poorer countries because of less 
stringent capacity constraints in terms of the availability of trained personnel.  
 
Four country dummies proved to be significant - for China, Ecuador, Sri Lanka 
and Thailand but the interactions with other explanatory variables did not 
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(Table 6. 3).  This shows that the value of the ratio differed compared to 
countries with similar levels of GDP per capita.  No other interactions proved 
to be consistently significant across the various models that were tried. 
  
The negative coefficient for hospital ownership (public = 1, private = 0) 
suggests that public hospitals are likely to spend a higher proportion of their 
resources on an inpatient day than an outpatient visit. We are not sure of the 
explanation. Perhaps public hospitals have fewer physical amenities in 
outpatient wards than private hospitals that must compete for paying patients. 
Finally, the negative coefficient of the variable denoting the inclusion of food 
costs (food included =1; no food costs included =0) simply reflects the effect on 
the ratio when the unit cost per bed-day, the denominator, does not include 
food.   The dummy for ancillary costs was not significant. 
 
 
Table 6. 2  Ordinary Least Squares Regression coefficients and SE 
Dependent variable: Natural log ratio of cost per outpatient visit to cost per 
bed-day in 1998 I $  
 
Adjusted R2= 0.61  F statistic = 101  p of F statistic <0.00001         N: 832 
Variable β Coef SE T P 
Ln GDP per capita 0.1303 0.0237 5.497 <0.0001 
Ln occupancy rate 0.1683 0.0636 2.645 0.011 
Ln hospital beds 0.0884 0.0221 4.007 <0.0001 
Public  -0.4890 0.1564 -3.125 0.004 
Food costs -0.1985 0.0765 -2.595 0.013 
Sri Lanka -1.2401 0.0828 -14.979 <0.0001 
Thailand -0.2998 0.0778 -3.855 <0.0001 
China 0.3449 0.0510 6.763 <0.0001 
Ecuador -0.8187 0.1040 -7.872 <0.0001 
Constant -2.2698 0.2567 -8.843 <0.0001 
 
 
Figure 6. 1 shows the three regression lines for level one, two and three 
hospitals, respectively, plotted against the log of GDP per capita (the Y-axis is 
log of cost per bed-day). The ratio is estimated for public hospitals with 80% 
occupancy rate, including food costs. The number of beds for a level one 
hospital was set at the sample average - 106, at 273 for level 2, and at 673 for 
level 3 hospitals. These values are consistent with the definition of hospital 
levels in Barnum and Kutzin (1993),67 see Annex 6. 1. The regression lines are 
slightly higher than the mid point of the raw data points from Ecuador and Sri 
Lanka and lower than the mid point of the data from some of the Chinese 
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provinces. This is because the graphs are based on the country dummies being 
set at zero.  
 
Figure 6. 1 shows that, holding constant all variables except GDP per capita 
and hospital level, the estimated ratio gets higher as hospital complexity 
increases, although the absolute difference between levels is relatively small. 
This is probably because tertiary, and in some cases, secondary hospitals have 
specialist outpatient services which are not provided at primary hospitals.  
The ratio is also inelastic with respect to changes in GDP per capita.  
 
The regression lines hold other determinants constant.  The raw data plotted 
on the Figure illustrate that the unadjusted ratio varies substantially across 
hospitals, even within a given country.  Examination only of the countries 
with a relatively large number of observations shows a minimum five fold 
variation in the ratio for Thailand, and a maximum of a 52 fold variation in 
Ecuador.   
 
 
Figure 6. 1  Regression lines for level one, two and three hospitals against 
the natural log of GDP per capita. (The Y-axis is the dependent variable: 
natural log ratio of cost per visit to cost per bed day)    N=832 
 
Natural log GDP per capita (1998 I$)
 Natural log ratio (raw data)  level 1 hospital
 level 2 hospital  level 3 hospital
6.02446 10.0971
-5.44
1.19
N
at
ur
al
 lo
g 
ra
tio
 o
f c
os
t p
er
 v
is
it 
to
 c
os
t p
er
 d
ay
 in
 1
99
9I
 $
 
 
 
Sri Lanka
China
Thailand 
Ecuador 
                                                                CHAPTER 6 
 96 
Table 6. 3 presents the mean predicted ratios of inpatient unit costs to inpatient 
unit costs, and their uncertainty intervals, for a selected number of in and out-
of-sample countries. Estimates are based on the equation reported in Table 6. 2 
and the methods described earlier. Like Figure 6. 1, the ratio is estimated for 
public hospitals with 80% occupancy rate, 106 beds for level 1 hospital, 273 
beds for level 2 hospital, and 673 beds for level 3 hospital, excluding drugs and 
ancillary costs (laboratory and other diagnostic procedures) and including 
food costs. Similarly, cost per bed day is estimated for public hospitals with 
80% occupancy rate, excluding drug costs and including food costs based on 
Adam et al 2003.188 
 
The selected countries represent different levels of income and different 
regions of the world. The four countries for which dummies were used in the 
model are also presented. The table shows that holding everything constant 
except GDP per capita, the ratio differs across countries. For example, the 
minimum ratio was 0.08 for level 1 hospitals in Sri Lanka, reflecting a ratio of 
the cost per inpatient day to an outpatient visit of 12.5. The maximum was 0.46  
in level 3 hospitals in China, where the cost per inpatient day was 2.1 times the 
cost of an outpatient visit.  
 
Table 6. 3 shows only the variation associated with differences in GDP per 
capita and hospital level.  The actual mean cost for any given country will also 
depend on the other determinants in Table 6. 2.  We tested the calculations of 
Table 6. 3 on experts from countries covering a wide range of GDPs per capita 
and hospital technologies.  The countries included Benin, Canada, Ecuador, 
Egypt, Kenya, Netherlands and Thailand. They were provided with a 
description of the estimated unit cost (e.g., which costs were included) and 
were asked whether they thought they approximated the average cost per 
hospital visit in their countries. All indicated that the results had face validity. 
 
 
6. 4  Discussion and Policy Relevance 
 
This paper describes recent work on developing models to explain the 
observed variation in the relationship between the cost per outpatient visit to 
cost per inpatient day across hospitals and countries. Results are based on a 
much larger data set that had previously been available.  The first objective 
was to determine the extent to which this ratio varied across hospitals.  This 
would show if simple rules of thumb can be used to allocate hospital costs 
between inpatient and outpatient departments in settings where detailed step-
down costing studies have not yet been undertaken.  
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Table 6. 3  Mean predicted ratio of cost per outpatient visit to cost per bed 
day and estimated unit costs for a selected number of countries in terms of 
2000 I$  
 
 
Predicted ratio of cost per 
visit 
to cost per bed day (i) 
Country GDP 
per 
capita  
 
Hospital 
level 
 
Mean 
Ratio 
 
 
 
(a) 
 
Low  
95% 
CI 
High 
95% CI 
SD 
Mean 
cost per 
bed day 
using 
Adam T 
et al 
2003188iv 
 
(b) 
Mean 
cost per 
outpatie
nt visit 
 
 
 
 
(a*b) 
I 0.20 0.17 0.22 0.02 7.37 1.45 
II 0.21 0.19 0.24 0.02 9.61 2.06 
Mali (ii) 
 
581 
III 0.23 0.20 0.26 0.02 13.12 3.04 
I 0.20 0.18 0.23 0.01 8.68 1.76 
II 0.22 0.20 0.25 0.02 11.31 2.49 
Mozambiq
ue (ii) 
720 
III 0.24 0.21 0.27 0.02 15.45 3.68 
I 0.22 0.20 0.24 0.01 14.80 3.28 
II 0.24 0.22 0.26 0.01 19.28 4.64 
Algeria (ii) 1,449 
III 0.26 0.23 0.29 0.02 26.33 6.87 
I 0.24 0.23 0.26 0.01 26.87 6.58 
II 0.27 0.25 0.29 0.01 35.02 9.32 
Indonesia 
(ii) 
3,167 
III 0.29 0.26 0.31 0.01 47.80 13.79 
I 0.11 0.09 0.13 0.01 27.47 2.99 
II 0.12 0.10 0.14 0.01 35.80 4.24 
Ecuador (iii) 3,260 
III 0.13 0.11 0.15 0.01 48.87 6.28 
I 0.07 0.06 0.08 0.01 25.13 1.79 
II 0.08 0.07 0.09 0.01 32.75 2.53 
Sri Lanka 
(iii) 
3,292 
III 0.08 0.07 0.10 0.01 44.70 3.74 
I 0.25 0.23 0.27 0.01 29.85 7.44 
II 0.27 0.25 0.29 0.01 38.90 10.54 
Romania (ii) 3,634 
III 0.29 0.27 0.32 0.01 53.09 15.59 
I 0.35 0.33 0.38 0.01 41.03 14.45 
II 0.38 0.36 0.40 0.01 53.47 20.47 
China (iii) 3,727 
III 0.41 0.39 0.44 0.01 72.96 30.26 
I 0.27 0.25 0.28 0.01 44.85 11.97 
II 0.29 0.27 0.31 0.01 58.45 16.96 
Greece (ii) 6,192 
III 0.31 0.29 0.34 0.01 79.76 25.08 
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Predicted ratio of cost per 
visit 
to cost per bed day (i) 
Country GDP 
per 
capita  
 
Hospital 
level 
 
Mean 
Ratio 
 
 
 
(a) 
 
Low  
95% 
CI 
High 
95% CI 
SD 
Mean 
cost per 
bed day 
using 
Adam T 
et al 
2003188iv 
 
(b) 
Mean 
cost per 
outpatie
nt visit 
 
 
 
 
(a*b) 
I 0.20 0.18 0.22 0.01 47.13 9.40 
II 0.22 0.19 0.24 0.02 61.37 13.31 
Thailand (iii) 6,626 
III 0.24 0.21 0.27 0.02 83.71 19.68 
I 0.28 0.26 0.29 0.01 54.74 15.11 
II 0.30 0.28 0.32 0.01 71.32 21.41 
Russian 
Federation 
8,035 
III 0.33 0.30 0.35 0.01 97.32 31.65 
I 0.30 0.28 0.31 0.01 84.42 25.07 
II 0.32 0.31 0.34 0.01 109.99 35.52 
Bahrain (ii) 14,159 
III 0.35 0.32 0.38 0.02 150.06 52.51 
I 0.31 0.29 0.33 0.01 111.34 34.65 
II 0.34 0.32 0.36 0.01 145.06 49.09 
United 
Arab 
Emirates (ii) 
20,330 
III 0.37 0.34 0.40 0.02 197.88 72.57 
I 0.32 0.30 0.34 0.01 127.81 40.72 
II 0.35 0.32 0.37 0.01 166.53 57.69 
United 
Kingdom 
24,348 
III 0.38 0.35 0.41 0.02 227.15 85.28 
I 0.32 0.31 0.35 0.01 142.59 46.27 
II 0.35 0.33 0.38 0.01 185.77 65.56 
Canada (ii) 28,087 
III 0.38 0.35 0.42 0.02 253.38 96.91 
 (i) The ratio is estimated for public hospitals with 80% occupancy rate, 106 beds 
for level 1 hospital, 273 beds for level 2 hospital, and 673 beds for level 3 
hospital, excluding ancillary costs (laboratory and other diagnostic 
procedures) and including food costs.    
 (ii) Country out of sample. 
(iii) Country dummy included in the model. 
(iv) Cost per bed day is estimated for public hospitals with 80% occupancy rate, 
excluding drug costs and including food costs. 
CI= confidence interval. 
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The results suggest that it would be misleading to use any simple rule of 
thumb, something that has been done a number of times in the recent 
literature, because inpatient costs - even holding determinants except GDP per 
capita and hospital level constant - could be as low as two, and as high as 12 
times the cost of an outpatient visit.  While this might not be totally surprising, 
another implication is that there was enormous variation in this ratio even for 
hospitals of the same type in the same setting.  This means that even where 
some step down costing studies have been undertaken, analysts would be 
unwise to base policy advice on the results of only one or two studies.  The 
hospital or hospitals for which data are available may well be atypical of other 
hospitals of the same type in that country.  The implication is that a 
sufficiently large random sample of hospitals is really required to provide 
accurate policy advice, further increasing the costs of doing such research. The 
second conclusion is that a high proportion of the observed variation in the 
ratio observed across hospitals can be explained. All regression diagnostics 
suggested a good fit with the data and the signs of the coefficients have face 
validity.  This suggests that the equations reported here could provide a viable 
alternative for estimating unit costs than rule of thumb if only a small number 
of observations from hospital costing studies is available. Knowledge of a few, 
readily obtainable explanatory variables (i.e. those in Table 6. 1) could be used 
to estimate the ratio, and hence, the costs of inpatient stays and outpatient 
visits.    
 
Moreover, we argue that the approach is more likely to provide a reliable 
estimate of the average costs than relying on a single, or a few, cost studies in a 
given setting, even if those studies use appropriate methods.  This is because 
of the great variation in unit costs observed for hospitals in the same country, 
described earlier.  This is the approach used in the WHO-CHOICE  
(www.who.int/choice) project on cost-effectiveness, and subsequently in the 
Disease Control Priorities in Developing Countries exercise that will be 
published shortly (http://www.fic.nih.gov/dcpp/).    
 
This work is the first attempt to compare unit cost ratios across countries 
taking into account hospital and country characteristics. The model 
incorporates a much more extensive database on unit costs by hospital level 
and ownership than has previously been available. Increasing the range of 
observations and including other possible explanatory variables will increase 
the explanatory power of the model and the validity of extrapolating the 
results to countries where full step-down studies across a range of hospitals 
have not yet been undertaken. Although it would be preferable for analysts to 
estimate hospital costs using the step-down procedure if time and financial 
resources permit, this paper shows that econometric analysis of existing data 
can provide useful estimates in the interim. 
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Annex 6. 1  Definition of facility types as coded in the unit cost database 
 
Facility type Description 
Primary-level 
hospital 
Has few specialities, mainly internal medicine, 
obstetrics-gynecology, pediatrics, and general 
surgery, or only general practice; limited laboratory 
services are available for general but not for 
specialized pathological analysis; bed capacity 
ranges from 30 to 200 beds; often referred to as a 
district hospital or first-level referral. 
 
Secondary-level 
hospital 
Highly differentiated by function with five to ten 
clinical specialities; bed capacity ranging from 200-
800 beds; often referred to as provincial hospital 
.  
Tertiary-level 
hospital 
Highly specialized staff and technical equipment, 
e.g., cardiology, ICU and  specialized imaging 
units; clinical services are highly differentiated by 
function; may have teaching activities; bed capacity 
ranges from 300 to1,500 beds; often referred to as 
central, regional or tertiary-level hospital. 
 Definition of hospital levels adapted from Barnum and Kutzin 1993 67 
 
 
Annex 6. 2  Percentage of missing data of the model variables prior to data 
imputation 
 
Variable name  Description % missing 
Ln GDP per capita Natural log of GDP per capita 
in 1998 I $ 
0 
Ln occupancy rate Natural log of occupancy rate 32 
Ln hospital beds Natural log of hospital beds 32 
Public Dummy variable for level 
public hospitals (1) 
0 
Ancillary costs Dummy variable for 
inclusion of ancillary (2) costs. 
Included =1 
34 
Food costs Dummy variable for 
inclusion of food costs. 
Included =1 
25 
Costs or charge Whether observation is cost or 0 
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Variable name  Description % missing 
charge data. Costs =1 
Sri Lanka Dummy variable for Sri Lanka. 
Sri Lanka=1 
0 
Thailand Dummy variable for Thailand. 
Thailand=1 
0 
China Dummy variable for China. 
China=1 
0 
Ecuador Dummy variable for Ecuador. 
Ecuador=1 
0 
 
 
 
Annex 6. 3  Countries included in the model 
 
Country N Country N 
Australia 1 Namibia 2 
Bangladesh 20 Nepal 3 
Benin 1 Netherlands 1 
Cambodia 1 New Zealand 1 
China 358 Papua New Guinea 8 
Ecuador 68 Poland 4 
Egypt 5 Russian Federation 17 
Ethiopia 1 Rwanda 4 
Indonesia 5 Saint Lucia 1 
Jamaica 3 Sri Lanka 90 
Kenya 7 Thailand 41 
Lebanon 4 United Kingdom 173 
Malawi 2 United Republic of Tanzania 7 
Mexico 2 Zimbabwe 2 
 Total 832 
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Chapter 7.    Understanding variations in 
department-specific hospital costs: An application of 
seemingly unrelated regressions to China     
 
 
 
Summary 
 
 
This paper tests whether there are simple but reliable methods to estimate 
hospital unit costs without having to undertake a full costing study.  Statistical 
methods for compositional data are used to estimate and predict department-
specific hospital costs using seemingly unrelated regressions. The model 
explains most of the variation in the department-specific ratio of inpatient to 
outpatient unit costs, which is shown to be close to the simple rules of thumb 
(e.g. 3:1 and 4:1) suggested by earlier studies.  However, it varies substantially 
by inpatient department and a number of other explanatory variables. The 
ratio can reach 6:1.       
 
 
7. 1  Introduction 
 
Information on hospital costs is valuable to researchers and health decision-
makers for at least two reasons. The first is for efficiency assessment, to 
identify if the benefits of undertaking a hospital-based intervention outweigh 
the costs, or which of the many possible interventions involving 
hospitalization is the best use of scarce health resources. The second is for 
budgeting purposes, to identify the resources necessary to undertake or 
sustain hospital-based interventions. The recommended approach involves a 
step-down costing process where overhead and general service  costs are 
distributed across the different patient departments on the basis of a set of 
allocation rules determined by the main cost drivers of these costs.15;67  Many 
countries lack this type of data because they are costly to collect and the 
analysis requires high levels of technical expertise.  Where such studies have 
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been undertaken, they are often limited to a small number of health facilities 
that may well be atypical of other settings.  
 
The total costs of an institution is, however, more easy to obtain than the 
disaggregated costs of inpatient and outpatient care.  Some studies have, 
therefore, used simple rules of thumb to allocate hospital costs between 
inpatient and outpatient departments as a quick method to estimate the costs 
of an inpatient stay or an outpatient visit, e.g., assuming that each bed-day 
costs either three or four times that of an outpatient visit.16;67  The ratio of 
inpatient to outpatient unit costs has, however, been shown to differ between 
hospitals within a country, varying by type (size) and degree of specialization. 
In Cape Town province, South Africa, it varied between 2:1 and 1.4:1.16   
 
We hypothesize that the ratio will also differ by inpatient department 
according to variation in the intensity of input use across departments, but to 
our knowledge, no previous study has tested this. The purpose of this paper is 
to explore the extent to which the ratio of inpatient to outpatient costs varies 
by inpatient department, whether there is a consistent pattern in this variation 
across hospitals and if so, what are the determinants of variation. This will 
reveal whether simple rules of thumb can be derived for allocating total 
hospital costs between the different inpatient and outpatient departments for 
use at times when it is not possible to undertake full step-down costing studies 
in a large number of hospitals.   
 
Previous studies had estimated the relationship between inpatient and 
outpatient unit costs using multivariate regression analysis.16  As our aim is to 
distinguish between the different types of inpatient departments, an 
alternative to the use of independent regression models for each department is 
offered by compositional models, with applications found in a range of 
disciplines including economics, political science and epidemiology.189-194 This 
paper describes the adaptation of compositional models to the estimation of 
department-specific hospital costs in which we estimate the ratios of 
department-specific inpatient costs to the cost of outpatient departments at 
different types of hospital, with appropriate uncertainty intervals.  
 
Seemingly unrelated regressions as developed by Zellner 195 are ideal for this 
purpose as they simultaneously estimate a system of equations that appear 
unrelated but where the errors are potentially correlated across equations. This 
leads to significant improvement in efficiency of the estimation model.193;195;196 
In this case the errors of the equations are likely to be correlated because of 
factors common to all departments in a particular hospital, such as its location, 
the hospital type, and the availability of medical specialties. One of the 
advantages of this system is that fewer observations are required to obtain 
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reliable parameter estimates than if each of the equations is estimated 
separately.  
 
The paper begins by defining the characteristics of modelling compositional 
data using the seemingly unrelated linear regression model. Next, it describes 
the data sources and methods. It concludes with a discussion of the results, the 
application of the models, and future directions. 
 
 
7. 2  Methods 
 
7.2. 1  Data 
 
Forty-one hospitals from 12 provinces of China were included in the empirical 
analysis (see Annex 7. 1). The data were for the years 1997 and 2000. Based on 
the frequency of their existence in the data-set, the following inpatient 
departments were selected for analysis: internal medicine, obstetrics and 
gynaecology, surgery and paediatrics. All other inpatient departments were 
grouped into one category called “others”. The number of departments 
included in this category varied between one and seven depending on the 
hospital, and included ear nose and throat, dermatology, ophthalmology, 
physiotherapy and Chinese traditional medicine. The outpatient department 
was the final category. 
 
The database variables included total and unit cost per bed day and per case 
for each department estimated using full step-down allocation methods; 
hospital and department-specific indicators such as type of hospital, number 
of beds, occupancy rate, average length of stay and utilization rates (e.g., 
number of bed-days). Details of standard step-down allocation methods are 
available elsewhere.15;67 Other variables included the year to which the cost 
data referred, province name and provincial GDP per capita. Costs were 
converted to year 2000 Chinese Yuan by means of the overall  GDP deflator 
from the World Bank as no health-specific deflators were available for 
China.197 
 
 
7.2. 2  Statistical model 
 
Compositional data are vectors of proportions describing the relative 
contributions of each of J categories to unity. Seemingly unrelated regressions 
are commonly used for estimation purposes of compositional models, where 
the model typically contains several equations and an additional 
identity.189;198;199 This identity implies that the j dependent variables sum to a 
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fixed known value. The implicit adding-up condition causes the seemingly 
unrelated dependent variables to be correlated.  Haupt and Oberhofer199 show 
that in regression analysis the residuals inherit this correlation from the 
dependent variables, resulting in a singular covariance matrix. As noted by 
Bewley, deleting one equation before the estimation procedure is one possible 
way of solving this problem as the J - 1 linear independent equations contain 
the entire statistical information required for estimation.200 The choice of the 
equation that should be dropped does not affect the estimated parameters, so 
one arbitrary equation can be dropped and the remaining J - 1 equations 
estimated.189;199 
 
Estimating the parameters of a set of regression equations can be more 
efficient if the independent variables in different equations are not highly 
correlated and if the disturbance terms are highly correlated.195;196  We return 
to this later.  
 
In this paper, we used seemingly unrelated regression methods for 
compositional data to estimate the ratio of department-specific costs to total 
hospital costs. Clearly, the department-specific costs must sum to the total 
hospital costs.  In order to model compositional data with J different hospital 
departments, we first define a vector of cost-proportions. The description 
below uses the same notation as a general statistical model for compositional 
data that has been presented in an application to multiparty electoral data.191 
 
iijij TCDCP /=  ,       (1) 
 
where ijP  ( iJij PP ,..., ) denotes the proportion of a particular department’s cost 
for each department j ( j=1,…, J) to total hospital cost, for each hospital i ( i 
=1,…,N). Six proportions were calculated for each hospital using the 
departments described earlier.  
 
The second step follows where the compositional data is modelled using the 
additive logistic normal distribution.190 First, a (J-1) vector iY  is generated by 
calculating the log ratios of each department fraction relative to the dropped 
fraction J   (outpatient department):  
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=
iJ
ij
ij P
P
Y ln .  i=1, … , N   j=1, … , J-1   (2) 
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The vector ),...,( )1(1 −= Jiiij YYY is assumed to be multivariate normal with 
mean µ  and variance matrix Σ.  The expectation of each log-ratio is assumed 
to be a linear function of the explanatory variables in the model. 
 
 
7.2. 3  Model-fit 
 
The objective was to identify variables that would be likely to have a strong 
relationship to department-specific costs, but also variables for which 
estimates would be available in other areas of the country in the event that the 
model could be used for predictive purposes. Of further interest was the 
possibility to compare the results of this model with data from other countries 
in future work. The variables that were selected based on these criteria were 
occupancy rate reflecting capacity utilization; the ratio of department-specific 
bed days to total hospital bed-days as a measure of the proportion of overhead 
costs attributed to each department; and number of staff per department as a 
measure of department size.  In addition, various dummy variables were used 
to explore if hospitals from the different provinces in China behaved 
differently.  Only the dummy for Henan province − the province where 40% of 
the data come from - proved significant, so it is the variable reported here.  All 
except the last explanatory variable vary by department. The final version of 
the model reported here included all variables in the natural log form. This 
transformation ensured that the distributions were approximately normal. It 
also provided the best fit. 
 
A number of other explanatory variables were explored including: provincial 
GDP per capita, dummy variables for hospital type (primary, secondary, 
tertiary) and department-specific variables such as the average length of stay, 
number of beds, beds as a proportion of hospital beds and number of bed-
days. The equation with the best fit did not include these variables. 
 
Given the specification described above, the multivariate normal model for the 
log ratios may be written as a system of equations as follows: 
 
 1413121101 iiiiii GSZWy εααααα +++++= , i=1, … , N (3a)  
 2423222102 iiiiii GSZWy εγγγγγ +++++= , i=1, … , N (3b)  
        3433323103 iiiiii GSZWy εννννν +++++= , i=1, … , N           (3c) 
        4443424104 iiiiii GSZWy εκκκκκ +++++= , i=1, … , N (3d) 
        5453525105 iiiiii GSlZWy ελλλλλ +++++= ,  i=1, … , N (3e) 
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where 1iy  to 5iy  are the log-ratios as defined in Eq. (2); 1W  to 5W  are 
department-specific natural log of occupancy rate; 1Z  to 5Z  are department-
specific log ratios of department bed-days over total hospital bed-days; 1S  to 
5S  are department-specific log of number of staff; iG  is a dummy variable for 
Henan province; and 1iε  to 5iε  are residual terms which have expectations of 
0, variances of 12σ  to 52σ , respectively, and correlations of sρ . The variable 
names, description and mean values are shown in Table 7. 1. 
 
The asymptotically efficient, feasible generalized least-squares algorithm were 
computed using STATA 8 software.86;201 
 
 
7.2. 4  Goodness of fit  
 
The percentage of variance explained by the explanatory variables was 
summarized by the adjusted R-squared. F statistics for testing the hypothesis 
of equal parameter vectors were calculated for each equation.196  To test the 
hypothesis of independent equations, the correlation matrix of residuals and 
the Breusch-Pagan test for independent equations was performed.86  
 
 
 
  
Table 7. 1  Variable names, description and mean values 
 
Variable name  Description Variable 
notationvii 
Mean in 
natural 
units 
SE 
Lnpg  Dependent variable: natural log-ratio of cost of Ob/Gyn to cost 
of outpatient departments 
 0.04 0.004 
lng_occupancy Natural log of occupancy rate in Ob/Gyn department W1 0.86 0.066 
lng_bday_tbd Natural log of ratio of bed days in Ob/Gyn department to total 
bed days 
Z1 0.07 0.009 
lng_staff Natural log of number of staff in Ob/Gyn department S1 44.68 3.235 
Henan Dummy variable for Henan Province. Henan=1 Gi   
Lnpm Dependent variable: natural log-ratio of cost of Internal 
Medicine to cost of outpatient departments 
 0.15 0.015 
Lnm_occupancy Natural log of occupancy rate in Internal Medicine department W2 0.86 0.054 
Lnm_bday_tbd Natural log of ratio of bed days in Internal Medicine department 
to total bed days 
Z2 0.22 0.024 
Lnm_staff Natural log of number of staff in Internal Medicine department S2 134.83 13.70 
Henan Dummy variable for Henan Province. Henan=1 Gi   
Lnps Dependent variable: natural log-ratio of cost of Surgery to cost 
of outpatient departments 
 0.13 0.014 
lns_occupancy Natural log of occupancy rate in Surgery department W3 0.92 0.074 
lns_bday_tbd Natural log of ratio of bed days in Surgery department to total 
bed days 
Z3 0.22 0.026 
                                                 
vii See Equation 3(a) to 3(e) 
                                                                                                                              
 
Variable name  Description Variable 
notationvii 
Mean in 
natural 
units 
SE 
lns_staff Natural log of number of staff in Surgery department S3 114.33 9.885 
Henan Dummy variable for Henan Province. Henan=1 Gi   
Lnpp Dependent variable: natural log-ratio of cost of Pediatrics to 
cost of outpatient departments 
 0.02 0.002 
lnp_occupancy Natural log of occupancy rate in Pediatrics department W4 0.74 0.06 
lnp_bday_tbd Natural log of ratio of bed days in Pediatrics department to 
total bed days 
Z4 0.04 0.005 
lnp_staff Natural log of number of staff in Pediatrics department S4 27.30 1.998 
Henan Dummy variable for Henan Province. Henan=1 Gi   
Lnpoth Dependent variable: natural log-ratio of cost of other 
departments to cost of outpatient department 
 0.11 0.015 
lnoth_occupancy Natural log of occupancy rate in other departments W5 0.71 0.063 
lnoth_bday_tbd Natural log of ratio of bed days in other departments to total 
bed days 
Z5 0.12 0.018 
lnoth_staff Natural log of number of staff in other departments S5 35.27 6.731 
Henan Dummy variable for Henan Province. Henan=1 Gi   
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7.2. 5  Computing quantities of interest and uncertainty intervals 
 
We used the method described in Katz to derive the initial fraction vectors 
jP − the ratio of department-specific cost to total hospital cost8.191  This 
required several steps.  First multiple simulation methods were used where, in 
each of 1000 iterations, a random draw was taken from a multivariate normal 
distribution around the estimators, with a mean vector consisting of the 
maximum likelihood estimates of the coefficients and the variance-covariance 
matrix derived from the regression results. The expected values were then 
computed for the log-ratios P1 to P5, done 1000 times for each of the original 
values for the explanatory variables, using the variance matrix constructed 
from the regression estimates of 12σ  to 52σ  and sρ .  
 
Second, the simulated expected values were back-transformed by multiplying 
their exponent by the smearing correction factor to correct the bias introduced 
by the fact that while the expected value of the residuals in the log space has a 
mean of zero, it might not be the case in the natural scale.175  The smearing 
correction was calculated as follows: If the n residuals in log space are denoted 
by ri, and b is the base of logarithm used, the smearing correction factor, biasC , 
for the logarithmic transformation is given by: 
 
∑
=
=
n
i
r
bias ib
n
C
1
1
.       
 (4) 
 
Multiplying the anti-log of the expected value of the log-ratios jµ  by Eq. (4) 
gives: 
 
jbiasj CunbiasedY µexp*)( = .     
 (5) 
 
The smearing correction factor ( biasC ) of the best-fit model was 1.12. 
 
Third, the product from Eq. (6) was transformed into the initial proportions of 
department costs to total hospital costs (see Eq. (1)) using the multivariate 
logistic transformation: 
                                                 
8 Note that the model estimates the log-ratios of the department-specific costs to 
outpatient department costs. 
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YP ,       (6) 
with 6P calculated as 1 – 54321 PPPPP −−−− . 
 
Thus, in generating 1000 simulations of the fraction vector jP , we can 
summarize the probability distribution of the predicted proportions of the six 
departments given values of the explanatory variables. In this way, this 
analysis accounted for both types of uncertainty arising from using statistical 
models: estimation uncertainty arising from not knowing the estimated 
coefficients perfectly, and fundamental uncertainty represented by the 
stochastic component as a result of unobservable factors that may influence 
the dependent variable but are not included in the explanatory variables.170  
 
As a practical application of the model, two quantities of interest can be 
computed. The first is the department-specific average unit cost ratio - e.g. the 
cost of an inpatient day in that department to the cost of an outpatient visit. 
The second is the department-specific average cost per bed-day or outpatient 
visit. The derivation of these quantities is explained below. 
 
 
7.2.5. 1  Estimating department-specific average unit cost ratios 
 
Using the estimates from Eq. (6) and information on the number of bed days 
and outpatient visits we can derive the average department-specific unit cost 
ratios as follows. 
 
)*/()*()/( jJijij BdPVPucopvucw = ,    
 (7) 
 
where )/( ij ucopvucw  is the ratio of unit cost per bed day of the jth 
department to the unit cost per outpatient visit in the outpatient department, 
jP is the ratio of cost of the jth department to total hospital cost estimated 
from Eq. (6), iV  is total number of outpatient visits of hospital i, JP is the 
proportion that was omitted from the model (ratio of cost of outpatient 
department to total cost) which corresponds to 6P  in Eq. (6) , and jBd  is the 
number of bed-days of the jth department. 
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7.2.5. 2  Estimating department-specific unit costs 
 
From the ratios computed in Eq. (6), the unit cost of a particular department 
can be calculated as:  
ijjiij BdPTCUC /*=  ,      (8) 
where ijUC  is the unit cost of the jth department of hospital i, iTC   is total 
hospital cost, jP is the ratio of cost of the jth department to total hospital cost 
(assuming an average ratio is used but the specific ratio for hospital i could be 
used instead) and ijBd  the number of bed days of the jth department. 
 
 
7. 3  Results     
 
Table 7. 2 shows the results of the feasible generalized least squares estimates 
of the system of equations described in Eq. (3a-3e). The model variables 
explained a large proportion of the variation in department-specific ratios, the 
R-squared varied between 0.83 and 0.92. The F statistics for each equation are 
highly significant, varying between 112 and 372. The null hypothesis of a zero 
correlation between residuals was rejected (Breusch-Pagan test, chi2(10) =  297, 
p < 0.00001), which confirms the appropriateness of using seemingly unrelated 
regression for this analysis rather than estimating each equation separately, 
see Table 7. 3. 
 
The signs of the estimated parameters conformed with microeconomic theory 
and the expected determinants of cost. For example, the higher the number of 
staff and bed days in the inpatient department, the higher the ratio of the costs 
of that department to the costs of the outpatient department. Given that the 
number of bed-days is included in the equation, the occupancy rate can be 
considered to be an efficiency variable so that holding bed-days constant, a 
higher occupancy rate reduces the ratio because of the increased efficiency.  
 
As mentioned earlier, 40% of the data come from Henan district. The raw data 
from this province showed systematically lower proportions for all 
departments than the rest of the provinces, which is the reason for the 
statistical significance of the dummy variable for this province. The sign of the 
regression coefficient suggests also that the ratios were systematically lower in 
this province, holding other explanators constant. Possible reasons for this 
finding are discussed in the conclusions. 
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Table 7. 2  Results of the seemingly unrelated regression using iterated 
feasible generalized least squares estimates. 
 
Seemingly unrelated regression, iterated     Observations = 41 
Equation RMSE R-squared F-Statistic      P>F 
lnpg 0.5229 0.8579 306.17 <0.0001 
lnpm 0.4402 0.9095 238.45 <0.0001 
lnps 0.4384 0.9201 372.83 <0.0001 
lnpp 0.5951 0.8942 112.91 <0.0001 
lnpoth 0.5418 0.8309 134.94 <0.0001 
 
 B Coef Std. Err. t P>t 95% Conf. Interval 
Lnpg   
Lng_occupancy -0.2411 0.0468 -5.16 <0.0001 -0.3334 -0.1489 
Lng_bday_tbd 0.6620 0.0321 20.61 <0.0001 0.5986 0.7254 
Lng_staff 0.2692 0.0301 8.94 <0.0001 0.2098 0.3287 
Henan -0.5654 0.1651 -3.42 <0.0001 -0.8912 -0.2397 
constant -1.3783 0.1917 -7.19 <0.0001 -1.7565 -1.0002 
Lnpm       
Lnm_occupancy -0.0024 0.0613 -0.04 0.9690 -0.1236 0.1187 
Lnm_bday_tbd 0.7797 0.0349 22.32 <0.0001 0.7109 0.8488 
Lnm_staff 0.2755 0.0353 7.80 <0.0001 0.2058 0.3452 
Henan -0.4916 0.1514 -3.25 0.0010 -0.7904 -0.1928 
constant -0.8996 0.1958 -4.60 <0.0001 -1.2859 -0.5133 
Lnps       
Lns_occupancy -0.1143 0.0287 -3.98 <0.0001 -0.1709 -0.0577 
Lns_bday_tbd 0.7813 0.0289 27.05 <0.0001 0.7243 0.8383 
Lns_staff 0.2914 0.0336 8.66 <0.0001 0.2250 0.3578 
Henan -0.4528 0.1469 -3.08 0.0020 -0.7427 -0.1629 
constant -1.1119 0.1883 -5.90 <0.0001 -1.4835 -0.7403 
Lnpp       
Lnp_occupancy -0.3607 0.1310 -2.75 0.0060 -0.6191 -0.1023 
Lnp_bday_tbd 0.9024 0.0621 14.54 <0.0001 0.7799 1.0248 
Lnp_staff 0.3459 0.0795 4.35 <0.0001 0.1889 0.5027 
Henan -0.6970 0.2392 -2.91 0.0040 -1.1691 -0.2249 
constant -0.3166 0.2759 -1.15 0.2530 -0.8609 0.2277 
Lnpoth      
lnoth_occupancy -0.2559 0.0532 -4.81 <0.0001 -0.3609 -0.1509 
lnoth_bday_tbd 0.6355 0.0356 17.86 <0.0001 0.5652 0.7057 
lnoth_staff 0.2346 0.0559 4.19 <0.0001 0.1242 0.3449 
Henan -0.6787 0.1729 -3.93 <0.0001 -1.0197 -0.3376 
constant -1.6446 0.2572 -6.39 <0.0001 -2.1523 -1.1369 
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Table 7. 3  Correlation matrix of residuals: 
Breusch-Pagan test of independence: chi2 (10) =   297  P < 0.00001 
 
             lnpg     lnpm     lnps    lnpp      lnpoth 
  lnpg    1.00 
  lnpm    0.94 1.00 
  lnps    0.97 0.94 1.00 
  lnpp  0.97 0.93 0.94 1.00      
  lnpoth    0.67 0.72 0.60 1.00 
 
 
This model can be used to estimate two quantities of interest for hospitals with 
any set of characteristics. The first is the department-specific average unit cost 
ratio and the second is department-specific average cost per bed day and per 
outpatient visit.   
 
Table 7. 4 shows the average unit cost ratios for the four main inpatient 
departments, which varied between 3.14:1 to 4.64:1. These are based on the 
expected proportions calculated from the model (see Eq. (7)) and the observed 
values of the explanatory variables from the data set. All department-specific 
unit cost ratios are significantly different to each other except the ratios of the 
unit cost per bed-day at the obstetrics/gynaecology and surgical departments 
to the unit cost per outpatient visit (paired t test, p<0.0001). 
 
The fact that the coefficients in the equations of Table 7. 2 are statistically 
significant does not necessarily imply that each explanatory variable 
substantially effects the ratio of inpatient to outpatient unit costs. These effects 
are illustrated in Figure 7. 1 for the two explanatory variables with the smallest 
absolute value of the coefficients, occupancy rate and number of staff. Except 
in the case of occupancy rate on the internal medicine department, the effect 
on the cost ratio of varying the explanatory variables can, in fact, be 
substantial. 
 
Occupancy rate has a non-linear negative relationship to the ratio of inpatient 
to outpatient unit costs (except for the internal medicine department). For 
example, the variation in the occupancy rate observed across the sample 
causes the ratio to vary from 4:1 to 6:1 for the surgery department. The ratio 
for the pediatrics department varies between 3:1 and 5:1. Changing the 
number of staff has the opposite effect on all four departments where a higher 
number of staff increases the unit cost ratio − from a minimum of 2:1 to a 
maximum of 6:1 for the surgery department, for example. 
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Table 7. 4  Ratio of department-specific cost per bed-day to the cost per 
outpatient visit     Observations = 41 
 
Variable Mean Std. Err. [95% Conf. Interval] 
ratio_go 4.00 0.28              3.43            4.57 
ratio_mo 4.64 0.33              3.98            5.31 
ratio_so 4.12 0.29              3.53            4.70 
ratio_po 3.14 0.24              5.33            7.45 
*ratio_go = ratio of unit cost of Ob/Gyn to outpatient department, mo = 
Internal medicine to outpatient, so = surgery to outpatient, po = pediatric to 
outpatient. 
 
 
Figure 7. 1  The relationship between the department-specific ratio of cost 
per bed day to cost per outpatient visit (Y axis) on department-specific 
determinants (X axis). 
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BD: bed day, OPV: outpatient visit, OB/GYN. Obstetrics and gynaecology. 
 
 
Finally, Table 7. 5 presents the second quantity of interest that can be 
calculated from the model, the department-specific cost per bed-day or visit. 
The average unit costs are estimated as shown in Eq. (8) using the observed 
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values of explanatory variables in the data set. The actual estimates from the 
detailed step-down costing procedure are also presented for comparative 
purposes. The way this information can be used is discussed in the next 
section. 
 
Table 7. 5  Model estimates of department-specific costs per bed-day in 2000 
Chinese yuan (CY)    (US$ in parenthesis: $1 = 8.3CY)  Observations = 41 
 
Variable* Mean 
(observed) 
Mean (Model) Std. Err. 
(Model) 
[95% Conf. Interval] 
(Model) 
ucg 259.88 (31) 306.41 (37) 28.89 248.02          364.80 
ucm 300.79 (36) 355.50 (43) 34.51 285.74          425.26 
ucs 199.32 (32) 237.20 (38) 22.34 192.05          282.34 
ucp 269.04 (24) 313.34 (29) 28.70 255.34          371.34 
ucopv 80.29 (10) 78.18   (9) 4.95  68.174          88.18 
*uc = cost per bed-day, g= Ob/Gyn, m= internal medicine, s= surgery, p= 
pediatric, opv = outpatient visit 
 
 
7. 4  Conclusion 
 
In this paper we have described a model to examine the determinants of 
department-specific ratios of inpatient to outpatient costs.  We then showed 
how the model could be used to estimate the cost of an inpatient bed-day or an 
outpatient visit for a hospital with any given set of characteristics. The 
statistical basis relies on the adaptation of models for compositional data that 
were previously developed for the estimation of demand shares and electoral 
votes, among others. Compositional models take account of the key features of 
this type of data, namely that the share attributable to each fraction is bounded 
by zero and one, and that all of the fractions must sum to one. As 
demonstrated by Smith, using seemingly unrelated regressions leads to 
significant improvement in efficiency of the estimation of compositional data 
through modelling, rather than ignoring, the correlated errors between 
equations. This is most valuable when most of the independent variables vary 
across equations, as in this case.193 
 
The results showed that the ratio of inpatient to outpatient unit costs in this 
sample of Chinese hospitals is, on average, close to the simple rules of thumb 
(e.g. 3:1 and 4:1) suggested by earlier studies. However, it varies substantially 
by type of inpatient department according to a number of other explanatory 
variables, so that it is not uncommon for the ratio to be 5:1 or even 6:1. Much 
of the variation was due to differences in the number of staff and the 
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proportion of department-specific bed-days to total bed-days, although some 
variability was also due to differences in occupancy rates. 
 
All cost ratios from Henan province were significantly lower than the 
proportions estimated from the other 11 provinces in the data set. 
Consultation with the Henan Provincial Department of Public Health clarified 
that during the period 1988 to 1998, the global public health policy of the 
provincial government and the ministry of health declared investment on the 
infrastructure (e.g., building) of public hospitals as a priority. In China, public 
hospitals are usually designed to consist of two main buildings, one for 
outpatient services and the second for inpatients. Each building includes 
general and specialty clinics and wards, but the outpatient building also 
includes the laboratory, radiology and imaging (e.g., Computerized 
Tomography, Magnetic Resonance Imaging) services. As a result, the 
outpatient building absorbed most of the capital investment during this 10-
year period. It is not surprising, therefore, to find lower cost ratios (due to 
higher costs of outpatient departments, the denominator of the ratio) in Henan 
compared with the other provinces.  
 
The most accurate way of developing cost estimates is to undertake a full step-
down costing study.  Where this information does not exist for a given 
hospital, the analysis in this paper suggests that equations such as those 
reported above could be used to estimate unit costs if explanatory variables 
such as occupancy rate, staff and the number of bed days are known.  
Uncertainty intervals can also be estimated. This information can then be used 
for planning, monitoring and forecasting purposes such as in the allocation of 
budgets between departments. The model can also be used in analyzing the 
expected changes in total costs or cost per bed-day if certain parameters were 
varied, e.g., the impact of a reduction in the number of staff or a higher 
occupancy rate.  
 
The results also suggest that caution should be taken when using the result of 
a single hospital costing study as the basis of subsequent cost-effectiveness 
studies or in estimates of the costs of increasing coverage of particular 
interventions.202  These studies might well use unit costs that are 
unrepresentative of the country as a whole if they do not assess whether the 
levels of capacity utilization, staff and bed days, shown here to influence 
hospital costs, are representative.180   
 
This work is the first to attempt to explain the determinants of variation of 
hospital costs across departments, applied to Chinese hospitals. Further 
innovations may be possible in future development of this work, including 
development of compositional models designed specifically for panel data or 
using a multi-country analysis to explain variation in determinants of 
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department-specific hospital costs across countries. If there is a standard 
relationship of the determinants of hospital costs across countries, this would 
be particularly valuable for cost-effectiveness studies or national scaling up 
estimates in countries where full step-down costing studies do not exist.4;203  
Although it would be preferable for analysts to estimate department-specific 
costs using the step-down procedure if time and financial resources permit, 
this paper shows that econometric analysis of existing data can provide useful 
estimates in the interim. 
 
 
Annex 7. 1 List of provinces included in the data-set 
 
Province Frequency Percent Cumulative percent 
Beijing 1 2.44 2.44 
Fujian 1 2.44 4.88 
Gansu 1 2.44 7.32 
Guangdong 3 7.32 14.63 
Guizhou 2 4.88 19.51 
Hebei 3 7.32 26.83 
Henan 17 41.46 68.29 
Hubei 3 7.32 75.61 
Jiangxi 3 7.32 82.93 
Shandong 1 2.44 85.37 
Sichuan 2 4.88 90.24 
Zhejiang 4 9.76 100.00 
Total 41  100  
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Chapter 8.     Capacity constraints to the 
adoption of new interventions: Consultation time and 
the Integrated Management of Childhood Illness in 
Brazil  
 
 
 
Summary 
 
 
Information on how health workers spend their time can help programme 
managers determine whether it is possible to add new services or activities to 
their schedules and at what cost. One intervention with the potential to reduce 
under-five mortality is the Integrated Management of Childhood Illness 
(IMCI). Although it has been shown that IMCI is associated with improved 
quality of care, it is important to determine if it also requires additional 
consultation time. To investigate the amount of time required to provide 
clinical care to children under-five based on IMCI compared with routine care, 
a time and motion study was conducted in Northeast Brazil.  
  
IMCI-trained providers spent 1 minute and 26 seconds longer per consultation 
with under-fives than untrained providers, holding confounding factors 
constant.  The difference was greater when patient load was low, and 
decreased as the number of patients a provider saw per day increased.  This 
has three implications.  Firstly, the ability of the system to absorb new 
technologies depends on current capacity utilization.  Second, the cost of 
treating a child also depends on the level of capacity utilization, at least in 
terms of provider time.  Thirdly, where patient loads are high it is important to 
determine if the quality of care required for IMCI can be maintained.   
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8. 1  Introduction 
 
The decision to provide a new intervention, or to modify an old one, poses 
important questions regarding the resources required, one of which is staff 
time. At the margin, if health workers are currently fully occupied, it would 
not be possible to incorporate new activities that require additional time 
inputs unless new staff were employed or existing activities were eliminated 
or reduced.  Information on how health workers currently spend their time 
can help programme managers determine whether it is possible to add new 
services within existing capacity constraints on health worker time. 
 
The World Health Organization has estimated that almost 50% of global 
childhood deaths are due to pneumonia, diarrhoea, measles or malaria, in 
combination with malnutrition, all of which are preventable or treatable.204  
One of the interventions that has been shown to improve the quality of child 
care and has the potential to reduce under-five mortality is the Integrated 
Management of Childhood Illness (IMCI).70;73;91;205;206 The strategy includes 
three components: improving case-management skills of health workers, 
improving health system support and improving family and community 
practices.68;207 It started to be introduced in Brazil in 1996 and is moving ahead 
in several states, particularly in the northeast and northern regions that exhibit 
the country’s poorest socioeconomic and health indicators.208 The strategy 
adopted by Brazil focused on care at the level of the primary health facility, 
and no community component specific to IMCI has yet been implemented.209 
 
At the time IMCI was developed, it was expected to have a positive impact on 
health outcomes,68 but it was also expected to be more costly than routine care 
partly because it involves more clinical tasks which would take more time for 
a provider to deliver.75  To investigate the amount of time required to provide 
clinical care to under-fives based on IMCI in a setting where it has been 
incorporated into primary health care facilities, as opposed to a trial setting, a 
time and motion study was conducted in Northeast Brazil, one of five sites 
participating in the Multi-Country Evaluation of the effectiveness, cost and 
impact of IMCI (MCE). See www.who.int/imci-mce for more details on IMCI 
and the MCE.   In order to isolate the effect of IMCI from other causal factors, 
the study also sought to identify other determinants of variations in 
consultation time across providers. 
 
IMCI in Brazil has been implemented in the context of a Family Health 
Program (FHP), supported by the World Bank and the Ministry of Health 
(MoH). The FHP teams are based in first-level government facilities (known as 
Family Health Program facilities) and a given facility may have one or more 
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family health teams depending on the size of its catchment area. Each FHP 
team includes a family physician, a registered nurse, two health auxiliaries, 
and 4-6 community health workers (CHW). For more information about IMCI 
implementation in Brazil see Amaral et al 2004.205 
 
In this paper we report the results of the time and motion study conducted 
early in 2003. The main objectives were to identify the length of time spent by 
providers in consultations with under-fives, to isolate the effect of IMCI 
training on the length of consultations from the impact of other possible 
determinants, and to determine if any additional time IMCI providers devoted 
to under-fives was related to constraints on the amount of time they had 
available.  Other types of capacity constraints, such as the availability of 
consulting rooms or equipment, were not explored.  
 
 
8. 2  Methods 
 
8.2. 1  Methods of the time and motion study 
 
Two methods have been used in time and motion studies in health services 
research: continuous observation CO, and work sampling WS.5 In CO, an 
observer measures on a continuous basis the time consumed by the observed 
person in carrying out the different activities of the day. This method requires 
a constant physical presence of the observer with the person being observed. 
In the WS method, one or more than one health workers can be observed at a 
time. The observer records what each person is doing at a certain point of time 
either at fixed intervals - perhaps each 5 or 10 minutes - or on a random basis. 
Typically, an inference is made about the portion of overall work time spent 
on an activity, based on the percent of observations that relate to that activity.  
The observer does not need to follow the member of personnel but can be 
located at a presumably unobtrusive observation point.6  
 
We used the CO method as it has the advantage of providing an exact estimate 
of the time spent with each patient encounter, which is the main purpose of 
this analysis. In addition, the WS methods is more appropriate when health 
workers are in a circumscribed area such as a hospital ward setting,5 while in 
the primary health facilities we visited there were no obvious places where 
observer could have good visual access to most of the health workers at the 
same point of time.  
 
One of the main limitations of time and motion studies is the bias introduced 
via the Hawthorne effect, where observed health workers, being conscious of 
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the fact they are being observed, may change their usual working patterns. 
This is an inevitable consequence of any time and motion study, perhaps more 
in the CO method due to the direct observation.5 However, this does not 
change the fact that time and motion studies are  considered to be the most 
accurate method of measuring staff time compared with the alternatives of 
personnel interviews, self administered time sheets and patient flow analysis 
methods.7 In addition, it can be argued that busy health workers will not be 
able to change their normal practice patterns for a long period of time, so after 
the initial observation period they soon return to their normal working 
patterns.  To allow for a possible short term Hawthorne effect, in the analysis 
we tested whether the results from the first day of observation differed 
significantly from those of subsequent days.   
 
8.2. 2  Selection of the study facilities and providers 
 
The larger evaluation of IMCI in Brazil (i.e. the MCE) has a mixed 
retrospective-prospective design, since IMCI was already well implemented in 
many municipalities at the time the study was designed.  Four states in 
Northeast Brazil - Bahia, Ceará, Paraíba and Pernambuco - were included 
based on the fact that IMCI implementation was reported to be strong in 
selected municipalities in those states. Health workers would, therefore, be 
more likely to have developed long-term practice patterns based on IMCI.  The 
initial IMCI training had lasted eight days in Bahia and Pernambuco and six 
days in the two other states. For more detail on sampling methods and the 
rationale see Amaral et al 2004.205 
 
The time and motion study was performed in only three of the four states 
included in the MCE, Ceará, Paraíba and Pernambuco.  Preliminary 
information from Bahia suggested that IMCI had not yet been widely enough 
implemented to warrant the comparison. Data were collected from a sub-
sample of facilities included in the Health Facility Survey (HFS) conducted in 
2002 for the evaluation of IMCI. The sample size was determined using the 
mean and standard deviation estimates of consultation times for IMCI and 
non-IMCI trained providers from the MCE study in Tanzania, the only other 
site which had undertaken such a study, with an alpha of 5% and acceptable 
error of 2 minutes. Data were collected from a total of 32 facilities, of which 
half were practising IMCI.  In each state, facilities were selected at random 
from those included in the HFS, stratified by the availability or not of an IMCI-
trained provider. At the time of data collection, the observer selected one 
provider at random from those available at the first day of observation and 
who reportedly examined under-five children. Where the selected provider 
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was absent on one of the subsequent  days of observation, the observer was 
required to randomly select another provider, who would then be observed 
for the remaining days of observation.  
Health facilities in Northeast Brazil have two modes of service delivery: 
integrated, where the health worker offers all types of health services every day 
of the working week; and vertical, where a different kind of health service is 
offered each day – for example, prenatal care on Monday; sick children on 
Tuesday; etc. Therefore, two methods of observation were used, one for 
vertical and another for integrated-service facilities.  
 
In integrated-service facilities, data were collected for two consecutive days, 
selected at random.  This was to ensure that some days where there might be 
high levels of utilization and some where there could be low levels, were 
included.  The sample of integrated-service facilities included 16 facilities (8 
IMCI and 8 comparison) with a total of 32 observation days. 
 
In vertical-service facilities, data were collected for one working week (5 days) 
in each of the sampled facilities. Facilities were selected at random, and the 
order of data collection weeks was selected on the basis of logistic 
considerations. The one-week data collection period was to explore whether 
sick children sought care on non-children days and to explore variation in the 
use of staff time on the different days of the week, and the effect of this form of 
service delivery on the availability and duration of “down” time. The sample 
included 16 vertical-service facilities (8 IMCI and 8 comparison), with a total of 
80 observation days.  As described above, only the provider seeing patients on 
the day of the visit was observed.  This resulted in 47 providers observed in all 
types of facilities, 34 physicians and 13 nurses. Only two providers had to be 
replaced due to absence on one of the observation days.  The analysis reported 
here focuses on physician providers, the main providers of curative care, 
because the number of observations for nurses was too low to carry out the 
analysis.  
 
 
8.2. 3  Data collection 
 
The study took place in April-May 2003. The data collection tool was 
developed and pre-tested in English by the MCE team. A full field test of the 
survey instrument, which was translated into Portuguese, was carried out 
during the one week training of the survey teams. Three surveyors collected 
data, one in each state, to avoid problems of inter-rater variability within 
states. All of them were qualified nurses and had spent part of their working 
career in health facilities.  Each surveyor recorded the time at which every 
activity, including all breaks and pauses, began and ended, and what activity 
was being carried out. Before the data collection started, the observer used a 
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standard, field tested, introduction to explain the purpose of the study to the 
person in charge of the facility and to the randomly selected provider. The 
introduction emphasized that the purpose of the observation was to record the 
usual types of activities performed by the health worker during a routine 
working day; that it was not concerned with the quality of work involved; that 
he/she was selected at random to represent their facilities. Finally, their 
consent to participating in the study was obtained.   
 
 
8.2. 4  Quality control 
 
Supervision visits were made to all three states at least twice during the two 
month data collection period to check that the surveyors were carrying out the 
observation and were filling in the forms correctly, and for solving data-
related problems. The supervisors checked all the forms for completeness and 
consistency during the supervisory visits and when data were being entered. 
Through this mechanism we sought to reduce the inter-rater variation across 
states. 
 
 
8.2. 5  Methods of Analysis 
 
As described above, the aim of the time and motion study was to record the 
time health workers who examined under-fives spent on the different 
activities in primary health facilities.  Following Bratt et al. (1999),7 the main 
activities are classified into three categories: contact time, non-contact 
productive time, and non-productive time. Contact time, or time spent with 
patients (or healthy people for preventive services such as immunization) is 
further divided into time spent caring for over-fives and for under-fives.   
 
This paper focuses on consultation time with under-five children. 
Consultation time was estimated in two ways. The first computes the average 
consultation time for IMCI and non-IMCI providers, by state, without 
controlling for any possible confounders. The second uses regression analysis 
to explore and control for other possible determinants of consultation time.  
STATA  software was used for the analysis.86   
 
 
8.2.5. 1  Unadjusted average consultation time 
 
The average consultation time was estimated as the total minutes a provider 
spent with children under five divided by the number of children seen. 
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Because there were instances where more than one person presented for a 
given consultation or the health worker was interrupted to perform another 
activity, (e.g. to examine another emergency case or resolve urgent 
administrative issues), the average time was estimated separately for 
consultations with and without these factors. This information is used in the 
regressions.   
 
8.2.5. 2  Regression analysis 
 
8.2.5.2. 1  Model specification 
 
The possible determinants of consultation time for which information could be 
collected are included in Table 8. 1.  The choice of explanatory variables was 
partly related to economic theory and partly determined by the nature and 
purpose of the exercise. For example, the number of consultations per 
provider per day  is used as a measure of workload or the constraints on 
provider time; the total hours a provider works per day is also a measure of 
time availability, in particular as an indicator of whether the provider works 
part  or full time, something that might modify behaviour.  We also controlled  
for factors such as  morning versus afternoon shifts to explore if patterns of 
behaviour changed during the day; the sex of provider; where multiple people 
presented for a particular consultation; and whether the consultation was 
interrupted for any reason.  
 
 
Table 8. 1 Description of variables explored in the regression analysisi 
 
Variable name Definition 
IMCI  IMCI-trained =1, otherwise = 0  
Single visit Single or multiple persons presenting at the same visit: 
single visit =1, otherwise = 0 
Interruption Whether the consultation was interrupted by another 
consultation or activity: interrupted=1, otherwise = 0 
Home visit Consultation took place at the patient’s home: home visit 
=1, otherwise = 0 
Outreach visit Indicates a consultation at an outreach (usually a small 
health post in remote areas) site, outreach =1, otherwise = 0  
Day one First day of observation (to assess a possible Hawthorne 
effect): Day one=1, otherwise=0 
Morning-
afternoon 
Whether consultation occurred during  the morning or the 
afternoon shift. Morning=1, afternoon = 0 
                                                                CHAPTER 8                                              
                                                                  
                                                           
                                                                                       
 128 
Variable name Definition 
Facility type 
 
Indicate facility size. 1=small facility, 0= health centre, 
serving more than one facility 
Sex Sex of provider: male =1, female = 0 
Ceará Observation is from Ceara state, Ceara=1, otherwise = 0 
Paraíba Indicate observation is from Paraíba state, Paraíba=1, 
otherwise= 0 
Ln visits per 
provider per day 
Natural log of consultations per provider per day 
Ln hours per 
provider per day 
Natural log of working hours per provider per day 
Ceará_lnvisits Joint effect of Ceará with natural log of consultations per 
provider per day 
Paraíba_lnvisits Joint effect of Paraíba with natural log of consultations per 
provider per day 
Ceará_lnhours Joint effect of Ceará with natural log of working hours per 
provider per day 
Paraíba_lnhours Joint effect of Paraíba with natural log of working hours per 
provider per day 
i Note: Only those variables included in the final model are shown in the 
Results Section. 
 
 
The inclusion of state-specific variables makes it possible to control for 
differences in state characteristics that might affect the behaviour of health 
providers, such as the duration of IMCI training, degree of financial and 
political support to child health services and frequency of supervision.  It was 
not possible to obtain information on these variables specific to each facility 
and provider, so the state variable was used instead.   
 
Finally, we explored the joint effect of key variables on consultation time.201  
For example, if the relationship between number of consultation per provider 
per day varies by state. Only those which were included in the final model are 
presented here.  
  
Double log transformation was used to normalize the dependent variable and 
to linearize the regression model.210 Log transformation has the added 
advantage that coefficients can be readily interpreted as elasticities.211 Natural 
logs were used. Finally, robust estimation methods was used to control for 
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clustering associated with having multiple observations per provider. The 
functional form can be written as:  
∑∑∑
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where 5uT  is the natural log of time per consultation with an under-five child 
(in minutes); 0α  is the intercept; iα  are the estimated parameters for the n 
explanatory variables  iΧ ; ),( ijjiijij ≠= ααα  are the estimated parameters 
for the joint effect of selected X variables, as described in Table 8. 1. Only those 
variables included in the final model are shown in the Results Section.  
 
 
8.2.5.2. 2  Model fit 
 
Regression diagnostics were used to judge the goodness-of-fit of the model. 
They included the tolerance test for multi-collinearity, its reciprocal variance 
inflation factors and estimates of adjusted R square and F statistics of the 
regression model.  
 
 
8. 3  Results 
 
8.3. 1  Univariate analysis 
 
Results of the univariate analysis are shown in Table 8. 2. IMCI-trained 
providers spent on average 7.27, 8.57 and 13.44 minutes in consultation with 
under-five children in Ceará, Paraíba and Pernambuco respectively. The range 
was much smaller in the comparison group where they spent 7.56, 6.16 and 
6.29 respectively.  Although IMCI-trained providers spent less time per 
consultation on average than the comparison group in Ceará, the difference is 
small and not statistically significant. In addition, these results did not hold 
after controlling for confounders, as described below. In the two other states, 
Paraíba and Pernambuco, IMCI-trained providers spent significantly longer 
than their counterparts in the comparison group, the difference being greatest 
in Pernambuco at almost 7 minutes per consultation.  Taken together, and 
without adjusting for confounders, IMCI-trained providers spent almost 4 
more minutes per average consultation than providers in the comparison 
group (p<0.0001).   
 
These results raise the question of whether IMCI-trained providers in Paraíba  
and Pernambuco compensated for spending more time with under-fives by 
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spending less time with over-fives. Table 8. 2 shows that this was not the case. 
IMCI-trained providers in those states also spent significantly more time with 
patients over five years than their counterparts who were not trained in IMCI.   
 
 
Table 8. 2  Average time spent (in minutes) by physicians in consultations at 
health facilities —presented separately for under-five and over-five years of 
age. 
 
Under-five Over-five 
IMCI 
 
Compa-
rison 
IMCI Compa-
rison 
 
Mean 
(SD) 
Mean 
(SD) 
P (t) 
 
Mean 
(SD) 
Mean 
(SD) 
P (t) 
 
Ceará 7.27 
(3.20) 
7.56 
(3.52) 
0.53 
(0.62) 
5.58 
(3.23) 
8.34 
(6.34) 
<0.0001 
(5.43) 
Paraíba 8.57 
(5.01) 
6.16 
(3.36) 
0.002 
(-3.11) 
7.17 
(5.14) 
5.35 
(3.13) 
<0.0001 
(-4.10) 
Pernambuco 13.44 
(6.22) 
6.29 
(3.21) 
<0.0001 
(-11.27) 
13.12 
(7.29) 
8.03 
(4.36) 
<0.0001 
(-8.46) 
Average 11.08 
(6.15) 
6.46 
(3.34) 
<0.0001 
(-9.04) 
7.55 
(5.51) 
7.56 
(5.09) 
0.12 
(-1.56) 
 
 
This was not found in Ceará, however, where IMCI-trained providers spent 
significantly less time with over-fives compared with their counterparts (5.58 
and 8.34 minutes respectively, p<0.0001). As in the case of the time spent in 
consultation with under-fives, it would be important to determine if this is due 
to IMCI or other possible determinants of consultation time.  The purpose of 
this paper is to focus on children under-five, so that analysis is not undertaken 
here.   
 
 
8.3. 2  Regression analysis 
 
The results of the best fit model to explore whether consultation time remains 
correlated with the presence of IMCI even after controlling for potential 
confounders are presented in Table 8. 3, see Table 8. 1 for description of 
variable names. The adjusted R-square was 0.32, with an F statistic of 38.92 
(p<0.0001).. The tolerance fell between 0.43 and 0.97 and the mean variance 
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inflation factors (VIF) was 1.48, so no evidence of multi-collinearity was 
detected— tolerance less than 0.05 and VIF more than 20 indicate presence of 
multi-collinearity. Residual plots showed a uniform distribution of the model 
residuals with a mean of zero and no specific pattern of distribution. 
 
The positive signs of the coefficient of the variable denoting IMCI-trained 
providers and interrupted consultations; and the negative signs of the 
coefficients of number of consultations per provider per day and single visit 
are consistent with a priori expectations. The results show that, holding all 
other variables constant,  IMCI trained providers spent 1 minute and 26 
seconds more on average in consultation with under-fives than untrained 
providers (p<0.0001). Consultation time was negatively correlated with the 
number of consultations per provider per day — each 1 % increase in the 
number of consultations results in a 0.50% decrease in consultation time per 
under-five child (p<0.0001), see Table 8. 3 and Figure 8. 1a. 
 
 
Figure 8. 1  Effect of (a) number of consultations per provider per day  or (b) 
hours worked per day (X axes) on consultation time with under-fives (Y 
axis), estimated separately for each state and for IMCI-trained and non-
trained providers. 
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 It is worth noting that the number of consultations per provider per day may 
be mediated by IMCI, i.e., people may choose to use IMCI providers due to 
perceived higher quality associated with IMCI training. This did not seem to 
be the case in our sample, as the mean consultations per provider per day was 
similar in facilities with and without an IMCI-trained provider (31 and 36 per 
day respectively, p=0.09).  Accordingly, we treat this variable as a potential 
exogenous confounder rather than endogenous to the model. 
 
 
Table 8. 3  Results of  the multivariate regression model (dependent 
variable: natural log of time (minutes) per consultation with under-five 
child).  
 
Adjusted R2 = 0.32         F-statistic = 38.92   p <0.0001          N = 730  
95%confidence-
Interval 
Variable β  
coef. 
   S E t    P 
   Low      high 
IMCI 0.36 0.04 9.11 <0.0001 0.28 0.43 
Interruption 0.14 0.08 1.74 0.081 -0.02 0.30 
Single visit -0.40 0.05 -8.65 <0.0001 -0.49 -0.31 
Ln visits per 
provider per 
day -0.50 0.05 -10.34 
<0.0001 
-0.60 -0.41 
Ceará -2.96 0.63 -4.69 <0.0001 -4.20 -1.72 
Paraíba -13.04 4.81 -2.71 0.007 -22.48 -3.59 
Ceará_lnhours 1.32 0.28 4.69 <0.0001 0.77 1.88 
Paraíba_lnhours 5.84 2.18 2.68 0.008 1.56 10.13 
sex -0.09 0.04 -2.27 0.024 -0.17 -0.01 
Constant 4.12 0.19 22.08 <0.0001 3.75 4.48 
 
 
Consultation time was lower in Ceará and Paraíba than in Pernambuco, for 
both IMCI-trained and comparison providers. It is also worth noting that 
controlling for confounding factors showed that IMCI-trained providers spent 
longer per consultation with under-fives than the comparison group in Ceará 
as well as in the other states. This means that the findings of the univariate 
analysis presented in Table 8. 2, that IMCI providers seemed to spend less time 
than the comparison group, were due to confounding factors and not IMCI.  
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The effect of the number of consultations per provider per day did not vary by 
state, but the number of working hours per day did.  This is illustrated in  
Figure 8. 1b. The lines show the estimated consultation time based on the 
reported regression, controlling for all variables except hours worked per day,  
shown on the X axis in natural units. Consultation time (Y axis ) was converted 
into natural units (minutes) using the antilog of the dependent variable, and 
was estimated separately for IMCI-trained and comparison groups and for 
each of the three states. It was estimated for a single visit, uninterrupted, and 
performed at the health facility (e.g. not a home or outreach visit). The number 
of visits per provider per day was set at the mean value from the sample (34 
per day).  
 
The Figure shows that working more hours per day did not have any impact 
on consultation time in Pernambuco but did in Ceará and Paraíba (confirmed 
by the fact that hours per day was not significant in the final model while the 
joint effect of hours per day and the state variables was significant for Ceará 
and Paraíba). In those states, each 1% increase in hours worked per day per 
provider led to 1.32% and 5.84% increase in consultation time per under-five 
child respectively (Table 8. 3).   
 
Finally, the results show that male providers spent 55 seconds less per 
consultation with under-fives than female providers.  No statistically 
significant differences were found in consultation time between vertical versus 
integrated-service facilities, for “under-five” days versus “other” days within 
vertical-service facilities, for day one versus subsequent days of observation, 
or for home and outreach visits compared with consultations which took place 
at health facilities.  
 
 
8. 4  Discussion 
 
The main purposes of this study were to explore the effect of IMCI training on 
the length of consultation time with under-five children, and to examine how 
providers cope with any capacity constraints on their time.  The multivariate 
analysis confirms that IMCI-trained providers spent more time on the average 
consultation than non-IMCI-trained providers.  After controlling for other 
determinants, the difference was 1 minute and 26 seconds per consultation 
(p<0.0001), approximately 20% higher than the average consultation time of 
non-IMCI trained providers.  This is substantially less than the difference of 4 
minutes suggested by the univariate analysis and emphasizes the need to 
control for confounders in studies such as this.   
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The size of the difference is, however, crucially determined by constraints on 
providers’ time.  The higher the workload, the lower the difference, to the 
extent that the difference is relatively small where the workload exceeds 50 
consultations per provider per day.  This has key policy and methodological 
implications. In terms of policy, the average quality of care of IMCI providers 
has been shown to be higher than that of non-IMCI providers.70;73;91;205  It is 
important to determine if quality is also a function of the time spent per 
consultation, and if the quality of IMCI providers still exceeds that of non-
IMCI providers where workload is high.   
 
There is already some evidence that quality might well be a function of the 
time spent per consultation. The average time per consultation in Pernambuco 
was higher than that in the two other states.  At the same time, the component 
of the MCE study exploring quality of care found that IMCI providers in 
Pernambuco consistently made a higher percentage of correct disease 
classifications than IMCI providers in the other states. Significant differences 
between health workers who were trained or not trained in IMCI were found 
in the assessment of the sick child, classification of illness, treatment, as well as 
in communication with the caretaker.205  Whether this is due to more frequent 
supervision and more regular availability of drugs and vaccines in 
Pernambuco,205 to the fact that Pernambuco implemented IMCI earlier than 
the other states, to the strong support for IMCI from the State Health 
Secretariat in Pernambuco, or to the higher time per consultation is yet to be 
determined. It is important that the answer is found rapidly so as to design 
strategies to support providers facing capacity constraints on their time, if 
necessary, in all parts of Brazil where IMCI is being introduced.  
 
Methodological implications relate to the way costs are estimated for the 
purposes of cost-effectiveness analysis, for estimating the costs of benefits 
packages for health insurance, or for budgeting for the scale up of 
interventions.180;188 As  illustrated in this study, the cost per visit depends on 
the throughput of the health facility.  Where patient load is high, unit costs are 
relatively low because providers must spend less time per patient, and vice 
versa.  Moreover, the incremental cost of expanding is always less than the 
average cost of providing existing services, as expected from theory, and falls 
more rapidly where patient load is low. General policy implications should 
not be based on the results of costing studies that do not report capacity 
utilization and studies of scale-up costs will not be useful to policy-makers if 
they are based on the current costs of providing care.    
 
This result is also important for policy relating to child health.  Where current 
case loads are relatively low, providers spend additional time to provide child 
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health services based on IMCI as part of their current activities.  In our sample, 
the mean number of  consultations  per provider per day was 34 and 95% of 
the providers had case loads lower than 54 patients per day. If this is 
representative of the rest of Brazil, it would be possible to introduce IMCI 
relatively easily throughout the country without encountering capacity 
constraints in terms of provider time.  Interestingly, an unthinking cost 
analysis would suggest the opposite.  Because the observed additional time is 
greater in areas of low workload, it would suggest that the incremental 
financial costs of IMCI are higher where workload is low than where 
workload is high.  We believe the results can best be interpreted as showing 
that IMCI can be introduced without significant financial implications when 
capacity constraints on time are relatively low.   
 
It is interesting to find no evidence that the time spent per child in vertical-
service facilities differed from that in integrated facilities, or that time spent 
per child on vertical days differed to the time spent on other days in vertical-
facilities.  Indeed, we could find no evidence that the mix of patients varied by 
day in vertical-service facilities which is a relief from the medical perspective - 
it implies that patients in need of urgent care could obtain it on any day of the 
working week. This is useful information for future research in this region of 
Brazil, where it might not be necessary to account for the two different types 
of facilities in the design of future research. 
 
Another interesting finding is that there are sex differences in average 
consultation time by providers. It would be useful to explore the possible 
reasons for this in future studies. Of particular interest are questions such as 
the effect and suitability of IMCI-training materials to both sexes, and if the 
difference in time is also associated with difference between the sexes in 
quality of care.  
 
Finally, the fact that the times reported here are consistent with those observed  
in the MCE study in Tanzania, the only available comparative study, gives us 
some confidence in the results.212 The average consultation time with under-
fives in Paraíba and Ceará were very close to the 8.2 minutes observed in 
Tanzania, and only the consultation time in Pernambuco was somewhat 
longer.  In addition, Tanzanian workers spent longer on average with children 
under-five than with older people, something also observed in general in 
Brazil. The times are lower than those reported in an earlier study from 
Bangladesh,75 where IMCI providers spent on average 16 minutes per 
consultation with under-fives. That study did not try to determine how long 
they would have spent had they not been trained in IMCI.  It is not strictly 
comparable to the Brazilian study as it was undertaken immediately after 
training, while the Brazilian study was undertaken in settings some years after 
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the introduction of IMCI when the immediate effects of training are likely to 
have waned.   
 
In conclusion, the critical implication of this study is that at relatively low 
patient load, adoption of new interventions that improve quality can promote 
efficiency at primary care facilities - they can be delivered by the already 
available human resource capacity of the health system without the need to 
hire additional staff or to reduce other activities. At high patient load, IMCI-
trained providers do not spend as much additional time with children as 
providers with low patient loads.  It is important to determine if the quality of 
IMCI-trained providers is maintained in those settings.  This is an urgent need 
as countries move to scale with their delivery of child health services based on 
IMCI.   
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Chapter 9.    Achieving the WHO/UNAIDS 
antiretroviral treatment “3 by 5” goal: What will it 
cost?   
 
 
 
Summary 
 
 
The “3 by 5” goal to have 3 million people in low and middle income countries 
on antiretroviral therapy (ART) by the end of 2005 is ambitious. Estimates of 
the necessary resources are needed to facilitate resource mobilisation and 
rapid channelling of funds to where they are required. We estimated the 
financial costs needed to implement treatment protocols, by use of country-
specific estimates for 34 countries that account for 90% of the need for ART in 
resource-poor settings. We first estimated the number of people needing ART 
and supporting programmes for each country. We then estimated the cost per 
patient for each programme by country to derive total costs. We estimate that 
between US$5.1 billion and US$5.9 billion will be needed by the end of 2005 to 
provide ART, support programmes, and cover country-level administrative 
and logistic costs for 3 by 5.  
 
 
 
In September 2003, at the second UN General Assembly Special Session on 
HIV/AIDS, the World Health Organization (WHO) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) declared the lack of treatment 
in low- and middle-income countries a global public health emergency and 
launched the ‘3 by 5’ Initiative aimed at enrolling 3 million people on 
antiretroviral therapy (ART) by the end of 2005. For this ambitious goal to be 
reached, starting from a base of fewer than 200,000 patients on treatment, 
countries, donors, and multilateral agencies must know what resources need 
to be rapidly mobilised.  
 
Since previous estimates of the cost of scaling up interventions against HIV 
and AIDS were made202 new WHO recommended treatment protocols for 
resource limited settings have been published.213  We estimate the financial 
                                                                CHAPTER 9 
 140 
costs to implement these protocols using country-specific estimates for 34 
countries that account for 90% of the need for ART in resource poor settings. 
The ‘3 by 5’ strategy includes standardised treatment protocols, simplified 
clinical monitoring and record keeping, optimal use of existing health system 
resources, active involvement of communities and people living with HIV, 
plus efforts to minimise the cost of drugs and diagnostics.213;214   No major 
changes to the health system infrastructure, the quantity of available 
personnel, or in transmission as a result of ART are deemed possible given the 
short time frame.   
 
The number of people needing treatment is defined as those expected to die 
within two years in the absence of ART. People needing treatment in 2004, for 
example, are those expected to die before the end of 2006 without treatment. 
People who stop treatment or die while on treatment are replaced so that 3 
million people are alive and receiving ART at the end of 2005 (see web document 
at lancet.com for more details).  
 
The three main entry points for recruitment of eligible patients are: 
tuberculosis clinics, health facilities (in-patient and out-patient) and mother to 
child transmission prevention programmes in antenatal care clinics. Drug 
regimens and testing procedures vary by entry point (see web document at 
Lamvet.com). Two assumptions of the growth rates in coverage to reach the 
target are employed.  Slower scale-up reaches 10% of the target in 2004 and 
90% in 2005.  More rapid scale-up assumes 20% of the target met in 2004.  
 
Patient enrolment requires confirmation of positive HIV status by rapid 
testing with counselling.  A doctor or nurse confirms clinical eligibility. To 
stabilise patients starting ART and ensure continued well-being while on 
therapy, patients are diagnosed and treated for opportunistic infections (OIs). 
Medicines for prevention of OIs and laboratory tests for suspected toxicity 
help ensure successful ART, while those failing treatment require palliative 
care.   
  
Support costs at country level include training of existing health personnel, 
supervision of ART delivery, and volunteers (remunerated) providing 
adherence support to patients. Universal precautions and post-exposure 
prophylaxis are included, as are costs for limited upgrades to laboratories and 
drug storage and distribution systems. 
 
The number of facility-based visits for ART initiation and monitoring, 
frequency of adherence counselling and monitoring, laboratory tests for 
toxicity and estimated times associated with each of these activities are based 
on reports from a consensus meeting.213 Quantities of inputs used in other 
CHAPTER 9 
 141 
interventions are based on recommendations in published guidelines 
supplemented by expert opinion.  
 
Unit cost data were obtained from studies conducted in sub-Saharan Africa or 
Asia or, where no data existed, extrapolated using methods described 
elsewhere.188;215 Details of assumptions and the unit costs by intervention and 
activity for Botswana are in the web document.  
 
Two assumptions for the cost of drugs are used. The high cost option 
assumes:216;217 $304 for first line therapy (fixed-dose combination); $1108 for 
second line therapy; $706 for a switch due to toxicity; $505 for patients with TB 
($353 for 6 months then first line for the remaining 6 months); $831 for 
pregnant patients with TB ($679 for the 6 month switch). The low cost option 
uses $140 per patient per year, the price negotiated by the Clinton Foundation 
for standard first-line treatment in selected countries and which may become 
more generally available. Drug costs for other categories are assumed to 
undergo a similar cost reduction.  
 
The estimated costs for 2004-2005 are summarised in the Table 9. 1 for four 
combinations of assumptions of the rate of scale-up and pharmaceutical costs. 
The total cost is between US$ 5·1 and 5·9 billion for the two years. The mid-
point of US$ 5·5 billion dollars is used for advocacy purposes.  
 
Figure 9. 1 shows the breakdown of total two-year costs by category for 
scenario 2A of Table 9. 1. Patient costs account for over 77% of the total costs, 
with purchase and provision of ART responsible for over 43%. Universal 
precautions, post-exposure prophylaxis, and other programme costs account 
for less than 23%.  
 
 
Table 9. 1 Estimated cost of "3 by 5", 2004-2005 (US$ billions) 
 
Scenario: 2004  2005  TOTAL  
 
1A: 10%/90% with higher drug costs* $2·0 $3·8 $5·7 
1B: 10%/90% with lower drug costs $1·9 $3·2 $5·1 
2A: 20%/80% with higher drug costs $2·2 $3·7 $5·9 
2B: 20%/80% with lower drug costs $2·0 $3·1 $5·1 
10%/90% refers to 10% coverage in 2004 and 90% in 2005 
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Figure 9. 1 Distribution of total costs of "3 by 5" for 2004-2005 (Scenario 2A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The primary purpose of these estimates is to provide a global aggregate target 
to guide short run resource mobilization. Precise country estimates are being 
developed to help local planning. The figures presented here show how 
critical it is to intensify resource mobilization activities.  This is even more 
important for the longer run because the need for additional resources will 
continue to grow after 2005 as more patients are recruited, adding to surviving 
cohorts of patients. 
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OI Treatment
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OI Prophylaxis
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ART
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ART Monitoring Lab 
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Univ Precautions 
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Support Activities1 
12.2% 
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1Support Activities include post-exposure prophylaxis (PEP), and scale-up of 
preventing mother to child transmission of HIV (PMTCT) 
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Chapter 10.     Achieving the Millennium 
Development Goals for health: Methods to assess the 
costs and effects of interventions for improving health 
in developing countries 
 
 
 
Summary 
 
 
Five years after signing of the Millennium Declaration, the United Nations is 
reviewing progress towards achievement of the Millennium Development 
Goals (MDGs).  Three are exclusive to health, focusing on maternal and child 
health, HIV/AIDS, tuberculosis and malaria.  This is the first in a series of 
papers considering whether existing strategies targeting these diseases and 
conditions are the most efficient way of spending resources, and asking what 
should be done if additional resources become available.   
 
Sandardized analytical methods developed for cost-effectiveness analysis in 
the WHO-CHOICE project are used.  They allow the efficiency of the current 
use of resources to be assessed at the same time as indicating which 
interventions should be given priority when new resources become available.  
The papers also account for interactions between interventions undertaken 
simultaneously, in terms of costs and effects.  This is rarely done in cost-
effectiveness analysis despite the fact that interventions are seldom done in 
isolation.     
 
This paper provides a detailed description of the methods to assess the costs 
and effects of heath interventions in this series and how the results could lead 
to significant improvements in population health. 
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10. 1  Introduction 
 
The methods chosen to assess the cost-effectiveness of interventions designed 
to achieve the health MDGs must be capable of revealing the efficiency of 
current and possible new resource use, incorporating interactions between 
interventions undertaken at the same time, and incorporating the impact of 
expanding coverage on unit costs.218 They should also allow valid 
comparisons across a wide range of interventions. Here we describe how the 
standardized cost-effectiveness methods used in this series have addressed 
these issues.219-223     
 
 
10. 2  Methods 
 
10.2. 1 Level of the analysis  
 
The project divided countries into 14 regions based on geographical proximity 
and rates of child and adult mortality (see table A on bmj.com). Results for all 
regions are available at www.who.int/choice , but the papers in this series 
give details for just two regions: Afr-E, which  includes countries in sub-
Saharan Africa with high child mortality and very high adult mortality, and 
Sear-D, which  comprises countries in South East Asia with high child and 
adult mortality. 
 
 
10.2. 2 Definition and selection of interventions 
 
The term intervention is defined to include any preventive, promotive, 
curative or rehabilitative action that improves health. They are analysed 
individually and then in combinations or packages that could be undertaken 
together (see Box 10. 1), taking into account interactions in costs and/or 
effectiveness.  
 
Interventions were chosen for analysis either because they are commonly used 
or because disease control experts have advocated their introduction. In each 
case, some evidence was needed that the intervention could be effective. The 
list is not exhaustive, and excluding an intervention does not imply it is cost 
ineffective. 
 
All interventions and combinations are assessed assuming they are 
implemented for 10 years starting in 2000, the year the Millennium Declaration 
was signed. Good policy making would then require a reassessment of 
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strategies. Costs, therefore, are only incurred over 10 years, but all benefits 
accruing because of actions taken between 2000 and 2010 are included. 
 
Box 10. 1 Analysis of individual and combined interventions 
 
 
Interventions are analysed individually and then in combinations that could 
be undertaken together. This requires a decision about whether interventions 
are independent (they can be done at the same time in a population, with or 
without interactions) or mutually exclusive (if one is chosen, another cannot 
be). Independent interventions can be added to existing interventions, while 
mutually exclusive interventions must replace an existing intervention. 
 
Consider three individual antenatal interventions: tetanus immunisation, 
screening for pre-eclampsia, and screening and treatment for asymptomatic 
bacteruria. They are independent, so all possible combinations of the 
interventions would be: 
Tetanus immunisation + screening for pre-eclampsia 
Tetanus immunisation + screening and treatment for asymptomatic 
bacteruria 
Screening for pre-eclampsia+ screening and treatment for asymptomatic 
bacteruria 
Tetanus immunisation + screening for pre-eclampsia and asymptomatic 
bacteruria 
 
All the scenarios are assessed for different coverage levels (50%, 80%, 95%), 
introducing the idea of mutual exclusivity. Coverage at 95% must replace 
coverage at 80%. Each of the combinations of interventions are analysed 
taking into account all possible interactions in costs or effectiveness. 
Combinations of interventions must be plausible. For example, emergency 
obstetric care interventions are not included unless skilled birth attendance is 
implemented at the same time. The number of possible combinations 
increases rapidly with the addition of each new intervention 
 
 
 
10.2. 3 Intervention Costs  
 
Costs are measured from the perspective of society as a whole, to understand 
how best to use resources regardless of who pays for them, or indeed, whether 
they are paid for at all.  For example, village volunteers working for maternal 
health must be included because they could be working for some other health 
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programme if they did not work for maternal health.  All resources used for 
each intervention or combination are included and valued.  
 
Data on the costs incurred by people to access services (e.g. travel costs) are 
rarely available, and we, like most other studies, have excluded them.224;225  
Domestic taxes were also excluded.  From the perspective of the society, they 
simply transfer financial resources from one person to another and do not use 
up a physical resource such as capital or labour.  The impact of interventions 
on the time and potential earnings of patients and unpaid carers - i.e. work 
time lost - is a vexing question in cost-effectiveness analysis but, as here, they 
are often excluded on ethical grounds.  Inclusion would give priority to 
extending the life of people who earn more (seeBox 10. 2).226;227  
 
 
Box 10. 2 Cost-effectiveness analysis and economic production 
 
 
Cost-effectiveness analysis (CEA) developed partly in reaction to ethical 
concerns about the implications of cost-benefit analysis (CBA).  CBA values 
health improvements in money terms.  If it is applied properly, it gives 
higher weight to health gains in people who earn more.  CEA values each 
unit of health improvement equally regardless of the income of the recipient.  
Accordingly, production gains resulting from health interventions have not 
generally been included in CEA, although this is not by any means a 
universal practice.2 We exclude them in this series for ethical reasons, 
arguing that health professionals and planners should seek to improve 
population health to the greatest extent possible for the available resources.228  
Questions of the impact of health actions on national income require 
interaction with other sectors of the economy.  However, it is important to 
acknowledge that CEA provides only one, though important, part of the 
information set required to decide how best to allocate resources.  In this 
series of papers, economic production concerns are most relevant to 
HIV/AIDS, where it has been argued that lack of action could even lead to 
the complete breakdown of societies.229 This is discussed further in that 
paper.222 
 
 
 
Costs are evaluated assuming capacity utilization (i.e. technical efficiency) is 
relatively high, though achievable - 80% for all interventions. This is to ensure 
that differences in cost-effectiveness ratios are due to fundamental differences 
in the technologies or strategies adopted, and not simply because an 
intervention has been implemented poorly in a dysfunctional health system.  
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Accordingly, the results provide practical information about the appropriate 
mix of interventions for various levels of resource availability, assuming 
interventions are undertaken relatively efficiently. 
 
10.2.3. 1    Classification of costs 
 
Costs are divided into those incurred at the patient or programme level.  
Patient-level costs involve face to face delivery by a health provider (broadly 
defined) to a recipient - e.g. medicines, outpatient visits, in-patient stays, 
individual health education messages.  Programme-level costs include all 
resources required to establish and maintain an intervention - administration, 
publicity, training, delivery of supplies.  Interventions like radio delivery of 
health education messages largely involve the former, while treatment at 
health centres largely involves the latter.   
 
10.2.3. 2   Cost measurement  
 
A standardized ingredients approach was used, requiring information on the 
quantities of physical inputs needed and their unit cost. Total costs are 
quantities of inputs multiplied by their unit costs. 
For programme-level costs, the physical inputs - human resources, office 
space, vehicles, electricity, other services, and a variety of consumables - 
required to introduce and run a programme were collected in 17 countries by 
costing experts commissioned for this purpose, using a standard 
template.188;215;230 This was supplemented by information from programme 
managers in other countries known by WHO staff.   
 
For patient-level costs, quantities were taken from a variety of sources.  Where 
effectiveness estimates were available from published studies, the resources 
necessary to ensure the observed level of effectiveness were identified.  In 
other cases, the resources implied by the activities outlined in WHO treatment 
practice guidelines231-234 were estimated.  Programme experts checked the face 
validity of all estimated quantities. It was not always possible to identify the 
quantities of primary inputs (human resources, consumables) necessary for 
patient-level costs, so quantities and prices were estimated at an intermediate 
level for several inputs - inpatient days at different hospital levels, outpatient 
visits and health center visits.  
Unit costs for each input were derived from an extensive search of published 
and unpublished literature and databases along with consultation with costing 
experts.  The full costing data base is available at www.who.int/choice. 
 
For goods that are traded internationally, the most competitive price available 
internationally was used.  For example, the prices of medicines were taken 
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from the latest WHO negotiated prices. A mark up was included for 
transportation costs.  
For goods available only locally (e.g. human resources, inpatient bed days) 
unit costs have been shown to vary substantially within countries. As a result, 
cross country regressions were run using the collected data to estimate the 
average cost (with adjustments for capacity utilization) for each 
setting.188;215;230;235  
 
10.2.3. 3   Variations in scope and scale 
 
Some interventions can share resources like vehicles, buildings, and 
administrative staff, so the costs of doing both together is less than the sum of 
the costs of the two individual programmes.  Careful attention was paid to 
identifying possible shared costs when combinations of interventions were 
evaluated (see Box B on bmj.com).    
 
Costs were estimated at three standard levels of coverage - 50%, 80% and 95%.  
We assumed that interventions are first provided to, or obtained by, easy-to-
reach populations.  Coverage then expands to more outlying, sparsely 
populated areas.  Facilities still need to be built despite the lower population 
density, so capacity utilization will be lower, and the costs per patient treated 
correspondingly higher at higher levels of coverage. On the other hand, some 
interventions require a fixed number of staff, or office space, or equipment, to 
begin work.  The same people and resources cope with increases in coverage 
so the programme-level costs can be spread over a larger population, reducing 
the costs per person covered.  Both types of effects are included in the costing 
exercise, and the net effect varies by intervention. 
 
Costs are reported in international (I$) rather than US dollars (US$) with 2000 
the base year (see Box 10. 3).  Future costs are discounted to 2000 values using 
a 3% discount rate.2 These costs do not translate directly into the financial or 
cash requirements to run or expand interventions. Estimates of the cash 
requirements are already available.4;187;236-238 Here we estimate the opportunity 
cost of all resources required to provide interventions, regardless of who pays 
for them, to explore the combination of interventions that makes the best use 
of these resources.  
 
 
10.2. 4 Assessing the health impact of interventions 
 
Interventions improve health through their effect on incidence, remission, 
severity and case-fatality. Efficacy data were obtained, in order of preference, 
from systematic reviews with meta-analysis; randomized studies; and before-
and-after evaluations of country programs.   
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Effectiveness was obtained by adjusting efficacy by a factor between zero and 
one to allow for less than perfect adherence to recommended practices. The 
adjustment factor was taken from the literature wherever possible, with expert 
opinion the last resort.  Finally, the eligible population was multiplied by 
coverage to determine the total numbers benefiting from estimated 
effectiveness.  Although some information on the effect of increasing coverage 
on unit costs was available, this was not the case for health impacts. We 
assumed, therefore, that the health benefit of each child treated for pneumonia 
(i.e. unit effectiveness), for example, did not vary with coverage.  
 
Box 10. 3 International dollars 
 
 
International dollars are used to account for differences in price levels across 
countries. The exchange rate for domestic currency into international dollars 
is the amount of domestic currency required to purchase the same quantity of 
goods and services as $1 could purchase in the US. For low income countries, 
national income measured in terms of international dollars is generally 
higher than it is in US dollars because domestic costs for many goods are 
lower than in the US. Table B on bmj.com gives conversions from 
international to US dollars. 
 
 
10.2.4. 1   The impact of interventions undertaken simultaneously  
 
It was rarely possible to obtain information on the joint effectiveness of 
multiple interventions undertaken simultaneously. In its absence, the health 
impact was assumed to be additive for interventions that impact on different 
health outcomes. For interventions acting on the same outcome the joint effect 
was estimated by multiplying the individual relative risks (see Box C on 
bmj.com)   
  
10.2.4. 2   Population health effects of interventions 
 
A population model, PopMod, was used to project the impact of interventions 
on the aggregate healthy years of life lived by a population, combining 
incidence, prevalence and mortality rates, and estimates of disease severity, 
with information on intervention coverage and effectiveness.239 The exception 
was for HIV/AIDS, where a model that allows death rates to increase with 
time spent ill was used.  Regional epidemiology was taken from the latest 
internal WHO update of the Global Burden of Disease study.240   
PopMod projects regional population over time, allowing people to move in 
and out of disease states, or die, in accordance with incidence and remission 
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rates. To derive a single indicator of population health, time spent in each state 
is given a weight (i.e. health-state valuation or disability weight) reflecting 
disease severity.  Weights were taken from Murray and Lopez.241 The 
population is projected for the length of time necessary for people affected by 
the intervention to live their full life course. The difference between the 
aggregate number of healthy years lived by the projected population in the 
intervention and in the do-nothing scenario is the population health gain 
attributable to the intervention.  
The outcome indicator is essentially the number of healthy years of life gained 
by an intervention, also called the number of disability adjusted life years 
(DALYs) averted.  The mechanics of estimating DALYs are virtually identical 
to those required to estimate quality adjusted life years (QALYs), another 
common outcome indicator, although there are some differences in the 
interpretation (see box D on bmj.com).  In the base case analysis discounts 
DALYs averted in the future at 3% and gives greater weight to DALYs averted 
during adulthood.  This is relaxed in the sensitivity analysis.   
 
 
10.2. 5 Calculating cost-effectiveness 
 
Traditional CEA generally considers the costs and effects of adding new 
interventions to current practice or of replacing one existing intervention with 
another targeting the same condition.  Here we evaluate the full set of existing 
interventions by first considering what would happen to population health if 
they all ceased to be implemented today.  This is the "null" or do-nothing 
scenario (see Box E on bmj.com).  The current population is followed over time 
in PopMod assuming that all interventions cease, using the information on 
epidemiology, effectiveness and the current coverage of interventions 
described earlier. 
 
Next, we trace the implications for population health of adding all possible 
interventions singly and in various combinations, against the baseline of doing 
nothing.  The difference is the gain in health due to the reduction in disease 
burden from the intervention(s) (DALYs averted).  The costs of each scenario 
are then compared with the gain to identify the most cost effective set of 
interventions at different levels of resource availability. The comparison of the 
current mix against the optimal set for the resources currently available 
reveals areas of inefficiency.  The optimal set for higher resource levels shows 
what should be done if existing efforts to raise more resources are successful.   
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10.2. 6 Interpreting results  
 
For each paper in this series, the cost of every intervention and package is 
plotted against the corresponding population health impact relative to the do-
nothing scenario for that condition. We then determine the order in which 
interventions would be chosen and combined at given levels of resource 
availability if cost-effectiveness were the only consideration. The graphical 
depiction we call the Expansion Path. To understand this process, two cost-
effectiveness ratios are defined. The incremental cost-effectiveness ratio (ICER) 
denotes the additional costs and benefits of a new intervention or package 
relative to what existed before - the previous point on the expansion path. The 
ICER compared to doing nothing is sometimes called the average cost-
effectiveness ratio (ACER). Box F on bmj.com provides an example of how the 
expansion path is determined and interpreted.  
 
 
10.2. 7 Uncertainty   
 
Cost-effectiveness is an inexact science, particularly where data are limited 
and quality poor.  Many sources of uncertainty cannot be captured by 
statistical confidence intervals because no sampling is involved.  Probabilistic 
uncertainty analysis has been developed for these circumstances, but technical 
limitations do not yet allow it to include the complex correlations inherent in 
combining the very large set of interventions in this series (see box G on 
bmj.com).242;243 
 
Accordingly, the individual papers incorporate relatively simple forms of 
sensitivity analysis that are easier to understand.  In the final paper, the results 
of all the disease-specific analysis are integrated to develop priorities from the 
perspective of a policy-maker responsible for all health MDGs, not just one.  
For this cross-disease analysis, we believe it is not possible to recommend that 
an intervention shown to cost $45 per DALY averted is more efficient than one 
costing $60 given the nature of the uncertainties involved.  However, we are 
much more confident that $45 per DALY is better than $450 per DALY.  For 
the broad comparison across MDGs we, therefore, interpret cost-effectiveness 
figures in broad order of magnitude ranges (see box H on bmj.com). 
 
 
10.2. 8 Documentation and transparency 
 
Details of the specific data sources and assumptions made to obtain costs and 
effects are presented in the individual papers and are available from the 
WHO-CHOICE website (www.who.int/choice). Data inputs are also available 
in the form of a contextualization tool, currently being tested in a number of 
                                                                                           CHAPTER 10                                              
 154 
countries, that allows analysts to adapt and modify the regional parameters to 
their own settings.  They can modify prices, capacity utilization, epidemiology 
and effectiveness assumptions. This tool is available from the authors on 
request.    
 
 
10. 3  Conclusions 
 
Progress in the five years since the Millennium Declaration was signed has 
been disappointing.218 More funds to improve health in poor countries is 
urgently required, but this alone will not be sufficient to achieve the MDGs.  
Open discussion of ways of increasing their impact is required, both to allow 
countries to improve the health of their populations more quickly, and to give 
potential donors confidence that new funds would be used effectively.  The 
methods outlined in this paper are applied in the next six papers to facilitate 
open debate and encourage changes in strategies where necessary.   
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Chapter 11.     Achieving the Millennium 
Development Goals for health: Cost-effectiveness of 
strategies for maternal and neonatal health in 
developing countries  
 
 
 
Summary 
 
 
To determine the costs and benefits of interventions for maternal and newborn 
health in order to assess the appropriateness of current strategies and guide 
future plans to attain the Millennium Development Goals. 
 
The standard methods of the WHO-CHOICE project were used. The analyses 
included 21 maternal and newborn health interventions and almost 300 
combinations, taking into account joint costs and effects when they are 
implemented together. Interventions included in this analysis are those 
delivered during pregnancy, childbirth and the newborn period for which 
evidence of effectiveness exists. Results are presented as cost per disability 
adjusted life year (DALY) averted in 2000 international dollars.   
 
Overall, the most cost-effective mix of interventions was similar in the African 
(Afr-E) and Southeast Asian (Sear-D) regions. These were the community-
based newborn care package, followed by antenatal care, skilled attendance at 
birth offering basic maternal and neonatal care around childbirth and finally 
emergency neonatal and obstetric care around and after birth. There were 
some potentially important differences for particular interventions. Screening 
and treatment of maternal syphilis was relatively less cost-effective in Sear-D 
while community-based management of neonatal pneumonia was relatively 
more cost-effective in Afr-E. Scaling up the above set of interventions to 95% 
coverage would halve neonatal and maternal deaths in these two regions.    
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Preventive interventions at the community level for newborns and the 
primary care level for mothers and newborns are extremely cost-effective.  
However, universal access to clinical services is also essential if the 
Millennium Development Goals for maternal and child health are to be met. 
 
 
11. 1  Introduction 
 
Each year over 500,000 mothers die during pregnancy or childbirth244 and 
more than 4 million babies die in the first four weeks of life, accounting for 
38% of under-5 child mortality worldwide.245 The contrast between countries 
is stark.  Of every 1000 children born in Africat and South East Asia, 44 and 38 
die in the neonatal period respectively, compared with four deaths in high 
income countries. A similar gulf exists for maternal mortality with rates in 
Sub-Saharan Africa more than 2.5 times those in Asia, which are in turn more 
than 20 times those in developed countries.244 Effective interventions to reduce 
maternal and neonatal deaths exist,246 but the unacceptable fact is that they are 
not available to people living in the poorest parts of the world.187 
Recognizing this, the member countries of the United Nations (UN) agreed to 
reduce child mortality by two thirds, and maternal mortality by three quarters 
by the year 2015 as part of the Millennium Development Goals (MDG goals 
four and five respectively). Progress has been slow and few of the poorest 
countries in the world will achieve this at current rates. Although many 
bilateral and multilateral donors have committed funds, they have not been 
sufficient.  Policy makers must decide every day how best to allocate the 
limited resources they have and, hopefully, what they should do when 
additional resources become available.   
To aid these decisions, information on the costs and effectiveness of current 
and possible new interventions is critical to show what would be the 
improvement in health associated with different expenditure options.  This 
information should, however, be realistic and include interventions in the type 
of combinations that would be undertaken in practice, rather than assuming 
that each intervention can be evaluated in isolation from others - the usual 
practice in cost-effectiveness analysis.   
Indeed, cost-effectiveness analyses (CEA) of maternal and newborn 
interventions have usually been restricted to the analysis of individual 
interventions247-249 with considerable variation in the analytical methods used.  
This, combined with variability in the settings in which the analyses have been 
undertaken, limits the value of the existing literature.   
Recently, as part of a series on neonatal survival, the cost-effectiveness of 
antenatal, intrapartum and postnatal interventions of proven benefit for 
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reducing neonatal mortality was estimated.246   It used a standardized 
methodology and a form of analysis that allows existing interventions to be 
evaluated at the same time as possible new interventions.246 In this paper and 
the current series on the health MDGs, we develop this work further by 
including a more comprehensive list of maternal interventions provided 
during pregnancy, childbirth and the neonatal period. As sufficient 
information on effectiveness is not available for all maternal and newborn 
interventions, this analysis focuses on those for which evidence is available.  
By using the standardized methods of the WHO-CHOICE (CHOosing 
Interventions that are Cost-Effective) project,226 our work allows valid 
comparisons not only among the interventions presented in this paper but also 
the published neonatal series,246 previous WHO-CHOICE analyses for other 
diseases and risk factors,250-252 and papers in the present series.219;221-223 A 
summary paper to this series will consider the overall implications of the 
results presented in this MDG series for priority setting in the health sector as 
a whole.253 This paper, however, provides policy-makers with information 
necessary to evaluate if they are using the resources currently available for 
maternal and neonatal conditions effectively and efficiently, and how they can 
best achieve MDGs four and five as new resources become available. 
 
11. 2  Methods 
 
11.2. 1  Interventions 
 
The analysis included 21 interventions and all possible combinations that 
could be undertaken programmatically, taking into account interactions in 
costs or effectiveness when interventions are implemented together.  Table 11. 
1 lists the interventions, categorized according to the level of care required to 
deliver them (first level maternal and newborn care vs referral level maternal 
and newborn care vs community-based newborn care), and the time period of 
implementation (antenatal vs intrapartum vs post-partum care vs newborn 
care).  
 
All interventions are assumed to run for a period of 10 years (2000-2010), after 
which policy-makers would typically re-evaluate their strategies.  
Interventions are compared against a scenario of doing none of the 
interventions in Table 11. 1.254 This shows the most cost-effective mix for any 
level of resource use.  Comparison of the current mix of interventions with the 
ideal mix reveals inefficiencies in current resource use to be identified.226;254 
The uses and limitations of this form of analysis are further discussed below 
and in the first paper of this series.254  
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Table 11. 1  Description of maternal and neonatal intervention packages and 
components 
 
Intervention Description 
Primary level care, including outreach 
Antenatal care:  
 Tetanus toxoid Two tetanus toxoid immunisations 
 Screening for pre-
eclampsia 
Blood pressure measurements for all pregnant 
women, urine test for proteinuria, and pre-referral 
care of women with pre-eclampsia or eclampsia 
 Screening and treatment  
  Asymptomatic 
bacteriuria 
Screening urine of all pregnant women at antenatal 
visits and treatment of bacteriuria with amoxicillin 
  Syphilis Screening all pregnant women by rapid plasma 
reagin test and treatment of syphilis with 
benzathine penicillin 
Skilled maternal care and 
immediate care of newborn 
(intrapartum): 
 
 Normal delivery by 
skilled attendant 
Includes safe delivery, cord care, identification of 
complications, first aid, and referral of complicated 
cases 
 Active management of 
third stage of labour 
Administration of prophylactic oxytocin, cord 
clamping, and delivery of placenta by controlled 
cord traction 
 Initial management of 
post-partum haemorrhage 
Management of post-partum haemorrhage with 
additional oxytocin, uterine massage, manual 
removal of placenta, repair of lacerations, and 
management of shock 
Neonatal resuscitation Detection of breathing problems and resuscitation 
of newborn when required 
Referral level care 
Treatment of severe pre-
eclampsia or eclampsia 
(antenatal and 
intrapartum)* 
Inpatient care, including airway management, 
treatment with magnesium sulphate, treatment 
with antihypertensives, and birth care when 
undelivered 
Antibiotics for preterm 
premature rupture of 
membranes (antenatal and 
intrapartum)* 
Administration of oral antibiotics to women with 
preterm premature rupture of membranes, and 
care during labour 
CHAPTER 11 
 
161 
Steroids for preterm births 
(antenatal and 
intrapartum)* 
Administration of steroids and inpatient care of 
women with suspected preterm labour 
Management of obstructed 
labour, breech 
presentation, and fetal 
distress* 
External cephalic version for breech presentation; 
management of obstructed labour, persistent 
breech presentation, and fetal distress by operative 
delivery (vacuum extraction, forceps and vaginal 
breech delivery, and caesarean section) 
Management of severe 
post-partum haemorrhage 
(intrapartum and post 
partum)* 
Inpatient care of post-partum haemorrhage, 
including blood transfusion, treatment for shock, 
and hysterectomy 
Management of maternal 
sepsis (intrapartum and 
post partum)* 
Inpatient care of maternal sepsis, including 
treatment with intravenous or intramuscular 
antibiotics 
Emergency neonatal care:  
Management of very low 
birthweight babies* 
Inpatient care for very low birthweight babies, 
including special feeding support, additional 
warmth, close monitoring, and treatment with 
oxygen if necessary 
Management of severe 
neonatal infections* 
Inpatient care for severe neonatal infections, 
including treatment with intravenous or 
intramuscular antibiotics 
Management of severe 
neonatal asphyxia* 
Inpatient care for neonatal encephalopathy 
including treatment with oxygen 
Management of neonatal 
jaundice* 
Inpatient care for severe neonatal jaundice, 
including phototherapy 
Community care of newborn  
Community newborn care 
package (first two 
components): 
 
 Support for 
breastfeeding mothers 
(antenatal and neonatal) 
Home visits to promote early and exclusive breast 
feeding provided by skilled care providers and 
community health workers 
 Support for low birth 
weight babies 
Home visits to promote extra warmth for low birth 
weight babies and to support breastfeeding 
mothers provided by skilled care providers and 
community health workers 
Community based 
management of neonatal 
pneumonia 
Home visits for diagnosis and management of 
pneumonia in neonates and treatment with oral 
antibiotic therapy provided by community health 
workers 
*Includes costs for transportation. 
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11.2. 2  Regions 
 
The costs, population health effects and cost-effectiveness of each of the 
interventions are evaluated for 14 epidemiological regions of the world (see 
www.who.int/choice  for the list). Two are discussed in detail here – Afr-E, 
comprising countries in sub-Saharan Africa with very high adult and child 
mortality rates, and Sear-D, countries in South-East Asia with high adult, and 
very high child mortality. 
 
11.2. 3  Intervention effects 
 
The effectiveness of all interventions and the estimated coverage levels in the 
year 2000, the starting point for the analysis, are provided in Annex 11 A and 
B. Interventions are evaluated at 50%, 80%, and 95% population coverage 
levels. Effects are estimated through their impact on incidence, remission and 
case-fatality (see table D on bmj.com). In the absence of clinical trials showing 
the effectiveness of interventions implemented in combination, joint effects of 
interventions addressing the same cause of death are assumed to be a 
multiplicative function of the individual effects.254  The impact of interventions 
on maternal mortality and morbidity, and on neonatal mortality, where 
available, are included. A lack of reliable data prevents inclusion of the impact 
on neonatal morbidity or stillbirths, so the benefits of some interventions 
isunder-estimated.  
The population health effects of the interventions compared to the no 
intervention scenario are assessed using the population model PopMod, 239;254 
with effects measured as the number of disability adjusted life years (DALYs) 
averted. This can also be interpreted as the number of healthy life years 
(HLYs) gained by the intervention. Age-weights and a 3% discount rate are 
applied to the calculation of DALYs averted. 
 
 
11.2. 4  Intervention costs   
 
Costs are divided into programme and patient costs. Programme costs are 
those involved in establishing and managing an intervention or package, and 
includes planning, administration, supervision, training, monitoring and 
evaluation. Patient costs are those involved with delivering a direct service to 
patients or beneficiaries and include items such as remuneration, equipment, 
supplies, medicines and facility. Costing methods are based on a previously 
published standard ingredients approach to ensure comparability of 
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results.188;215  More details are in the first paper of this series ( Chapter 10) and 
at www.who.int/choice . 
The quantities of resources used are based on WHO evidence-based 
guidelines231-234 as well as information obtained from the studies used for the 
estimates of effectiveness, to ensure consistency between costs and 
effectiveness.  When these could not be used, expert opinion on the resource 
needs to introduce and run a programme was sought. More detail on costing 
methods and the main assumptions on resource use are available in Table E on 
bmj.com.  
Costs are calculated for the 10 year implementation period of the intervention 
and are presented in international dollars (I$) referenced to the year 2000, with 
future costs discounted at 3% per annum.  
 
11. 3  Results 
 
The costs and benefits of almost 300 combinations of the individual 
interventions were examined. Selected results for the most cost-effective set of 
interventions are presented here (Tables 11. 2 and 11. 3 and Figures 11. 1 and 
11. 2) with full results on www.who.int/choice or www.bmj.com. The order in 
which interventions would be purchased at given levels of resource 
availability, if cost-effectiveness is the only consideration, is called the 
Expansion Path. Tables 11. 2 and 11. 3 show the intervention packages and the 
additional interventions chosen at each step of the expansion path. The average 
cost-effectiveness ratio (ACER) denotes the cost-effectiveness of each package 
relative to the no intervention scenario - the incremental costs and benefits 
compared to doing nothing. The incremental cost-effectiveness ratio (ICER) 
denotes the additional costs and benefits of the new intervention or package 
relative to what has already been purchased - the previous point on the 
expansion path.  
                                                                                                                
                                                            
 
Table 11. 2  Annual costs, effects and cost-effectiveness of interventions for Afr-E in 2000 
 
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(millions 
$Int) 
ACER ICER Additional 
yearly 
resources 
required 
(millions 
$Int) 
Intervention packages on the optimal expansion path  
A1 Community-based case 
management for neonatal 
pneumonia  (95%) 
  1 1 1 1 1 
A2 Community newborn package + 
Community-based pneumonia 
(95%) 
Community newborn 
package: 
Support for 
breastfeeding 
mothers 
Support for low birth 
weight babies   
9 58 7 8 57 
A3 Community newborn package + 
Tetanus Toxoid + Community-
based pneumonia (95%) 
Tetanus toxoid 12 125 11 22 67 
A4 Community newborn package + 
ANC + Community-based 
pneumonia (95%) 
Screening for pre-
eclampsia 
Screening & 
treatment of 
13 160 12 27 35 
  
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(millions 
$Int) 
ACER ICER Additional 
yearly 
resources 
required 
(millions 
$Int) 
asymptomatic 
bacteruria 
Screening & 
treatment of syphillis  
A5 Community newborn package + 
ANC + Community-based 
pneumonia + SMNC (95%) 
Normal delivery by 
skilled attendant 
Active management 
of the third stage of 
labour 
Initial management of 
post-partum 
haemorrhage 
Neonatal 
resuscitation 
16 284 18 40 124 
A6 Community newborn package + 
ANC + Community-based 
pneumonia + SMNC + Treatment 
of severe PEE (95%) 
Treatment of severe 
pre-
eclampsia/eclampsia 
16 306 19 42 22 
A7 Community newborn package + 
ANC + Community-based 
pneumonia + SMNC + Treatment 
Facility-based care of 
very low birth weight 
babies, severe 
20 498 25 61 192 
                                                                                                                
                                                            
 
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(millions 
$Int) 
ACER ICER Additional 
yearly 
resources 
required 
(millions 
$Int) 
of severe PEE + ENC (95%) neonatal infections, 
severe neonatal 
asphyxia and 
neonatal jaundice 
A8 Community newborn package + 
ANC + Community-based 
pneumonia + SMNC + Treatment 
of severe PEE + Management of 
OL + ENC (95%) 
Management of 
obstructed labour, 
breech and fetal 
distress 
21 589 28 73 91 
A9 Community newborn package + 
ANC + Community-based 
pneumonia + SMNC + Treatment 
of severe PEE + Management of 
OL + Steroids pre-term + ENC  
(95%) 
Antenatal steroids for 
pre-term births 
22 706 32 117 117 
A10 Community newborn package + 
ANC + ENC care  + SMNC + 
Treatment of severe PEE + 
Management of OL + Steroids 
pre-term + Maternal sepsis + 
Management of 
maternal sepsis 
22 748 34 125 42 
  
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(millions 
$Int) 
ACER ICER Additional 
yearly 
resources 
required 
(millions 
$Int) 
Community-based pneumonia 
care (95%) 
A11 Community newborn package + 
ANC + ENC care  + SMNC + 
Treatment of severe PEE + 
Management of OL + Steroids 
pre-term + Maternal sepsis + 
Antibiotics pPROM + 
Community-based pneumonia 
care (95%) 
Antibiotics for pre-
term premature 
rupture of 
membranes (pPROM) 
22 781 35 178 34 
A12 Community newborn package + 
ANC + ENC care  + SMNC + 
Treatment of severe PEE + 
Management of OL + Steroids 
pre-term + Maternal sepsis + 
Antibiotics pPROM + PPH 
referral + Community-based 
pneumonia care (95%) 
Referral care for 
severe post-partum 
haemorrhage 
22 801 36 223 19 
Average GDP per capita in AfrE= Int $ 1576 
                                                                                                                
                                                            
 
Table 11. 3  Annual costs, effects and cost-effectiveness of interventions for Sear-D in 2000 
 
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
Intervention packages on the optimal expansion path  
  
D1 Support for breastfeeding 
mothers  (50%) 
Support for breastfeeding 
mothers (50% coverage) 
8 49 6 6 49 
D2 Support for breastfeeding 
mothers  (80%) 
Support for breastfeeding 
mothers (expanded to 80% 
coverage) 
14 80 6 6 31 
D3 Support for breastfeeding 
mothers  (95%) 
Support for breastfeeding 
mothers (exapnded to 95% 
coverage) 
16 98 6 7 18 
D4 Breast feeding + Tetanus 
toxoid (80%) 
Tetanus toxoid (80% 
coverage) 
24 155 7 8 57 
D5 Breast feeding + Tetanus 
toxoid (95%) 
Tetanus toxoid (expanded 
to 95% coverage) 
28 194 7 9 39 
D6 Community newborn 
package + Tetanus Toxoid 
(95%) 
Support for low birth 
weight babies   
28 195 7 20 1 
D7 Community newborn Normal delivery by skilled 31 426 14 88 231 
  
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
package + Tetanus Toxoid 
+ Normal delivery by 
skilled attendant + Active 
management and initial 
treatment of PPH (95%) 
attendant 
Active management of 
third stage & initial 
treatment of post-partum 
haemorrhage 
D8 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + Normal 
delivery by skilled 
attendant + Active 
management and initial 
treatment of PPH (95%) 
Screening for pre-eclampsia 
Screening & treatment of 
asymptomatic bacteruria 
31 476 15 123 49 
D9 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + Normal 
delivery by skilled 
Community-based 
management of pneumonia 
31 485 16 144 9 
                                                                                                                
                                                            
 
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
attendant + Active 
management and initial 
treatment of PPH + 
Community-based 
pneumonia (95%) 
D10 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + SMNC + 
Treatment of severe PEE + 
Community-based 
pneumonia  (95%) 
Neonatal resucitation 
Treatment of severe pre-
eclampsia/eclampsia 
31 537 17 218 52 
D11 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + SMNC + 
Treatment of severe PEE + 
PPH referral + Community-
Referral care for severe 
post-partum haemorrhage 
32 571 18 261 34 
  
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
based pneumonia  (95%) 
D12 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + SMNC + 
Treatment of severe PEE + 
PPH referral + Community-
based pneumonia  + 
Maternal sepsis (95%) 
Management of maternal 
sepsis 
32 654 21 290 83 
D13 Community newborn 
package + Tetanus Toxoid 
+ Pre-eclampsia screening 
+ Asymptomatic bacteruria 
screening + SMNC + 
Treatment of severe PEE + 
PPH referral + Community-
based pneumonia  + 
Maternal sepsis + ENC 
(95%) 
Facility-based care of very 
low birth weight babies, 
severe neonatal infections, 
severe neonatal asphyxia 
and neonatal jaundice 
32 1,039 32 614 385 
                                                                                                                
                                                            
 
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
D14 Community newborn 
package + ANC + SMNC + 
Treatment of severe PEE + 
PPH referral + Community-
based pneumonia  + 
Maternal sepsis + ENC 
(95%) 
Screening & treatment of 
syphillis  
33 1,049 32 699 9 
D15 Community newborn 
package + ANC + SMNC + 
Treatment of severe PEE + 
Management of OL + PPH 
referral + Community-
based pneumonia  + 
Maternal sepsis + ENC 
(95%) 
Management of obstructed 
labour, breech and fetal 
distress 
33 1,234 38 2,638 186 
D16 Community newborn 
package + ANC + SMNC + 
Treatment of severe PEE + 
Management of OL + PPH 
referral + Community-
Antibiotics for pre-term 
premature rupture of 
membranes (pPROM) 
33 1,299 40 2,808 65 
  
 Intervention package Additional intervention 
components 
Yearly 
DALYs 
averted 
(millions) 
Yearly 
Cost 
(million
s $Int) 
ACER ICER Addition
al yearly 
resources 
required 
(millions 
$Int) 
based pneumonia  + 
Maternal sepsis + ENC + 
Antibiotics pPROM (95%) 
D17 Community newborn 
package + ANC + ENC care  
+ SMNC + Treatment of 
severe PEE + Management 
of OL + Steroids pre-term + 
Maternal sepsis + 
Antibiotics pPROM + PPH 
referral + Community-
based pneumonia care 
(95%) 
Antenatal steroids for pre-
term births 
33 1,619 50 16,93 319 
 Average GDP per capita in SearD= Int $ 1449  
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The expansion path is illustrated by the solid diagonal line in Figures 11. 1 and 
11. 2. It is determined by first selecting the intervention or package with the 
lowest ACER. Subsequent interventions on the expansion path are chosen by 
selecting from the remaining options the one with the lowest ICER compared 
to those already purchased.  
  
Figure 11. 1 Expansion path of the most cost-effective mix of interventions 
in Afr-E region in 2000 
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The expansion paths for both regions suggest that interventions for newborn 
care at the community level are highly cost-effective (e.g. promotion of 
breastfeeding), followed by selected antenatal care interventions (e.g. tetanus 
toxoid), interventions deliverable by a skilled attendant at birth in a health 
facility (e.g. normal delivery care by a skilled attendant), then by more 
complex interventions that require referral to a higher level health facility. 
There are, however, important differences between regions. Given the lower 
prevalence of syphilis in Sear-D, screening and treatment of syphilis is 
relatively less cost-effective in this region. Community-based management of 
neonatal pneumonia is relatively more cost-effective in Afr-E because of the 
greater contribution of pneumonia deaths there compared with Sear-D.  
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Figure 11. 2 Expansion path of the most cost-effective mix of interventions 
in Sear-D region in 2000 
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The expansion path shows not only the relative cost-effectiveness of 
interventions but also allows decision makers to see the absolute value of 
resources necessary to move to the next point on the expansion path.  
Sometimes, however, there may be insufficient resources to move to the next 
point.  For example, if A9 is not affordable, a decision maker may choose to 
implement a lower cost, but less cost-effective package such as B2 (purchasing 
referral care of post-partum haemorrhage (PPH)), B3 (purchasing referral care 
of maternal sepsis and PPH) or B4 (purchasing referral care of maternal sepsis 
and PPH and antibiotics for pre-term premature rupture of membranes 
(pPROM)). Further examples are provided of alternative interventions for 
scaling up maternal and newborn health services in the event that the 
preferred intervention is unaffordable (see Tables H and I on bmj.com).   
There is considerable uncertainty around the inputs used in this analysis but 
rather than undertake a complex multivariate uncertainty analysis, for 
practical policy purposes we prefer to interpret the results by ICER bands. For 
example, it is difficult to say with certainty that tetanus toxoid (ICER Int$22 
per DALY averted in Afr-E) is more cost-effective than other ANC 
interventions (ICER Int$27 per DALY averted in Afr-E). We can be more 
certain, however, that interventions under Int$50 per DALY, such as 
community newborn care, ANC and SMNC, are more cost-effective than those 
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greater than Int$100 per DALY averted such as antibiotics for pPROM.   This 
means that the order in which the most cost-effective interventions are 
introduced is up to the specific circumstances of a country.  The important 
thing is to obtain high coverage with the group of very cost-effective 
interventions before those of high cost and low effectiveness are implemented.   
Eliminating discounting for health benefits resulted in approximately 2.5 times 
more DALYs averted (data not shown).  No age-weighting decreased the 
DALYs averted by 10-15%. Costs were 5-20% higher without discounting. 
While removing age weighting and discounting of DALYs favours 
interventions for newborns over those for mothers, the ranking of 
interventions and the expansion path, on the whole, remains the same. 
Implementation of all the interventions covered in this analysis at 95% 
coverage would avert 52% of the year 2000 neonatal deaths and 51% of 
maternal deaths in Afr-E, and 56% of neonatal deaths and 51% of maternal 
deaths in Sear-D.  
 
 11. 4  Discussion 
 
There are several strengths of the analysis undertaken for this paper and the 
series that set it apart from traditional cost-effectiveness analysis, and increase 
the value of this information for decision making. Firstly, the methods 
explicitly account for the fact that the total cost of a package of interventions is 
often less than the sum of the costs of each component evaluated separately.  
This is mainly due to economies of scale as many costs can be shared between 
activities. Total benefits are also not additive across interventions in some 
cases.  Largely due to synergies on costs, packages of maternal and newborn 
interventions proved, on the whole, more cost-effective than individual 
interventions. This highlights the importance of considering effective 
integration of services and implementation of maternal and newborn 
interventions in parallel, particularly those with common delivery modes. 
 
Secondly, the method allows the cost-effectiveness of interventions that are 
currently implemented to be evaluated as well as those that could be 
introduced if new resources become available. It identifies whether maternal 
and newborn health could be improved by scaling down some interventions, 
while scaling up others, even without additional resources.  
Overall, community-based and antenatal care packages were found to be 
highly cost-effective. However, it is only with accessible and good quality 
clinical services - skilled attendance to allow appropriate early diagnosis and 
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treatment of complications, along with appropriate, timely referral to hospitals 
for more complex care - that the large numbers of maternal and neonatal 
deaths will be reduced. Although these services require much more resources, 
they are also very effective in reducing maternal and neonatal morbidity and 
mortality, and as such, are also highly cost-effective. Sustained efforts to scale 
up coverage of skilled attendance at birth from the 44% in Afr-E and 28% in 
Sear-D (in 2000) are therefore crucial to meet the MDG goals for maternal and 
child health. In addition, while increasing efforts have been directed towards 
improving antenatal coverage,187 implementation of key components such as 
tetanus toxoid remains sub-optimal (51% in Afr-E and 77% in Sear-D). 
Furthermore, in regions where pneumonia is a leading cause of neonatal 
mortality, coverage of pneumonia case management is also very low (13% in 
Afr-E).246 Where resource availability is unlikely to increase in the near future, 
it may be worthwhile to scale down implementation of less cost-effective 
interventions such as antibiotics for pPROM and antenatal steroids for pre-
term births, and to reallocate these resources to more cost-effective options 
such as community-based newborn packages, ANC and skilled attendance.  
As resource allocation decisions are not based solely on considerations of cost-
effectiveness, the results presented here should not be used in a formulaic 
way, but rather cost-effectiveness information enters policy debates to be 
considered alongside other health system goals such as equity and 
acceptability to stakeholders. Of particular importance is the need to consider 
the feasibility of implementing these interventions. Clinical services for 
maternal and newborn health, in particular, require well functioning health 
systems, appropriate human resources, timely referral systems and 
institutional infrastructure.  
In line with accepted practice for cost-effectiveness studies, the resources used 
to provide the interventions were valued from an economic perspective. They 
should not, therefore, be interpreted as the extra cash that countries will have 
to pay to provide the intervention. But taking a financial perspective, the 
incremental costs of scaling up maternal and newborn health services, from 
the current coverage level of 43% with a limited package of care, to 73% in 
2015 with a full package of care, was estimated recently for 75 countries to 
require an initial investment of US$0.22 per capita in 2006 rising to US$1.18 
per capita by 2015.4 
As with any cost-effectiveness analysis, possible limitations of the analysis 
need to be carefully considered. Due to the paucity of large-scale effectiveness 
trials as well as the difficulty of measuring efficacy of some of the key 
interventions, particularly those done in combination, many of the 
interventions analysed are based on limited efficacy trials and/or expert 
opinion. These sources of treatment efficacy are often derived from studies of 
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good quality services provided by highly skilled professionals in developed 
settings and care needs to be taken when extrapolating to less developed 
countries. In these circumstances, feasibility studies are recommended before 
wider implementation is undertaken. The lack of information on neonatal 
morbidity and stillbirths meant that only the impact of interventions on 
neonatal mortality could be included (although we were able to include the 
impact on maternal morbidity). As a result, our analysis underestimates the 
total benefits of some of the interventions in this paper.  
Moreover, some interventions which are beneficial or are potentially beneficial 
were not included in this analysis. Exclusion of these interventions was largely 
due to a lack of information on either intervention effectiveness or disease 
burden necessary for cost-effectiveness analysis, but this does not imply that 
they are not necessarily cost-effective. They include, among others, safe 
abortion, family planning, and surfactant therapy for respiratory distress 
syndrome.255-257 Several of these interventions, such as the prevention of 
mother-to-child transmission of human immunodeficiency virus (HIV), 
malaria prevention and treatment, maternal and infant micro- and macro-
nutrient supplementation, and vaccine preventable diseases are covered by 
other papers that will appear as part of this series, as well as previously 
published WHO-CHOICE analyses.219;221;223;258 It should be noted that 
provision of these other interventions should be delivered in an integrated 
manner along with the ones covered in this paper to ensure a better coverage 
of care, as well as maximize on economies of scale and cost-effectiveness.  
This paper demonstrates that while effective and efficient maternal and 
newborn health services are available at different resource levels, universal 
access to the clinical facility-based health services covered here are required to 
halve current levels of maternal and newborn mortality. While this will go 
some way to achieving MDGs 4 and 5, they are by themselves not enough to 
reach the targets. A coordinated and inter-sectoral response with other child 
and reproductive health services as well non-health sectors to reduce poverty 
and improve education is needed. Although not insubstantial resources are 
required, the interventions outlined here are highly cost-effective, which 
highlights the importance of overcoming other barriers to attaining the 
Millennium Development Goals Four and Five such as health system 
strengthening, financial commitment as well as the moral and political will to 
do so. 
  
 
Annex 11. A 1 Summary of intervention effectiveness on neonatal and maternal outcomes. 
No. Intervention Neonatal 
outcome(s) 
Risk 
reduction on 
neonatal 
outcome(s) 
Maternal outcome(s) Risk reduction on 
maternal 
outcome(s)** 
Reference(s) 
Primary-level health facility or Outreach care 
  
1 Tetanus toxoid Deaths from tetanus 90%     1-4 
2 Screening for pre-eclampsia Pre-term deaths 15%* Deaths from 
hypertensive disorders 
during pregnancy 
48%* 5-6,30 
3 Screening & treatment of 
asymptomatic bacteruria 
Pre-term deaths 10% Deaths from sepsis and 
cases of infertility 
10% 6-8,30 
4 Screening & treatment of syphilis  Deaths from severe 
infection & 
congenital 
abnormality 
Depends on 
prevalence 
level. 
Low: <1%, 
moderate: 1-
2%, high: 4-
5%. 
    6, 9-11,30 
5 Normal delivery by skilled attendant Deaths from severe 
infection & tetanus 
15% (severe 
infection) 
60% (tetanus) 
Deaths from sepsis  40%* 4,6, 12-14,30 
6 Active management of the third stage 
of labour 
    Deaths from PPH & cases 
of anaemia 
62%* 15 
7 Initial management of post-partum 
haemorrhage 
    Deaths from PPH & cases 
of anaemia 
75%* 15 
8 Neonatal resuscitation Deaths from 
asphyxia 
38%     6, 16-18,30 
              
Referral care interventions at secondary or tertiary health care level 
   
9 Treatment of severe pre-
eclampsia/eclampsia 
Deaths from 
asphyxia 
  Deaths from 
hypertensive disorders 
during pregnancy 
59% 19-20 
10 Antibiotics for pre-term premature 
rupture of membranes (pPROM) 
Deaths from severe 
infection 
6%     6, 21-23,30 
                                                                                                                                                     
 
No. Intervention Neonatal 
outcome(s) 
Risk 
reduction on 
neonatal 
outcome(s) 
Maternal outcome(s) Risk reduction on 
maternal 
outcome(s)** 
Reference(s) 
11 Antenatal steroids for pre-term births Pre-term deaths 38%     6, 24,30 
12 Management of obstructed labour, 
breech & fetal distress (OL) 
Deaths from 
asphyxia 
40% Deaths from obstructed 
labour & Cases of urinary 
incontinence and 
obstetric fistula 
95%* 6, 25-28,30 
13 Referral care for severe post-partum 
haemorrhage (PPH) 
    Deaths from PPH & cases 
of anaemia 
75%* 15 
14 Management of maternal sepsis     Deaths from sepsis & 
cases of infertility 
90%* 29 
15 Management of very low birth weight 
babies (vLBW) 
Pre-term deaths 25%     6, 30 
16 Management of  severe neonatal 
infections 
Deaths from severe 
infection 
50%     6, 30 
17 Management of  severe neonatal 
asphyxia 
Deaths from 
asphyxia 
3%     6, 30 
18 Management of neonatal jaundice Deaths from 
jaundice as part of 
other causes of 
death 
4%     6, 30 
             
Community newborn care 
   
19 Support for breastfeeding mothers  Deaths from severe 
infection & 
diarrhoea 
Region-
specific  
see Table 
11.A.2 below 
    6, 31-37 
20 Support for low birth weight babies  Pre-term deaths 40%     6, 30,38-43 
21 Community-based case management 
for neonatal pneumonia  
Deaths from severe 
infection 
40%     6, 30,44-48 
*Based on expert panel assessment of available evidence 
**Impact is assumed to be the same for reduction in mortality and morbidity outcomes unless otherwise specified 
  
Annex 11. A 2  Region specific effectiveness of breastfeeding promotion1 
 
Region % mortality reduction attributable the intervention (through reduction of diarrhea and ARI mortality) Year 1 
% reduction attributable the intervention (through 
reduction of all cause mortality) Year 2 
50 % coverage  
 % Total deaths % female deaths % male deaths % Total deaths % female deaths % male deaths 
AfrD 12% 13% 10% 19% 19% 19% 
AfrE 13% 14% 11% 19% 19% 19% 
AmrB 10% 10% 11% 20% 20% 20% 
AmrD 10% 12% 8% 17% 17% 17% 
EmrB 15% 14% 16% 37% 37% 37% 
EmrD 14% 11% 16% 22% 22% 22% 
SearB 6% 7% 6% 14% 14% 14% 
SearD 9% 9% 9% 9% 9% 9% 
WprB 11% 15% 7% 18% 18% 18% 
              
80% coverage  
 % Total deaths % female deaths % male deaths % Total deaths % female deaths % male deaths 
AfrD 12% 13% 11% 21% 21% 21% 
AfrE 13% 15% 12% 21% 21% 21% 
AmrB 11% 10% 11% 11% 11% 11% 
AmrD 10% 12% 8% 18% 18% 18% 
EmrB 17% 16% 18% 39% 39% 39% 
EmrD 15% 13% 17% 18% 18% 18% 
SearB 7% 8% 7% 19% 19% 19% 
SearD 10% 10% 11% 9% 9% 9% 
WprB 12% 18% 6% 8% 8% 8% 
              
              
95% coverage  
 % Total deaths % female deaths % male deaths % Total deaths % female deaths % male deaths 
AfrD 12% 13% 11% 21% 21% 21% 
AfrE 14% 15% 12% 21% 21% 21% 
AmrB 11% 10% 12% 7% 7% 7% 
AmrD 11% 12% 9% 17% 17% 17% 
EmrB 17% 16% 18% 39% 39% 39% 
EmrD 15% 13% 18% 18% 18% 18% 
SearB 7% 7% 6% 11% 11% 11% 
1Adam T and Lauer JA. Modeling of breastfeeding-attributable reductions in neonatal mortality, diarrhea, and pneumonia by region 
(unpublished). World Health Organization, 2004. 
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Annex 11.B 1: Current coverage of antenatal care, tetanus toxoid and 
institutional delivery for AfrE and SearD 
 
Intervention 
(number) 
AfrE SearD Source 
        
Antenatal care 
(ANC) 
76% 50% 1-2 
Tetanus toxoid 51% 77% 3 
Institutional delivery 
(ID) 
44% 28% 3 
 
 
Annex 11.B 2: Estimated coverage for remaining interventions in 2000 
 
Intervention Estimated coverage* 
Antenatal care (ANC)   
Screening & treatment of asymptomatic 
bacteriuria 
ANC coverage x 0.2 
Other ANC interventions ANC coverage x 0.5 
    
Institutional delivery (ID)   
Neonatal resuscitation ID coverage x 0.2 
Antibiotics for pPROM ID coverage x 0.5 
Referral care of neonatal sepsis ID coverage x 0.7 
Other skilled attendant & referral care 
interventions 
ID coverage x 0.5 
 * Based on expert panel estimates for effective coverage of these 
interventions in the base year (2000). 
 
References for Annex 11. B 
1 UNICEF Global Database - Antenatal care: 
http://www.childinfo.org/eddb/antenatal/database1.htm 
2 The State of the World's Children 2004: 
http://www.unicef.org/files/Table8.pdf   
3 Weighted average for the WHO sub-region from the Demographic and 
Health Surveys (DHS): http://www.measuredhs.com 
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Chapter 12.     Achieving the Millennium 
Development Goals for health: Evaluation of current 
 strategies and future priorities for improving health 
in developing countries         
 
 
 
Summary 
 
 
This September, the United Nations is reviewing progress towards the 
Millennium Development Goals (MDGs), five years after signing of the 
Millennium Declaration.  A series of papers has already been published in this 
Journal highlighting the areas in which current strategies aimed at an 
individual condition or disease could be modified to move more rapidly 
towards the targets.  This paper, the last of the series, summarized the 
implications of all papers taken together for decision makers wishing to make 
the best use of the resources available across all diseases and conditions.    
 
The standardized methods developed for the WHO-CHOICE project are used.  
They allow the efficiency of the current use of resources to be assessed at the 
same time as indicating which interventions should be given priority should 
new resources become available.  The analysis also takes interactions between 
interventions undertaken at the same time into account, something rarely 
found in cost-effectiveness studies but important for understanding what 
actually happens in countries.   
 
At present, a set of very cost-effective interventions are not fully implemented 
while money is spent in the health sector on higher cost, less effective 
activities.  The paper identifies which interventions should be given priority 
now, and in the future if new resources become available.   
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12. 1  Introduction 
 
Five years after the Millennium Declaration was signed, few of the poorest 
countries in the world are on track to achieve the Millennium Development 
Goals (MDGs) for health.218;257 In September 2005, Heads of State renewed, in 
the UN, their commitment to these goals and to finding the resources to 
achieve them.  The needs are substantial.  An additional US$73 billion in 
external aid will be needed in 2006 alone for all the MDGs, with approximately 
$18.5 billion for health.254 In this series of papers we have considered a 
different, but related question.  We have examined whether the strategies 
adopted to date for using the available resources, and those planned for the 
future as more resources become available, are appropriate in view of the 
disappointing progress, changing circumstances and new evidence.   
 
Five papers each focused on one of the conditions mentioned in the 
Millennium Development Goals or their targets - child health, maternal and 
neonatal health, HIV/AIDS, malaria and tuberculosis (TB).219-223 Each analysed 
the costs and effects of key interventions.   
 
This paper summarizes their key findings, providing information for 
programme managers and donors focusing on a particular area.  We then take 
the perspective of a policy-maker concerned about how best to achieve the 
health MDGs as a group. Resources must be allocated across the three health 
goals and five conditions, balancing the costs and effects of a large number of 
technically feasible interventions addressing quite different health problems.  
This requires explicit comparison of all the interventions considered in the 
earlier papers. 
 
 
12. 2  Methods 
 
The analysis uses the results of the preceding papers.219-223  Methods were 
described in Evans et al.254 and in earlier publications.115;188;215;239  Box 12.1 
provides only essential details.  Two innovations were involved to ensure the 
results had more relevance to practical policy decisions than traditional cost-
effectiveness analysis.  First, the cost-effectiveness of the existing resource use 
could be evaluated at the same time as the cost-effectiveness of possible future 
courses of action should new resources become available.  Traditional cost-
effectiveness analysis has usually considered only the second.  Second, 
interactions in costs and effects between interventions that are undertaken 
simultaneously, as they would be in practice, were incorporated.  Previous 
studies have generally assumed, mostly implicitly, that every intervention is 
undertaken in isolation from related activities.   
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Box 12.1.  Summary Methods* 
 
 
- Health gains are measured as the number of disability adjusted life years 
(DALYs) averted by an intervention or combination.  
- Costs are reported in international dollars (I$). Web Table 1 allows 
readers to translate the results to US dollars if desired.254    
- Afr-E includes countries from sub-Saharan Africa with high child and 
very high adult mortality rates.  Sear-D consists of countries in South-
East Asia with high child and adult mortality.  Malaria is not a major 
cause of mortality in Sear-D so that set of interventions was not 
evaluated.   
- Costs and DALYs averted depicted in Figures 1 and 2 are the additional 
costs and additional effects of adding the intervention to those already 
existing.  The exceptions are A1 and B1, where costs and effects are 
incremental on doing nothing.   
 
*  Full details were provided in Evans et al.254  
 
The major addition for the analysis in this paper is that more synergies 
between interventions undertaken concurrently were included. For example, 
different interventions that would be delivered as part of a basic obstetric 
package, often by the same person during the same visit, had been analysed 
separately in the maternal and neonatal health5 (e.g. tetanus toxoid), 
HIV/AIDS6 (prevention of mother to child transmission) and malaria7 
(intermittent presumptive treatment) papers.  Cost synergies between tetanus 
toxoid and the other interventions addressing maternal and neonatal health 
were included in that paper, but here we add synergies resulting from 
common delivery platforms across all the health MDGs.   
 
The individual papers have eliminated a number of interventions from further 
consideration because they proved to be more costly, with lower health 
benefits than others.  These are complementary feeding without growth 
monitoring and health promotion in both regions and alternative regimens to 
artemisinin-based combination therapy to treat malaria in Africa (WebTable 2 
on bmj.com).     
 
The remaining interventions were then classified in a way that is useful for 
setting priorities across multiple health conditions.  We earlier argued that the 
uncertainty around estimates of costs and health gains, especially when 
information must be taken from a limited number of data points, precludes 
basing policy advice on the point estimates of cost-effectiveness.254 For policy 
purposes, interventions should be compared in terms of order-of-magnitude 
cost-effectiveness bands.  Interventions were deemed to be highly cost-
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effective if they cost less than GDP per capita to avert each DALY, and cost-
effective if each DALY could be averted at a cost of between one and three 
times GDP per capita.  Other interventions are not cost-effective.236   This 
incorporates an element of affordability.  Regions and countries with lower 
levels of national income have lower cut-points, but within any band, 
individual decision-makers have a menu of interventions to choose from.   
 
    
12. 3  Results  
 
Recommended strategy changes, by MDG  
 
In some cases, current strategies and plans were found to be essentially 
appropriate, while more opportunities to reallocate resources existed in others.  
The main modifications to strategies implied by the results of the earlier 
papers are reported in Box 12.2 and two illustrations are provided here.   
Significant reductions in maternal and neonatal mortality require, for example, 
increased access to clinical facility-based services providing basic and 
emergency obstetric and neonatal care, but also increased community-based 
prevention, including the encouragement of breastfeeding, support of low 
birth-weight babies, treatment of neonatal pneumonia and wider provision of 
tetanus toxoid.  If  no new resources are forthcoming and  substantial 
resources currently support relatively high cost, low effect interventions such 
as antibiotics for premature rupture of membranes in both regions, or 
antenatal steroids for pre-term births in Sear-D, consideration could be given 
to reallocating current spending  to the more cost-effective interventions 
described above.   
 
Box 12. 2. Achieving the MDGs more rapidly: modifications to current 
strategies 
 
Disease/ 
Condition 
Main Changes 
Maternal and 
neonatal 
Higher priority should be given to increasing access to clinical 
facility-based services providing basic and emergency obstetric 
and neonatal care.  At the same time, there is insufficient coverage 
of a set of highly cost-effective preventive interventions, including 
community-based support for breastfeeding mothers and low 
birth-weight babies, treatment of neonatal pneumonia, provision 
of tetanus toxoid, and screening mothers for syphilis, bacteruria 
and pre-eclampsia/pregnancy induced hypertension. Lower 
priority should be given to high cost, low effect interventions such 
as antibiotics for pre-term rupture of membranes, and antenatal 
steroids for pre-term births (in Sear-D) until resource availability 
increases. 
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Child health Increased efforts to fortify processed food staples with multiple 
micronutrients; especially vitamin A and zinc. Current focus on 
personal interventions is appropriate - measles immunization, 
case management of pneumonia, oral rehydration therapy.  If 
more resources are available, vitamin A and zinc supplementation 
could replace fortification.  Where resources are very limited, 
these interventions should be given higher priority than higher 
cost, less effective alternatives e.g. food supplementation and 
nutrition advice. To combat malnutrition sustainable intersectoral 
action is critical but, in the meantime, research on health sector 
interventions that could contribute more cost-effectively to the 
problem is urgently needed.  
HIV/AIDS The MDGs focus on reducing transmission.  Strategies based on 
treatment of sexually transmitted infections, educating sex 
workers and some types of mass media messages are highly cost 
effective ways to do this.  There is considerable uncertainty 
around the effectiveness of school based education but for most 
assumptions it is not highly cost-effective in Sear-D.  With recent 
changes in prices, treatment with first line antiretrovirals is at least 
as cost effective as some of the well known preventive 
interventions, such as voluntary counselling and testing, and is in 
the spirit of the MDGs.      
Malaria In most countries of sub-Saharan Africa serious consideration 
should now be given to improved case management with new 
combination therapies (ACTs). Successful long-term malaria 
control requires an integrated approach of case management with 
ACTs supplemented by use of impregnated mosquito nets or 
indoor residual spraying. Where these are being successfully 
implemented, intermittent presumptive treatment of pregnant 
women can bring an important additional health benefit. Much 
greater efforts should be given to increasing coverage of malaria 
interventions to ensure efficient malaria control. 
Tuberculosis Effective treatment of infectious (sputum smear-positive) cases is 
the first priority in TB control, including for patients co-infected 
with HIV. This is in line with current practice in almost all TB 
control programmes, but improving case finding and cure rates 
should now be given high priority. Once the essential elements of 
TB control are in place, treatment should be extended to patients 
who are less infectious (sputum smear-negative), and to those 
carrying multidrug resistant strains of TB. Anti-retroviral therapy 
should be offered in conjunction with TB treatment for those 
infected with HIV.   
 
 
The HIV/AIDS target is to reduce transmission.  While there is no strong 
evidence yet that antiretroviral therapy has an impact on transmission, it is as 
cost-effective in improving health as some preventive interventions that are 
currently undertaken, such as voluntary counselling and testing, and is in the 
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spirit of the MDGs.   Some increase in resources available for the highly cost-
effective preventive and treatment options could be found by reallocating 
from less cost-effective options such as  school based education or even second 
line ART in Sear-D, although it is important to note the potential for the cost of 
second-line medicines to fall significantly in the near future.   
 
 
Priority setting across health MDGs 
 
Tables 12.1 and 12.2 classify interventions into the cost-effectiveness bands 
described above, for Afr-E and Sear-D respectively (See WebTables 3 and 4 on 
bmj.com for details of costs, effects and cost-effectiveness ratios).  This can be 
visualized using Figures 12.1 and 12.2.  The vertical and horizontal axes 
respectively depict total costs and DALYs averted per year in the region.  The 
diagonal lines join points of equal cost-effectiveness. As the axes are in natural 
logarithms, each band between the diagonals represents one order of 
magnitude difference in cost-effectiveness.  For example, interventions B1-B10 
in Sear-D cost between I$1 and I$10 per DALY averted, while B21-B33 cost 
between I$100 and I$1000 per DALY averted.  Although treatment of new 
smear-positive TB cases with 80% coverage (B6) has a very similar cost-
effectiveness ratio to the expansion of community-based support for 
breastfeeding mothers at from 80-95% (B7), the former averts many more 
DALYs, but also costs more.   
 
  
Table 1. Interventions to achieve health MDGs in Afr-E: highly cost-effective, cost-effective and cost-ineffective 
 
No. MDG 
Target 
Group 
Intervention 
Highly cost-effective interventions* 
A1 MNH Community-based case management for neonatal pneumonia (95%) 
A2 HIV/AIDS Mass media campaign to promote safer sex (100%) 
A3 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (50%) 
A4 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 
80%) 
A5 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 
95%) 
A6 TB Treatment of new smear-positive TB cases only under DOTS (50%) 
A7 MNH Community newborn package (95%): 
Support for breastfeeding mothers 
Support for low birth weight babies   
A8 TB Treatment of new smear-positive TB cases only under DOTS (expanded to 80%) 
A9 Malaria Case management of malaria with artemisinin-based combination therapy (95%) 
A10 TB Treatment of new smear-positive TB cases only under DOTS (expanded to 95%) 
A11 Under-5 Vitamin A fortification of food staple (95%) 
Zinc fortification of food staple (95%) 
A12 MNH Tetanus toxoid (95%) 
A13 HIV/AIDS Prevention of mother-to-child transmission (ANC coverage) 
A14 MNH Screening & treatment of pregnancy induced hypertension 
Screening & treatment of asymptomatic bacteruria 
                                                                                                           
                                                            
 
No. MDG 
Target 
Group 
Intervention 
Screening & treatment of syphilis  
A15 Under-5 Measles vaccination (80%) 
A16 MNH Normal delivery by skilled attendant 
Active management of the third stage of labour 
Initial management of post-partum haemorrhage 
Neonatal resuscitation 
A17 MNH Treatment of severe pre-eclampsia/eclampsia 
A18 Malaria Insecticide-treated bednets (95%) 
A19 Under-5 Measles vaccination (expanded to 95%) 
A20 MNH Facility-based care of very low birth weight babies, severe neonatal infections, severe neonatal 
asphyxia and neonatal jaundice 
A21 HIV/AIDS Treatment of sexually transmitted infections (current coverage) 
A22 Under-5 Case management for childhood pneumonia (80%) 
A23 MNH Management of obstructed labour, breech and fetal distress (95%) 
A24 HIV/AIDS Treatment of sexually transmitted infections (expanded to ANC coverage) 
A25 Under-5 Vitamin A supplementation (80%, replaces fortification)  
Zinc supplementation (80%, replaces fortification) 
A26 TB Treatment of smear-negative TB cases under DOTS (95%) 
A27 Under-5 Oral rehydration therapy for diarrhoea (80%) 
A28 MNH Antenatal steroids for pre-term births (95%) 
A29 Malaria Indoor residual spraying (95%) 
A30 TB Standardized second-line drug re-treatment of TB (95%) 
A31 MNH Management of maternal sepsis 
  
No. MDG 
Target 
Group 
Intervention 
A32 Malaria Intermittent presumptive treatment during pregnancy (95%) 
A33 MNH Antibiotics for pre-term premature rupture of membranes (pPROM) 
A34 HIV/AIDS Voluntary counseling and testing (95%) 
A35 MNH Referral care for severe post-partum haemorrhage 
A36 Under-5 Vitamin A Supplementation (expanded to 95%) 
Case management for childhood pneumonia (expanded to 95%) 
Zinc supplementation (expanded to 95%) 
Oral rehydration therapy for diarrhoea (expanded to 95%) 
A37 HIV/AIDS Treatment of sexually transmitted infections (expanded to 95%) 
A38 HIV/AIDS Antiretroviral therapy: no intensive monitoring, first-line drugs only (95%) 
A39 HIV/AIDS School-based education on safer sex (95%) 
A40 HIV/AIDS Antiretroviral therapy: intensive monitoring, first-line drugs only (95%) 
Not cost-effective interventions* 
A41 HIV/AIDS Antiretroviral therapy: intensive monitoring, first- and second-line drugs (95%) 
A42 Under-5 Improved complementary feeding, growth monitoring and promotion (95%) 
*Highly cost-effective if ratio is less than or equal to I$1,576.  
  Not cost-effective if ICER is greater than $4,728 
 
 
                                                                                                           
                                                            
 
Table 2. Interventions to achieve health MDGs in Sear-D: highly cost-effective, cost-effective and cost-ineffective. 
 
No. MDG 
Target 
Group 
Intervention 
Highly cost-effective interventions* 
B1 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (50%) 
B2 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 
80%) 
B3 HIV/AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 
95%) 
B4 MNH Community-based support for breastfeeding mothers (50%) 
B5 MNH Community-based support for breastfeeding mothers (expanded to 80%) 
B6 TB Treatment of new smear-positive TB cases only under DOTS (80%) 
B7 MNH Community-based support for breastfeeding mothers (expanded to 95%) 
B8 MNH Tetanus toxoid (80%) 
B9 TB Treatment of new smear-positive TB cases only under DOTS (expanded to 95%) 
B10 MNH Tetanus toxoid (expanded to 95%) 
B11 Under-5 Zinc fortification of food staple (95%) 
B12 MNH Community-based support for low birth weight babies (95%) 
B13 HIV/AIDS Mass media campaign to promote safer sex (100%) 
B14 TB Treatment of smear-negative TB cases under DOTS (95%) 
B15 Under-5 Vitamin A fortification of food staple (95%) 
B16 Under-5 Case management for childhood pneumonia (80%) 
B17 MNH Normal delivery by skilled attendant (95%) 
Active management of third stage & initial treatment of post-partum haemorrhage (95%) 
  
No. MDG 
Target 
Group 
Intervention 
B18 Under-5 Case management for childhood pneumonia (expanded to 80%) 
B19 Under-5 Measles vaccination (95%) 
B20 MNH Screening & treatment of pregnancy induced hypertension 
Screening & treatment of asymptomatic bacteruria 
B21 HIV/AIDS Treatment of sexually transmitted infections (95%) 
B22 MNH Community-based case management for neonatal pneumonia (95%) 
B23 Under-5 Zinc supplementation (95%, replaces fortification)  
Oral rehydration therapy for diarrhoea (95%) 
B24 MNH Neonatal resuscitation (95%) 
Treatment of severe pre-eclampsia/eclampsia (95%) 
B25 TB Standardized second-line drug re-treatment of TB (95%) 
B26 MNH Referral care for severe post-partum haemorrhage (95%) 
B27 MNH Management of maternal sepsis (95%) 
B28 HIV/AIDS Voluntary counseling and testing (95%) 
B29 Under-5 Vitamin A supplementation (95%, replaces fortification) 
B30 HIV/AIDS Prevention of mother-to-child transmission (ANC coverage) 
B31 MNH Facility-based care of very low birth weight babies, severe neonatal infections, severe neonatal 
asphyxia and neonatal jaundice (95%) 
B32 HIV/AIDS Screening & treatment of syphilis (95%) 
B33 MNH Antiretroviral therapy: no intensive monitoring, first-line drugs only (95%) 
B34 HIV/AIDS Antiretroviral therapy: intensive monitoring, first-line drugs only (95%) 
Cost-effective interventions* 
B35 HIV/AIDS School-based education (95%) 
                                                                                                           
                                                            
 
No. MDG 
Target 
Group 
Intervention 
B36 MNH Management of obstructed labour, breech and fetal distress (95%) 
B37 MNH Antibiotics for pre-term premature rupture of membranes (pPROM) 
Not cost-effective interventions* 
B38 HIV/AIDS Antiretroviral therapy: intensive monitoring, first- and second-line drugs (95%) 
B39 MNH Antenatal steroids for pre-term births (95%) 
B40 Under-5 Improved complementary feeding, growth monitoring and promotion (95%) 
*Highly cost-effective if ICER is less than or equal to Int$1,449 
 Cost-effective if ICER is greater Int$1,449 and less than or equal to Int$4,347 
 Not cost-effective if ICER is greater than Int$4,347 
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Figure 1. Interventions in Afr-E for the health MDGs: acceptability bands 
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Figure 2. Interventions in Sear-D for the health MDGs: acceptability bands 
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12. 4  Discussion 
 
In practice, resources are never allocated according to formulaic cost-
effectiveness rules described in text books - e.g. choosing the most cost-
effective intervention, then the next most cost-effective, until all resources are 
used.  This would sometimes suggest that only prevention should take place, 
or only treatment, but in reality mixes of interventions are generally found.  
Our analysis suggests this is appropriate.  The highly cost-effective group of 
interventions reported above includes a selection from each of the 
disease/condition groups in both regions, as well as mixes of treatment and 
preventive actions, and of population and individually focussed activities.  
This is true even if the threshold for highly cost-effective interventions is 
reduced to I$100 per DALY averted. 
 
In both regions covered in this series, there is so much unmet need and so 
many underused interventions, that the opportunities for reallocating 
resources currently spent on the MDGs are limited.  Purely on cost-
effectiveness grounds, however, it is clear that priority should be given to the 
highly cost-effective group rather than activities such as  second line 
antiretroviral therapy for AIDS (A41) and complementary feeding with 
growth monitoring and promotion (A42) in Afr-E.  More could be achieved if 
these resources were reallocated to any of the under-used, highly cost-effective 
group.  
 
A similar picture unfolds in Sear-D. Attention should be focused on scaling up 
interventions that are highly cost-effective rather than expanding second line 
antiretroviral therapy, antenatal steroids for pre-term births, and improved 
complementary feeding and growth monitoring and promotion (B38-B40), and 
even school-based education for HIV/AIDS (B35), management of obstructed 
labour, breech and fetal distress (B36) and antibiotics for pre-term premature 
rupture of membranes in pregnant women (B37), which fall into the cost-
effective rather than the highly cost-effective band.   
 
In both regions, a relatively large set of highly cost-effective interventions 
remain, offering considerable flexibility to adapt packages to particular 
contexts.  The relative size of this group reflects the unmet needs, but also the 
fact that the MDGs were well chosen and need to be better funded.  Many 
more interventions would fall outside the highly cost-effective group had the 
analysis included conditions outside the MDGs, and it is here that greater 
potential to reallocate resources toward the MDGs may well be found.    
 
We accept that in practice, prioritization sometimes takes little account of cost-
effectiveness information.  While we think that public health decision makers 
have the responsibility to consider how best to improve population health for 
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the resources that are available, we also accept that many other considerations 
do, and should, influence decisions on resource allocation.  There also 
continues to be important debates about the appropriateness of using cost-
effectiveness analysis (CEA) to drive decisions in health.  For example, the 
technique focuses only on the health gains associated with different uses of 
resources, so does not incorporate other effects of concern to society.  This may 
be particularly relevant to antiretroviral treatment for HIV/AIDS, which keeps 
health workers and school teachers in their posts and which could, at the limit, 
prevent a possible break down of society.259;260  These benefits cannot be 
captured in terms of DALYs.  There are also a number of ethical issues implicit 
in CEA and its use, particularly the fact that equity is not explicitly 
incorporated.260;261 
 
We recognize all of these concerns.  Policy makers, however, cannot escape 
from the unfortunate fact that the resources available are insufficient even to 
undertake all the interventions designated in this paper as highly cost-
effective, and it is not yet clear that the additional resources required to reach 
the MDGs will be found.  In such cases, informed decisions about how to 
allocate the available resources require knowledge of the likely impact on 
population health of different courses of action.  If not, decisions could be 
made to improve the health of a few people by a small amount at the expense 
of improving the health of more people by a larger amount, something that 
neither the proponents nor opponents of the use of CEA would want.   
 
To implement one or more of the less cost-effective interventions identified in 
this paper might be justified on many grounds - perhaps an intervention, such 
as feeding malnourished infants or management of obstructed labour, targets 
a group in society with particularly poor levels of health.  While this is 
perfectly legitimate, we argue that decision makers cannot make an informed 
decision without full information on the opportunities to improve population 
health that are foregone elsewhere.   
 
The results presented in this series represent the best available evidence 
currently available.  Costs and effects need to be re-evaluated from time to 
time, as new information becomes available or key parameters change.  If, for 
example, prices of second-line antiretrovirals fall by the same proportion as 
recently observed for first-line medicines, they could also enter the highly cost-
effective band. 
                                                                   
                                                                                   
 
                                                                   
                                                                                        
 
 
    13 
 
 
 
Discussion 
 
 
 
 
CHAPTER 13 
 207 
Chapter 13.     Discussion 
 
The central theme of this thesis was to explore sources of variability in the 
methods used in costing studies and the implications for the validity and 
transferability of the results.   
 
The first issue that was covered involved the reasons for variability in the 
methods used in costing and cost-effectiveness studies.  These were examined 
and classified into avoidable and unavoidable sources of variations ( Chapter 
2). Secondly, a full cost-effectiveness analysis of the Integrated Management of 
Childhood Illness (IMCI) was presented to assess the practicality of rigorously 
applying the recommendations of guidelines when conducting costing studies 
( Chapter 3) and in using the results to provide policy-relevant information 
( Chapter 4).  
 
Thirdly, a set of empirical studies was presented. The first explored the 
determinants of variation in hospital unit costs across hospital departments 
and countries ( Chapter 5) and the possibility of using the results to extrapolate 
unit costs across different hospitals and settings; the second examined, and 
improved on, commonly used short-cut methods to estimate hospital costs 
( Chapter 6); the third took the analysis in the previous two chapters a step 
further by exploring the determinants of variation in unit costs across different 
hospital departments ( Chapter 7); and the fourth explored the determinants of 
variation in staff time with the introduction of a new intervention (IMCI) in a 
facility-based setting  ( Chapter 8).  All this empirical work was aimed at 
improving the transferability of cost results across within a country, and 
across geographical areas, when local data do not exist.  
 
Finally, several applications of the results of these models were reported.  One 
involved estimating the cost of the “3 by 5” strategy, a global health initiative 
to reduce mortality due to HIV/AIDS ( Chapter 9).  Another calculated costs in 
a consistent and comparable manner as part of an evaluation of the cost-
effectiveness of interventions to achieve the Millennium Development Goal for 
maternal and neonatal health ( Chapter 11).  Both chapters related to specific 
diseases or disease problems.  The approach was expanded to the sectoral 
perspective by comparing the cost-effectiveness of interventions across 
multiple disease areas (Chapters 10 and 12). The main findings and 
conclusions from the analysis presented in this thesis are summarized below. 
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In  Chapter 2, a comparison between the nature of the recommendations of 
costing and cost-effectiveness guidelines and the methods used in published 
studies was presented. The results suggest that several, though not all, of the 
observed differences in the methods used in applied studies are avoidable 
and, therefore, could be reduced. This can be achieved, firstly, if studies 
comply with the recommendations of guidelines. In addition, reviewers of 
manuscripts for publication should ensure that only papers where it is clear 
that costs have been estimated appropriately get published, something that 
does not seem to happen. Secondly, variability in costing methods can be 
reduced if guidelines – or companion volumes to guidelines - provide more 
detail about how to follow their recommendations in practice, rather than 
discussing only principles. More empirical research is needed to guide this 
process, however, including research allowing different data collection and 
measurement methods to be compared.  Particularly valuable would be efforts 
to validate relatively rapid, low cost data collection techniques compared to 
more expensive gold standard methods.   
 
This thesis contributes to these methodological and practical issues in different 
ways. In  Chapter 3, a costing study was undertaken in Tanzania as part of a 
multi-country economic evaluation of the Integrated Management of 
Childhood Illness (IMCI) ― a new strategy to reduce under-five mortality. The 
study used a standardized costing methodology and data collection tools 
developed by the author for the evaluation sites in Brazil, Uganda and 
Bangladesh in addition to Tanzania.79  The study used the ingredients 
approach to collect, analyse and report cost information. The analysis was 
undertaken from the societal perspective and included costs incurred at the 
national, district, hospital, health facility and household levels. Using 
standardized methods made it possible to compare the results of the different 
settings. The fact that costs were collected and analyzed in similar ways 
eliminated the possibility that differences in the findings and interpretation of 
the results may be due to different methods.  
 
 Chapter 4 combined the standardized costing approach and the subsequent 
results with the effectiveness of IMCI.  This was measured in terms of the 
reduction in under-five mortality and compared intervention areas with IMCI 
with similar areas where IMCI had not been introduced.  Not only did IMCI 
incur no extra costs compared to the way children under five were treated in 
its absence, but it also led to a reduction in under-five mortality. Evidence 
such as this, based on rigorous evaluation methods and standard tools, is of 
great importance to policy makers because there can be no suspicion that the 
results were due to inappropriate costing methods.  
 
In  Chapter 5, cost data from 1171 observations and around 60 countries were 
used to explore the determinants of variations in cost per bed day across 
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different hospital types and countries.  The most important determinants of 
variation in the cost per bed day were the occupancy rate, an indicator of 
capacity utilization, hospital level as a proxy for case mix, and GDP per capita 
as an indicator of the availability of technology. A key result is that there is 
wide variation in the unit costs estimated from studies within a particular 
country.  These differences are sometimes of an order of magnitude, and 
cannot only be attributed to different methods.  This implies that analysts 
cannot simply take the cost estimates from a single study in a country to guide 
their assessment of the cost-effectiveness of interventions, or the costs of 
scaling-up activities.  In some cases, they could be wrong by an order of 
magnitude. The model presented in this chapter fit with the data well in a 
statistical sense, and included a large number of countries from all regions of 
the world.  It might, therefore, offer a  way of obtaining unit costs for countries 
where a reasonable sample of observations on which to base unit cost 
estimates does not exist.  It might also be preferable to extrapolating costs from 
another setting and using the official or purchasing power parity exchange 
rate, something that does not take into account the other determinants of costs 
explored this Chapter.   
 
 Chapter 6 addressed a different methodological issue - the use of simple rules 
of thumb to estimate hospital unit costs, something that has been used by 
some studies when data are lacking. For example, an assumed ratio of the cost 
of an inpatient bed day to that of an outpatient visit (commonly assumed to be 
3:1) has sometimes been used to allocate total hospital costs between inpatient 
and outpatient departments where the only available information is total costs 
and the number of beds days and outpatient visits. In this chapter, I first 
determined if the simple rules of thumb that have been suggested are 
relatively accurate for the countries and hospitals for which costing studies 
were not available or feasible.  Secondly, the determinants of the observed 
variations in the ratio of outpatient to inpatient unit costs were identified 
quantitatively, and then the estimated relationship was used to calculate unit 
costs for countries where data did not exist. The model was estimated using 
data from 832 hospitals in 28 countries.  
 
The results suggest that no simple rule of thumb describes the available data.  
Even holding all other determinants except GDP per capita and hospital level 
constant, the ratio of the cost of an inpatient stay to that of an outpatient visit 
could be as low as two, and as high as 12.  While this might not be totally 
surprising, there was also enormous variation in this ratio even for hospitals of 
the same type in the same setting.  This means that even where some step 
down costing studies have been undertaken, analysts would be unwise to base 
policy advice on the results of only one or two studies.  The hospital or 
hospitals for which data are available may well be atypical of other hospitals 
of the same type in that country.  The implication is that a sufficiently large 
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random sample of hospitals is really required to provide accurate policy 
advice, further increasing the costs of doing such research.   
 
The second conclusion is that a high proportion of the observed variation in 
the ratio observed across hospitals can be explained. All regression diagnostics 
suggested a good fit with the data and the signs of the coefficients have face 
validity.  This suggests that the equations reported here could provide a viable 
alternative for estimating unit costs than rule of thumb if only a small number 
of observations from hospital costing studies is available. Knowledge of a few, 
readily obtainable explanatory variables could be used to estimate the ratio, 
and hence, the costs of inpatient stays and outpatient visits.   Moreover, we 
argue that the approach is more likely to provide a reliable estimate of the 
average costs than relying on a single, or a few, cost studies in a given setting, 
even if those studies use appropriate methods.  This is because of the great 
variation in unit costs observed for hospitals in the same country, described 
earlier.   
 
 Chapter 7 took this analysis a step further by exploring the determinants of 
variation in hospital unit costs across various inpatient departments, partly 
motivated by the methodological issues raised in the previous chapter.  The 
analysis explored whether the ratio of inpatient to outpatient costs varies by 
type of inpatient department and sought to identify the determinants of any 
variation.  This analysis was based on costs taken from 41 Chinese hospitals 
covering 13 provinces.  A seemingly unrelated regression model for 
compositional data was used for the estimation process, where each 
dependent variable represented the share of a specific department’s costs to 
total hospital costs. Compositional models take account of the key features of 
this type of data, namely that the share attributable to each fraction is bounded 
by zero and one, and that all of the fractions must sum to one. Seemingly 
unrelated regressions is not widely used in economic analyses, except from 
some examples where the determinants of demand for different types of 
consumption have been estimated and where the sum of the different types 
must add to total consumption or expenditure. As illustrated by Smith 2000, 
the approach leads to a significant improvement in efficiency of the estimation 
of compositional data because it models, rather than ignores, the correlated 
errors between equations.193  
 
The model again explained a high proportion of the variation in the ratio of 
inpatient to outpatient costs.  The average across the sample was close to the 
rules of thumb suggested by earlier studies (3:1 and 4:1) but observations 
ranged from 1.5:1 to 6:1.  Much of the variation was due to differences in the 
number of staff and the proportion of department-specific bed-days to total 
bed-days, although some variability was also due to differences in occupancy 
rates. The model explained most of the variation between different hospital 
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departments (the adjusted R2 of the various equations ranged from 0.83 and 
0.92.).  This raises the question whether the relationship reported in this 
chapter could be used to estimate unit costs for any other hospital in China 
without having to under-take step down hospital costing studies. Further 
innovations in the future development of this work would be to use 
compositional models designed specifically for panel data or to explore the 
value of a multi-country analysis to explain variations in department-specific 
hospital costs across countries. If the estimated relationship could be used, it 
would be particularly valuable for cost-effectiveness studies and for estimates 
of the costs of scaling up interventions because there are many countries in the 
world where full step-down costing studies, the gold standard, do not exist.4  
 
The decision to provide a new intervention or to modify an old one poses 
important questions regarding the resources required, one of which is staff 
time. At the margin, if health workers are currently fully occupied, it would 
not be possible to incorporate new activities that require additional time 
inputs unless new staff were employed or existing activities were eliminated 
or reduced.  Information on how health workers currently spend their time 
can help programme managers determine whether it is possible to add new 
services within existing capacity constraints.  Chapter 8 addressed this research 
question by measuring the amount of time required to provide IMCI, a new 
technology compared with existing care, and the time spent in other clinical 
and non-clinical activities using a time and motion study conducted in 
Northeast Brazil. The study also explored possible determinants of variations 
in consultation time across providers. 
 
Multivariate regression analysis showed that, after controlling for other 
determinants, IMCI-trained providers spent significantly longer time on the 
average consultation with children than non-IMCI-trained providers.  The size 
of the difference, however, was crucially determined by constraints on 
providers’ time.  The higher the workload, the lower the difference, to the 
extent that the difference was relatively small when the workload exceeded 50 
consultations per provider per day.  These findings have key policy and 
methodological implications. In the study sample, the mean number of 
consultations per provider per day was 34 and 95% of the providers had case 
loads lower than 54 patients per day. If this is representative of the rest of 
Brazil, it would be possible to introduce IMCI relatively easily throughout the 
country without encountering capacity constraints in terms of provider time.  
Interestingly, an unthinking cost analysis would suggest the opposite.  
Because the observed additional time is greater in areas of low workload, it 
would suggest that the financial costs of adding IMCI are higher where 
workload is low than where workload is high.  On the contrary, these results 
are best interpreted as showing that IMCI can be introduced without 
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significant financial implications when capacity constraints on time are 
relatively low.   
 
Applications of the empirical analysis presented in the previous chapters are 
presented in Chapters 9-12.  Chapter 9 shows how the results of the country-
specific cost estimation models in  Chapter 5 and  Chapter 6 can be used to 
inform policy makers about the cost of achieving the WHO initiative of 
covering three million HIV/AIDS patients with antiretroviral therapy (ARVs) 
by the year 2005, i.e., over a 2 year period from when the analysis was 
undertaken. Decision-makers need not only evidence on the costs of different 
interventions to guide decisions about how to allocate resources from the 
social or economic perspective, but also need to know the financial resources 
needed for planning and fund raising activities. The advantage of basing this 
type of analysis on the results of such models is the possibility of using 
country-specific estimates of unit costs and the ability to vary unit costs 
according to the changes in capacity utilization that would result from 
increased coverage levels.  This takes into account both economies and 
diseconomies of scale.   
 
In Chapters 10-12, a standardized methodology was used to evaluate the cost-
effectiveness of interventions to achieve the health-related Millennium 
Development Goals (MDGs), see  Chapter 10. They were first applied to a 
cluster of interventions for maternal and neonatal health ( Chapter 11), then 
compared with the cost-effectiveness of the other interventions targeting the 
health-related MDGs, i.e., under-fives, Malaria, TB and HIV/AIDS estimated 
through the same methods of analysis ( Chapter 12).219;221-223 All interventions 
were first evaluated relative to "doing nothing" to allow the efficiency of the 
current use of resources to be assessed at the same time as indicating which 
interventions should be given priority if new resources become available. The 
next step was to trace out the implications for population health of adding all 
possible interventions and packages. The costs of each intervention scenario 
were then compared with the health gain to identify the most cost effective set 
of interventions at different levels of expenditure from this starting point. The 
analysis also takes interactions between interventions undertaken at the same 
time into account, something rarely found in cost-effectiveness studies but 
important for understanding what actually happens in countries ( Chapter 10).  
 
The most cost-effective mix of interventions for maternal and neonatal health 
was similar in the two regions that were studied in this analysis, both areas of 
high maternal and child mortality. These were the community-based newborn 
care package, followed by antenatal care, skilled attendance at birth offering 
basic maternal and neonatal care around childbirth and finally emergency 
neonatal and obstetric care around and after birth. There were some 
potentially important differences, however, for particular interventions. 
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Screening and treatment of maternal syphilis was relatively less cost-effective 
in the region located in South East Asia while community-based management 
of neonatal pneumonia was relatively more cost-effective in the African 
region.  Although preventive interventions at the community and the primary 
care level are extremely cost-effective, the largest health benefits came from 
clinical interventions. Universal coverage of clinical services at primary and 
referral levels of care are, therefore, essential if the Millennium Development 
Goals for maternal and child health are to be met ( Chapter 11).    
 
In the comparative analysis across intervention clusters ( Chapter 12), it is 
interesting to note that among the interventions costing less than $25 per 
DALY averted, at least one targets each of the health MDGs in both regions.  
They also include a mix of treatment and preventive actions, and a mix of 
population and individually focussed activities.  A similar mix is found in the 
interventions with a high cost per DALY averted and which are not, therefore, 
recommended on efficiency grounds when there are severed shortages of 
resources.  This confirms that generalizations implying that prevention is 
better than cure, or that population-based interventions are more efficient than 
those focusing on individuals, are simplistic.  Each intervention needs to be 
evaluated on its merits, and in the light not just of local disease patterns, but 
also what other interventions are already being undertaken.  These 
conclusions can only be made knowing that standard approaches to costing 
were used across all interventions, and that differences in total costs, and 
therefore in cost-effectiveness ratios, are due to true differences in the 
quantities or values of the resources used.  
 
In summary, this thesis highlighted several methodological and practical 
issues related to the reasons for variability in costing methods and the 
implications on the generalizability and external validity of the results. It 
argued that some of the variability can be avoided if researchers increased 
their compliance with the recommendations of guidelines and if reviewers and 
editors of journals applied stricter rules in accepting manuscripts for 
publications. In addition, some areas where there are gaps in guidelines were 
identified and empirical studies were undertaken to address some of them. 
This included identifying alternative ways of extrapolating unit costs when 
this data does not exist, rather than just extrapolating the results of previous 
costing studies using traditional methods. The analysis shows that caution 
should be taken when using the results of a single hospital costing study as the 
basis of subsequent cost-effectiveness studies or in estimating of the costs of 
increasing coverage of particular interventions.202 These studies might well use 
unit costs that are unrepresentative of the country as a whole if they do not 
assess whether the levels of capacity utilization, staff and bed days, shown 
here to influence hospital costs, are representative.180   
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Another important implication for the transferability of the results is reporting 
and adjusting for capacity utilization when estimating and presenting unit 
costs. General policy decisions should not be based on the results of costing 
studies that do not report capacity utilization. Given the way health workers 
adjust the time they spend in consultation with patients relative to increased 
case load, estimates of costs of scaling-up interventions will not be useful to 
policy-makers if they are only based on current costs of providing care.   
 
Finally, rules of thumb have been used by some studies to estimate hospital 
costs due to the high costs and complexity of undertaking step down costing 
studies. It was shown that applying them across all hospitals is not 
appropriate as there is enough evidence that they mask important differences 
in hospital unit costs across hospitals and countries. Acknowledging the fact 
that the best alternative, step-down costing, may not always be feasible or 
affordable to undertake in a representative sample of facilities, the work 
presented in this thesis suggests that a less costly but valid alternative can be 
used where sufficient studies exist to allow the determinants of the ratio of 
inpatient to outpatient costs to be estimated econometrically.  The unit costs of 
"out-of-sample" hospitals can be estimated using such a relationship if 
information on key determinants such as occupancy rates is available.   
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English summary 
 
To ensure that policy makers are provided with consistent and valid evidence, 
it is important that costing studies use comparable and appropriate methods. 
Otherwise it is not possible to compare the efficiency of the various competing 
alternatives or be sure that the interventions claimed to be cost-effective have 
been analyzed in an appropriate manner. 
 
A further complication relates to the fact that thorough economic evaluation of 
health interventions requires skilled economists and can be relatively 
expensive to undertake.  In many countries, the necessary financial and 
human resources are not available and policy makers must draw on the results 
of studies undertaken in other settings and try to apply them to their own. For 
this reason, it is not only important to use comparable methods but also to 
report results in a way that allows policy-makers to assess the replicability and 
transferability of results between settings. 
 
The need for consistency and standardization of methods for economic 
appraisals has been recognized for some time and has led to the development 
of several sets of guidelines for economic evaluation and for costs. Despite 
this, considerable diversity is still apparent in applied studies. Some of this 
diversity might be defensible, and some might not be. 
 
The overall objective of the thesis is to explore the reasons for variability in 
costing methods used in costing and cost-effectiveness studies; to test the 
practicality of applying the recommendations of guidelines when conducting 
costing studies and in using the results to provide policy-relevant information; 
to understand the determinants of variation in unit costs; and finally to 
explore valid methods of extrapolating cost information to other settings, 
when local data do not exist.    
 
The goal is to provide cost data in a way that allows the costs and cost-
effectiveness of many different types of interventions to be compared, and 
provides the maximum assistance to researchers in one setting to generalize 
from the results of studies undertaken in another setting.  Only then will the 
results of costing exercises be of widespread practical value to policy-makers 
and researchers.   
 
The Chapters of this thesis are organized as follows.  First, Chapter 2 explores 
the sources of variations in costing methods used in applied studies, discusses 
the nature of these variations relative to the recommendations of costing 
guidelines and the possibility of reducing some of them. Next, a full cost-
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effectiveness analysis of the Integrated Management of Childhood Illness 
(IMCI) is presented to assess the practicality of rigorously applying the 
recommendations of guidelines when conducting costing studies (Chapter 3) 
and in using the results to provide policy-relevant information (Chapter 4). 
Then, a set of empirical studies is presented. The first explores the 
determinants of variations in hospital unit costs across hospital departments 
and countries (Chapter 5) and the possibility of using the results in 
extrapolating unit costs across different hospitals and settings; the second 
examines, and improves on, commonly used short-cut methods to estimate 
hospital costs (Chapter 6); the third takes the analysis in the previous two 
chapters a step further by exploring the determinants of variation in unit costs 
across different hospital departments (Chapter 7); and the fourth explores the 
determinants of staff time spent in providing IMCI in a facility-based setting 
(Chapter 8), all providing potentially useful and more valid alternatives to 
extrapolating cost information when local data do not exist. Finally, several 
applications of the results presented in these models are presented, e.g., to 
estimate the cost of the “3 by 5” strategy, a global health initiative to reduce 
mortality due to HIV/AIDS (Chapter 9), and to evaluate the cost-effectiveness 
of interventions to achieve the health-related Millennium Development Goals 
in a consistent and comparable manner both from a disease/condition 
perspective, i.e., interventions for maternal and neonatal health (Chapter 11) 
and from a sectoral perspective comparing the cost-effectiveness of 
interventions across multiple disease areas (Chapters 10 and 12).  
 
This thesis highlighted several methodological and practical issues related to 
the reasons for variability in costing methods and the implications on the 
generalizability and external validity of the results. It argued that some of the 
variability can be avoided if researchers increased their compliance with the 
recommendations of guidelines and if reviewers and editors of journals 
applied stricter rules in accepting manuscripts for publications. In addition, 
some areas where there are gaps in guidelines were identified and empirical 
studies were undertaken to address some of them. This included using 
econometric methods to estimate unit costs in settings where no such data 
exist, rather than just extrapolating the results of previous costing studies 
using traditional methods. The analysis shows that caution should be taken 
when using the results of a single hospital costing study as the basis of 
subsequent cost-effectiveness studies or in estimating of the costs of increasing 
coverage of particular interventions.  These studies might well use unit costs 
that are unrepresentative of the country as a whole if they do not assess 
whether the levels of capacity utilization, staff and bed days, shown here to 
influence hospital costs, are representative.   
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Another important implication for the transferability of the results is reporting 
and adjusting for capacity utilization when estimating and presenting unit 
costs. General policy decisions should not be based on the results of costing 
studies that do not report capacity utilization. Given the way health workers 
adjust the time they spend in consultation with patients relative to increased 
case load, estimates of costs of scaling-up interventions will not be useful to 
policy-makers if they are only based on current costs of providing care.   
 
Finally, rules of thumb have been used by some studies to estimate hospital 
costs due to the high costs and complexity of undertaking step down costing 
studies. It was shown that applying them across all hospitals is not 
appropriate as there is enough evidence that they mask important differences 
in hospital unit costs across hospitals and countries. Acknowledging the fact 
that the best alternative, step-down costing, may not always be feasible or 
affordable, the work presented in this thesis suggests that a less costly but 
valid alternative can be used where sufficient studies exist to allow the 
determinants of the ratio of inpatient to outpatient costs to be estimated 
econometrically.  The unit costs of "out-of-sample" hospitals can then be 
estimated using such a relationship if information on key determinants such as 
occupancy rates is available.   
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Samenvatting : Summary in Dutch 
 
Bronnen van variabiliteit in berekeningsmethoden van kosten 
 
Gevolgen voor het overzetten van resultaten van kosten-
effectiviteitsanalyses van het ene land naar het andere land 
 
 
Om er voor te zorgen dat beleidsmakers voorzien worden van consistente en 
geldige gegevens, is het van groot belang dat men bij kostenstudies gebruik 
maakt van vergelijkbare en toepasbare berekeningsmethoden. Doet men dit 
niet, dan is het onmogelijk om de doelmatigheid van verschillende met elkaar 
concurrerende zorgprogramma’s te vergelijken, of kan men er  niet zeker van 
zijn dat de zogenaamde ‘kosteneffectieve interventies’ op een juiste manier 
geanalyseerd zijn.  
 
Een gerelateerd probleem is  dat grondige economische evaluaties van 
gezondheidsinterventies relatief duur kunnen zijn, en dat hier ervaren 
economen voor nodig zijn. In veel landen zijn hiervoor noch de financiele noch 
de  personele middelen voor beschikbaar en zijn beleidsmakers genoodzaakt 
de studieresultaten van andere landen toe te passen op de lokale situatie. Om 
deze reden is het niet alleen belangrijk om in kostenstudies vergelijkbare 
berekeningsmethoden te gebruiken, maar ook om de verkregen resultaten 
zodanig te rapporteren dat beleidsmakers de betrouwbaarheid en de 
overdraagbaarheid van deze resultaten naar andere landen kunnen 
beoordelen  
 
De behoefte aan consistente en gestandaardiseerde berekeningsmethoden voor 
economische studies bestaat al enige tijd en heeft geleid tot de ontwikkeling 
van verschillende richtlijnen voor economische evaluaties en voor kosten. 
Ondanks deze ontwikkeling ziet men nog steeds een aanzienlijke diversiteit in 
dit soort toegepaste studies. Sommige van deze verschillen zouden 
verdedigbaar kunnen zijn, andere wellicht niet.  
 
De doelstellingen van dit proefschrift zijn het verkennen van de redenen voor 
variabiliteit in kostenmethoden zoals die gebruikt worden in kosten- en 
kosten-effectiviteitsstudies; het nagaan van de toepasbaarheid van de 
aanbevelingen uit richtlijnen voor kostenstudies en of de verkregen resultaten 
beleidsrelevante informatie opleveren;   inzicht verkrijgen in de determinanten 
van variatie in kostprijzen; en tenslotte het bepalen van valide 
berekeningsmethoden voor het extrapoleren van kosteninformatie  naar 
andere landen in het geval dat lokale data ontbreken.  
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Het uiteindelijke doel is ervoor te zorgen dat kostengegevens zodanig worden 
aangeleverd dat de kosten en kosten-effectiviteit van verschillende typen 
interventies met elkaar vergeleken kunnen worden, en dat het onderzoekers 
ondersteunt om de resultaten van dit soort onderzoek te generaliseren  naar 
andere landen. Alleen dan zullen de resultaten van deze kostenstudies 
praktisch relevant zijn voor beleidsmakers en onderzoekers. 
 
De opzet van van dit proefschrift is alsvolgt. Allereest beschrijft hoofdstuk 2 
de bronnen van variabiliteit in kostenmethoden in toegepaste studies, en 
bediscussieert deze variabiliteit in het licht van aanbevelingen uit 
kostenrichtlijnen en de mogelijkheid deze variatie te reduceren. Ten tweede 
wordt er een volledige kosten-effectiviteitanalyse gepresenteerd van het 
zogenoemde Integrated Management of Childhood Illness (IMCI) om de 
toepasbaarheid in de praktijk te kunnen beoordelen  van aanbevelingen uit 
richtlijnen bij het uitvoeren van kostenstudies (hoofdstuk 3), en voor het 
gebruik van de  resultaten voor het aanleveren van beleidsrelevante informatie 
(hoofdstuk 4). Vervolgens wordt er een aantal empirische studies 
gepresenteerd. De eerste hiervan verkent de determinanten van variabiliteit in 
de kostprijs van ziekenhuizen tussen ziekenhuisafdelingen en landen 
(hoofdstuk 5), en de mogelijkheid om de resultaten te gebruiken voor het 
extrapoleren van kostprijzen naar verschillende ziekenhuizen en landen. De 
tweede studie onderzoekt veel gebruikte verkorte methoden om 
ziekenhuiskosten te bepalen en tracht deze te verbeteren (hoofdstuk 6); de 
derde studie gaat door op de analyse van de twee voorgaande hoofdstukken  
en bekijkt de determinanten van variabiliteit in de kostprijs tussen 
verschillende ziekenhuisafdelingen (hoofdstuk 7); de vierde studie gaat na 
welke determinanten de arbeidstijd beïnvloeden bij het aanbieden van IMCI in 
een ziekenhuis omgeving (hoofdstuk 8), waar potentieel bruikbare en meer 
valide alternatieven gegeven worden om kosteninformatie te extrapoleren 
wanneer lokale gegevens niet  voorhanden zijn. Tot slot worden verscheidene 
toepassingen van de resultaten uit deze modellen gepresenteerd, bijvoorbeeld 
om de kosten te schatten van de “3 by 5”strategie, een wereldwijd 
gezondheidsinitiatief van de Wereldgezondheids Organizatie (WHO) om de 
sterfte  als gevolg van HIV/AIDS te verminderen (hoofdstuk 9), en om op een 
consistente en vergelijkbare manier de kosten-effectiviteit te bepalen van 
interventies voor het bereiken van de gezondheidsgerelateerde Millennium 
Ontwikkelings Doeleinden. Dit laatste gebeurt zowel vanuit het perspectief 
van de ziekte/aandoening, bijvoorbeeld voor interventies voor kraamzorg en 
neonatale zorg (hoofdstuk 11), als vanuit een sectoraal perspectief waarbij de 
kosten-effectiviteit van interventies over verschillende ziektegebieden met 
elkaar vergeleken wordt (hoofdstukken 10 en 12). 
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In dit proefschrift zijn verschillende methodologische en praktische problemen 
aan het licht gekomen die te maken hebben met de oorzaken van variabiliteit 
in kostenmethoden, maar ook de gevolgen hiervan voor de 
generaliseerbaarheid en de externe validiteit van de verkregen resultaten. 
Beargumenteerd werd dat  een deel van deze variabiliteit vermeden kan 
worden wanneer onderzoekers zich beter aan de aanbevelingen van richtlijnen 
zouden houden en wanneer redacties van tijdschriften strengere regels zouden 
toepassen bij het accepteren van manuscripten voor publicatie. Tevens is er 
een aantal gebieden geïdentificeerd waar nog richtlijnen ontbraken, en zijn er 
empirische studies verricht om sommige van deze onder de aandacht te 
brengen. Een voorbeeld hiervan was het gebruik van econometrische 
methoden om kostprijzen te bepalen in landen waar deze data niet 
voorhanden zijn, in plaats van het slechts op traditionele wijze extrapoleren 
van resultaten van voorgaande kostenstudies.  De analyse toont aan dat 
voorzichtigheid is geboden bij het gebruik van de resultaten van een 
kostenstudie van slechts één ziekenhuis als basis voor kosten-
effectiviteitsstudies of voor het bepalen van de kosten van het opschalen van  
interventies. In deze studies zouden heel goed kostprijzen  gebruikt kunnen 
worden die niet representatief zijn voor het land als geheel, wanneer  niet is 
nagegaan of het niveau van capaciteitsgebruik, de inzet van personeel en 
ligdagen, waarvan duidelijk is dat deze de ziekenhuiskosten beïnvloeden, 
representatief is.  
 
Een ander belangrijk gevolg voor de overdraagbaarheid van resultaten is het 
bijhouden van capaciteitsgebruik en het corrigeren hiervoor wanneer 
kostprijzen geschat en gepresenteerd worden. Algemene beleidsbeslissingen 
zouden niet gebaseerd moeten zijn op de resultaten van kostenstudies waar 
geen rekening is gehouden met capaciteitsgebruik. Gezien de manier waarop 
gezondheidswerkers hun tijd die ze besteden aan het consulteren van 
patiënten aanpassen aan  verhoogde werkdruk, zijn schattingen van kosten 
om interventies op te schalen niet bruikbaar voor beleidsmakers als ze alleen 
gebaseerd zijn op de huidige kosten van de zorgverlening.  
 
Tenslotte zijn er bij bepaalde studies om ziekenhuiskosten te bepalen een 
aantal vuistregels gebruikt vanwege de hoge kosten en de complexiteit van 
‘step down’ kostenstudies. Duidelijk werd dat het niet wenselijk is deze regels 
toe te passen op alle ziekenhuizen, omdat er voldoende bewijs is dat ze 
belangrijke verschillen in kostprijzen over ziekenhuizen en landen 
verdoezelen. Het feit erkennend dat het beste alternatief, namelijk ‘step down’ 
kostenberekening, niet altijd praktisch of betaalbaar is, suggereert dit 
proefschrift dat een minder kostbaar maar valide alternatief gebruikt kan 
worden, in het geval dat er voldoende studies bestaan waarbij de 
determinanten van de ratio van klinische  ten opzichte van  poliklinische 
kostprijzen econometrisch bepaald worden. De kostprijs van ziekenhuizen 
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“buiten-de-steekproef” kunnen vervolgens geschat worden door zo’n 
verhouding te gebruiken wanneer informatie over sleuteldeterminanten als 
bezettingsgraad aanwezig is. 
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1. Variability in costing methods makes it very difficult to compare the 
results of different studies, diminishing their usefulness particularly 
outside their own setting and context (this thesis).   
2. The wide variation in the unit costs estimated from studies within a 
particular country implies that analysts cannot simply take the cost 
estimates from a single study in a country to guide their assessment of 
the cost-effectiveness of interventions, or the costs of scaling-up 
activities (this thesis).   
3. While the ideal method for estimating unit costs would be to conduct 
studies in a representative sample of facilities or activities, the 
econometric method presented in this thesis is more likely to provide 
a more accurate estimate of the average unit costs than relying on a 
single, or a few, cost studies in a given setting (this thesis).   
4. An important implication for the transferability of the results is 
accounting for variations in capacity utilization in cost calculations 
and therefore these should be routinely reported in all published 
study (this thesis).    
5. Estimates of the costs of scaling-up interventions will not be accurate, 
so not useful to policy-makers, if they are only based on the current 
costs of providing care as these are a function of current output (e.g., 
number of patient visits), and consultation time changes with changes 
in output (this thesis).       
6. "Not everything that can be counted counts, and not everything that 
counts can be counted." Albert Einstein (1879-1955).  
7. "Tell me and I'll forget; show me and I may remember; involve me and 
I'll understand." Chinese Proverb.   
8. Great ideas are useless if they are not communicated effectively. 
9. Evidence from cost-effectiveness analysis is only one element of the 
priority making process. 
10. International work is a great opportunity to learn other ways of doing 
things.    
11. Saying I do not know shows confidence, pretending you know shows 
insecurity.    
